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9 General introduction
Definition and pathogenesis
The denomination scleroderma is derived from the Greek word skleros, which means hard, 
and derma, which means skin, hence the term “hard skin”. Scleroderma is divided into two 
forms: localised and systemic. Localised scleroderma is restricted to the skin and subcutaneous 
tissues and includes disorders such as morphea, linear scleroderma and eosinophilic fasciitis. 
Systemic scleroderma or systemic sclerosis (SSc) affects not only the skin but also internal organs 
1. This thesis focusses on the systemic form. Systemic sclerosis is a generalised connective tissue 
disorder characterised by microvascular and larger vessel lesions, resulting in thickening of the 
skin, fibrotic degenerative changes in muscles, joints and viscera, mainly the intestinal tract, the 
heart, the lungs and the kidneys. These changes are caused by variable degrees of extra cellular 
matrix accumulation 2;3. Although its exact pathogenesis remains unknown, this disease is 
characterised by vascular damage, predominant T-cell activation, the production of specific auto 
antibodies, and cytokine release 4;5. Furthermore, endothelial cells and fibroblasts are important 
in the pathogenesis in SSc 6. Because of these characteristics SSc is generally considered to be 
an autoimmune disorder. 
Epidemiology
Systemic sclerosis is a rare disease, is globally distributed and has been described in all races. 
Women are 3-4 times more often affected and the onset is predominantly in the fourth and fifth 
decade 3. Published estimates of the prevalence of SSc vary widely, depending on the observation 
period, methods and diagnostic criteria used and geographical area, and it is reported from 0.4 
to 469 per 105 3;7-14. The annual incidence of SSc is reported in the USA to be 1.9 per 105, in 
Greece 1.1 per 105 and in the UK 0.4 per 105 3;14;15.
Diagnostic criteria
Diagnostic criteria for SSc are lacking, however, the American College of Rheumatology has 
designed preliminary classification criteria in 1980 16.
Classification criteria
According to the preliminary classification criteria of the American College of Rheumatology 
(Table 1) a patient can be classified as having SSc when either (a) proximal scleroderma is present, 
that is skin sclerosis proximal from digits, or (b) a patient has any two of the following symptoms: 
sclerodactyly, digital pitting scars and bibasilar pulmonary fibrosis 16. Furthermore, LeRoy and 
co-workers have determined classification criteria for early disease, which includes Raynauds 
phenomenon, nailfold capillaroscopy findings and SSc selective auto antibodies as shown in 
table 2 17. The preliminary classification criteria of the American College of Rheumatology 
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combined with the Leroy criteria for early disease enables clinical and epidemiological research 
in patients with this devastating disease 16;17.
Table 1  Preliminary criteria for classification of systemic sclerosis (scleroderma).  
Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee 16.
1.  Major criterion –  Proximal scleroderma
2.  Minor criteria –  Sclerodactyly
–  Digital pitting scars or loss of substance of the distal finger pad
–  Bibasilar pulmonary fibrosis
A patient can be classified as having systemic sclerosis when the major criterion or two minor criteria are present.
Table 2  Criteria for classification of early systemic sclerosis. 
Leroy and Medsger 17
Limited scleroderma (lSSc) Raynaud’s phenomenon (objective) 
 Plus any one: 
or 
 
Raynaud’s phenomenon (subjective) 
 Plus both:
 
– SSc-type nailfold capillary pattern 
or 
– SSc selective auto antibodies
 
– SSc-type nail fold capillary pattern 
and 
– SSc selective auto antibodies
Limited cutaneous scleroderma (lcSSc) Criteria for lSSc plus: – distal cutaneous changes
Diffuse cutaneous scleroderma (dcSSc) Criteria for lcSSc plus: – proximal cutaneous changes
Distal cutaneous changes: skin involvement present distal from the elbows and knees, usually with involvement of the face; proximal 
cutaneous changes: skin involvement also present more proximally and trunk.
Subset classification
Subset classification criteria are intended to identify and separate disease subsets in which the 
natural history and prognoses may vary 18. At present, the most widely used sub classification 
of SSc differentiates two clinical subsets, namely limited and diffuse cutaneous forms, which 
can be distinguished by the extent of skin involvement. In limited cutaneous SSc (lcSSc) skin 
involvement is only present distal from the elbows and knees, usually with involvement of the 
face, whereas in diffuse cutaneous SSc (dcSSc) skin involvement is also present more proximally 
and/or the trunk 4. The autoantibody profile and the pattern of organ involvement of the two 
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subsets may differ. Antinuclear antibodies are present in over 90% of the patients with SSc. 
Antitopoisomerase I antibodies are positive in 60% of the patients with dcSSc and associated 
with pulmonary fibrosis and poor survival, whereas anticentromere antibodies are present 
in about 50% of the lcSSc patients and are associated with pulmonary arterial hypertension 
(PAH) 19. Other disease selective antibodies are anti ribonucleoprotein and anti PM-Scl, the 
latter identifies patients with a high prevalence of skeletal myositis. Pulmonary fibrosis, renal 
complications and musculoskeletal manifestations are found to be more common in dcSSc, 
and often develop early in the disease course, whereas PAH is more common in lcSSc, usually 
developing late in the disease, resulting in differences in prognosis 20.
Prognosis
The prognosis of SSc is determined by pulmonary, cardiac and renal involvement causing a 
5-year mortality rate of at least 30% 21;22. The survival of SSc patients with and without organ 
involvement is shown in figure 1. The mortality in patients with dcSSc is worse than lcSSc. The 
10-year survival of patients with dcSSc is approximately 50%, whereas the survival of lcSSc is 
approximately 70% 23-25.
Figure 1  Long-term survival of low-risk and high-risk patients. Low-risk patients are defined as having no renal, cardiac or 
pulmonary organ involvement during the first three years after enrolment, limited cutaneous disease and no anti-topoisomerase 
I antibodies 22.
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The leading cause of death in SSc is pulmonary involvement consisting of pulmonary fibrosis 
with or without pulmonary hypertension (PH) or PAH, together accountable for 60% of the SSc-
related deaths 26-29. The EUSTAR (EULAR Scleroderma Trials And Research group) has reported 
the disease manifestations in the two subtypes in SSc in 3656 patients 19. 
Clinimetrics
Apart from the preliminary classification and subset classification criteria, validated activity 
and severity criteria are available 4;16;30-33. Despite their usefulness these criteria have several 
limitations. Diagnostic criteria aiding in early diagnosis as well as subset classification, disease 
activity criteria indicating active disease and severity criteria aiding in the estimation of prognosis, 
could help the clinician in daily clinical practice. To improve patient care in SSc, the clinician 
needs to initiate optimal, early treatment. Treatment with immunosuppressive drugs in an early 
stage of the disease in patients at risk of organ failure or death due to SSc could improve survival, 
emphasizing the importance of early diagnosis.
The disease activity criteria designed by the European Scleroderma Study Group (EScSG) 34 in 
1995 have been validated, but are rarely used in daily clinical care. The reasons for this are 
the following: these disease activity criteria were developed in patients with a wide range of 
disease duration, possibly resulting in symptoms caused by damage rather than activity of SSc. 
Furthermore, the criteria include three “change” items. These “change” items consisted of an 
evaluation by the patients of complaints caused by organ dysfunction compared to the previous 
month. However, the disease could have been active in the previous month and those change 
items are therefore not necessarily a reflection of actual disease activity.The revised preliminary 
SSc severity scale designed by Medsger and co-workers in 2002 could be of value in estimation of 
the prognosis of an individual patient with SSc, however, the sensitivity to change and prognostic 
value of this scale has not been tested yet 31. 
A measure of activity reflects the ongoing disease process and ideally predicts damage and 
thus indicates when intervention is needed, whereas a measure of damage reflects the extent 
of organ dysfunction 35. The Outcome Measures in Rheumatology Clinical Trials (OMERACT) 
collaboration provides validated outcome measurements for rheumatic diseases that are available 
for assessment of activity and damage 36. Because of the rarity of SSc international collaborations 
such as the EUSTAR and the North American Scleroderma Clinical Trials Consortium (SCTC) 
are necessary to provide optimal circumstances for clinimetric studies in SSc. Through these 
collaborations a prospective study which aims to design criteria for early SSc appears to be 
feasible.
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Complications
Organ complications
Skin involvement
Skin involvement in SSc consists of skin thickening, calcinosis and ulcers. In early disease, the 
skin can be edematous. Patients note that their fingers are “tight” and “puffy”. Gradually this 
edema is replaced by thickened, tight skin. In dcSSc this evolution can occur in the course of 
several months to years, and in lcSSc the development of thickening may occur slowly over 
the course of 15 to 20 years. During this process loss of hair, loss of sweat glands, and both 
hypo- and hyperpigmentation may develop. Facial changes result in a characteristic “mauskopf” 
appearance, resulting from reduced mobility of eyelids, cheeks, nose and mouth and perioral 
subcutaneous fibrosis. Skin involvement is measured using the modified Rodnan skin score, in 
which 17 body surface areas are assessed by palpation and scored 0 (no induration) to 3 (maximal 
tightness) 37. The tightened skin impairs mobility of muscles, tendons and joints. After several 
years, the thickened dermis softens and can become thinner than normal, more firmly adherent 
to the underlying subcutaneous fat, leading to tethering. Teleangiectasias, clusters of dilated and 
tortuous capillaries and venules, may increase in number 38. Calcinosis, either subcutaneous 
or intracutaneous can occur in both lcSSc and dcSSc. These deposits are located in digital 
pads, periarticular tissues and sites of repeated trauma, and may vary in size. Calcinosis may 
be complicated by ulceration and secondary bacterial infection. Ulceration of the skin is multi 
factorial. Digital tip ulcers are caused by ischemia, however, ulcers over the joints are probably 
attributable to contractures, tight stretching and thinning of skin, and extremely vulnerable to 
trauma. Ulcers frequently become infected secondarily causing pain and loss of function 38.
Pulmonary involvement
a.  Pulmonary fibrosis
Pulmonary interstitial lung disease is the leading cause of death in SSc. Although the initiating 
factor of pulmonary interstitial lung disease is unknown, studies have shown that endothelial 
and/or epithelial injury precedes inflammation and fibrosis 39. Pulmonary fibrosis is reported to 
be present in 80-90% of the patients, depending on the methodology used, such as a thoracic 
x-ray, a high resolution computer tomography scan of the chest (HRCT-scan), or pulmonary 
function tests, to identify fibrotic changes and the threshold of amount of disease that is used to 
define fibrosis 40. A uniform definition of pulmonary interstitial lung disease in SSc is lacking. 
This complication is suspected when patients complain of shortness of breath, but may also be 
present when pulmonary function testing reveals a decreased total lung capacity (TLC) and/or 
decreased diffusion capacity for carbonoxide (DLCO), and/or when fibrotic changes are present 
on the thoracic x-ray, or when fibrosis with or without ground glass opacity (GGO) is present 
on the HRCT-scan, (figure 2). Bronchoalveolar lavage (BAL) in SSc patients may demonstrate 
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an increase in the total cell count and an abnormal increase in neutrophils, eosinophils or 
lymphocytes. BAL may detect alveolitis in the early stage of SSc lung involvement, an increased 
number of neutrophilia of ≥ 3% and/or eosinophilia of ≥ 2% is considered to be indicative of 
alveolitis 41;42. Video assisted pulmonary biopsy can help in assessing the therapeutic potential of 
treatments for interstitial lung disease in SSc, but this method is flawed by sampling errors 43.
Figure 2  HRCT-scan of a patient with SSc showing both pulmonary fibrosis and ground glass opacity.
We primarily evaluate scleroderma patients with suspected interstitial lung disease by pulmonary 
function testing, including DLCO, and by HRCT-scan. For the assessment of the HRCT-scan the 
same method is used as described by Kaazeroni and co-workers 44 and it was used in a recent, 
large idiopathic pulmonary fibrosis trial 45. In short, this scoring method consists of the evaluation 
of the HRCT-scan at three levels: the midarch of the aorta, the main carina and 1 cm above the 
diaphragm. Both fibrosis and ground glass opacity (GGO) are graded from 0 to > 75% of the 
pulmonary surface, providing a score between 0 and 5. Left and right lung scores are averaged, 
resulting in a total GGO score and a fibrosis score, both between 0 and 15 44;45. Patients with a 
TLC ≥ 70% of predicted and a HRCT-scan score ≤ 3 for GGO and fibrosis, are considered to have 
minimal or absent interstitial pulmonary involvement. In patients with interstitial involvement, 
further evaluation by cardiopulmonary exercise testing on a cyclo ergometer to establish oxygen 
uptake disability amongst others, BAL fluid analysis for active alveolitis, and, when indicated, 
video assisted pulmonary biopsy are performed to establish pulmonary involvement 46;47. A 
biopsy is indicated in cases in which a discrepancy exists between the various tests results or 
when the diagnosis remains unclear. Such a biopsy most often shows a non-specific interstitial 
pneumonitis 48. 
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b.  Pulmonary hypertension
Pulmonary hypertension is classified into 5 groups according to the 2003 World Health 
Organization (WHO) classification 49.
Table 3  Revised WHO Clinical Classification of Pulmonary Hypertension. (Venice 2003) 49
1.  Pulmonary arterial hypertension 
Idiopathic 
Familial 
Associated with: 
– Collagen vascular disease 
– Congenital systemic to pulmonary shunts 
– Portal hypertension 
– HIV infection 
– Drugs/toxins 
– Other 
Associated with significant venous or capillary  
involvement 
– Pulmonary veno-occlusive disease 
– Pulmonary capillary haemangiomatosis 
Persistent pulmonary hypertension of the newborn 
 
2.  Pulmonary hypertension with left heart disease 
Left sided atrial or ventricular heart disease 
Left sided valvular heart disease
3.  Pulmonary hypertension associated with lung  
diseases and/or hypoxemia 
Chronic obstructive lung disease 
Interstitial lung disease 
Sleep disorder breathing 
Alveolar hypoventilation disorders 
Chronic exposure to high altitude 
Developmental abnormalities 
 
4.  Pulmonary hypertension due to chronic thrombotic  
and/or embolic disease 
Thromboembolic obstruction of proximal pulmonary arteries 
Thromboembolic obstruction of distal pulmonary arteries 
Non-thrombotic pulmonary embolism (tumour, parasites, 
foreign material) 
 
5.  Miscellaneous 
Sarcoidosis, histiocytosis X, lymphangiomatosis, compression 
of pulmonary vessels (adenopathy, tumor, fibrosing 
mediastinitis)
The basis of this classification (table 3) is the notion of common pathophysiological processes 
involving the pulmonary blood vessels in all forms of the disorder 50. These pathophysiological 
processes include (a) endothelial dysfunction which results in exaggerated vasoconstriction and 
impaired vasodilatation, promoting vascular remodeling of all layers of the vessel wall 51; (b) 
proliferation of the adventitia limiting vascular elasticity; (c) hypertrophy of the medial smooth 
muscle promoting vasoconstriction and (d) occlusion of the vascular lumen due to intima 
proliferation and in situ thrombosis 52. Once diagnosed, pulmonary hypertension should be 
classified according to the WHO classification and to the degree of functional disability, based 
on exercise performance, according to the New York Heart Association (NYHA) criteria (table 4), 
in order to establish the treatment options 53. 
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Table 4  Modified New York Heart Association functional classification 53.
1 Class I 
Patients with pulmonary hypertension in whom there is no limitation of usual physical activity. Ordinary physical activity does 
not cause increased dyspnoea, fatigue, chest pain, or near syncope.
2 Class II 
Patients with pulmonary hypertension who have mild limitation of physical activity. They are comfortable at rest. There is no 
discomfort at rest, but normal physical activity causes increased dyspnoea, fatigue, chest pain, or near syncope.
3 Class III 
Patients with pulmonary hypertension who have a marked limitation of physical activity. There is no discomfort at rest, but 
less than ordinary physical activity causes increased dyspnoea, fatigue, chest pain, or near syncope.
4 Class IV 
Patients with pulmonary hypertension who are unable to perform any physical activity without symptoms and who may have 
signs of right ventricular failure. Dyspnoea and/or fatigue may be present at rest and symptoms are increased by almost any 
physical activity.
Pulmonary arterial hypertension (PAH) is a fatal complication of SSc. By expert consensus, PAH 
is diagnosed when at right heart catheterisation a mean pulmonary arterial pressure >25 mmHg 
at rest or >30 mmHg during exercise is measured, together with a normal wedge pressure and 
a normal or reduced cardiac output 54. The exact pathophysiological process of PAH is yet to 
be determined, but is characterised by vascular remodelling within small-calibre pulmonary 
arteries, resulting from endothelial injury, in SSc or other connective tissue diseases probably 
caused by the systemic disease itself. The endothelial injury causes overproduction of mediators 
such as endothelin-1, angiotensin II and serotonin, leading to vasoconstriction and smooth 
muscle cell proliferation, whereas a decreased production of vasodilating mediators such as 
nitric oxide and prostacyclin occurs at the same time. Pulmonary hypertension in SSc consists 
of PAH, PH associated to pulmonary fibrosis, PH caused by left sided heart disease, the rare 
pulmonary veno-occlusive disease and chronic thrombo-embolic pulmonary hypertension. 
Every patient suspected of PH, for example patients with unexplained dyspnea, should have 
a full work-up including an echocardiography, pulmonary function tests, a HRCT-scan, a right 
heart catheterisation, perfusion scintigraphy and other investigations when indicated as stated 
in the international guidelines 55. However, in scleroderma patients, PAH and a mild interstitial 
lung disease often co-exist. We consider patients with a mean pulmonary arterial pressure > 25 
mmHg and a restrictive lung disease with a TLC > 70% of predicted and mild GGO or fibrosis on 
HRCT-scanning (score ≤ 3) to have PAH, and patients with TLC ≤ 70% of predicted and a HRCT-
scan score > 3 to have pulmonary hypertension secondary to hypoxia due to interstitial lung 
disease. However, recently it became clear that some patients with moderate to severe interstitial 
lung disease develop severe PH without accompanying chronic hypoxia. Those patients have 
levels of pulmonary arterial pressure that are “out of proportion” to the degree of fibrosis 56;57. The 
survival of these patients is similar to the patients with PAH, suggesting that they had a primary 
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vasculopathy along with some fibrosis 57. The distinction between PH and PAH is important to 
evaluate the treatment options, since specific treatment is only available for patients with PAH, 
but could be beneficial for patients with “out of proportion” PH to the degree of fibrosis.
PAH has been widely studied in SSc and the estimated prevalence of 12-15% is based on studies 
with right heart catheterisation 26. The prognosis of SSc-associated PAH is worse than in patients 
with idiopathic PAH, with a 3-year survival of 48.2% and 83.6% respectively, as shown in figure 
3 58;59. Since PAH is considered a fatal complication of SSc, all patients with SSc should be 
closely monitored for evidence of PAH and assessed for treatment when appropriate 1;60.
Figure 3  Kaplan-Meier survival estimates from time of diagnosis to the time of death in patients with idiopathic pulmonary 
arterial hypertension) IPAH) compared with patients with scleroderma-related pulmonary arterial hypertension (PAH-Scl). 
Significantly poorer survival is evident in patients with PAH-Scl. The 1- and 3- year survival was estimated to be 97.4% and 
88.6%, respectively, in patients with IPAH and 82.5% and 48.2%, respectively, in patients with PAH-Scl.59.
Cardiac involvement
Although cardiac involvement is often clinically asymptomatic, it is common in SSc 61. Autopsy 
studies have shown the presence of cardiac involvement in 30-81% of the patients 62. Cardiac injury 
may result from micro vascular alterations and overproduction of extracellular matrix proteins by 
fibroblasts 63. These processes lead to ischemic, fibrotic and inflammatory lesions involving the 
pericardium, myocardium and cardiac conduction system 61;64. Myocardial involvement in SSc 
is typically a patchy fibrosis, which leads to ventricular diastolic dysfunction. Ventricular systolic 
dysfunction is present in a minority of the patients and is mostly a complication of atherosclerotic 
disease and arterial hypertension 62. Dysrhythmias and conduction disturbances are a hallmark 
of cardiac involvement, facilitated by autonomic dysfunction. Cardiac autonomic dysfunction is 
characterised by reduction of the heart rate variability and arrythmias, both supraventricular and 
18
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ventricular 65;66. All structures of the heart can be involved, resulting furthermore in pericardial 
effusion, valvular disease and finally heart failure 67.
Renal involvement
The classic kidney involvement in SSc is “scleroderma renal crisis” (SRC). Scleroderma renal crisis is 
defined as the new onset of severe hypertension associated with a rapid increase in serum creatinine 
concentration, microangiopathic haemolytic anaemia or both. Patients with dcSSc, particularly 
those with early, rapidly progressive skin thickening and serum anti-RNA polymerase III antibodies 
are at highest risk to develop renal crisis. Another risk factor is high dose corticosteroid use, defined 
as > 15 mg/day prednisone or equivalents 68. Scleroderma renal crisis occurs in approximately 
20% of patients with dcSSc 69. The pathophysiological process seems to be determined by vascular 
changes in de kidney, such as intimal hyperplasia and fibrinoid necrosis, causing vasoconstriction 
and renin production. Renin promotes the formation of angiotensin II, which causes further renal 
vasoconstriction and worsens the renal ischemia and hypertension 70. Besides SRC, other kidney 
symptoms occur infrequently in SSc and are nonprogressive: in less than 5% of the patients without 
SRC some kidney disease is present, mostly consisting of drug toxicities, unexplained proteinuria 
or an increase in serum creatinine 69. 
Involvement of digestive tract
Involvement of the gastrointestinal tract in SSc is second in frequency only to the skin, and 
consists of motility disturbances and vascular changes 71;72. The most frequently affected organ is 
the oesophagus. Oesophagus dysmotility occurs in 75-90% of the patients 73, and is characterised 
by decreased or absent peristalsis in the distal two thirds of the oesophagus and reduced lower 
oesophageal sphincter pressure, and may lead to reflux oesophagitis, and even to strictures 74. The 
pathophysiological changes of oesophageal dysmotility in SSc are initiated by local cholinergic 
neural dysfunction, followed by smooth muscle atrophy and fibrosis, occurring in the early 
course of SSc 74-76. Gastric dysmotility occurs in a high proportion of patients with scleroderma, 
leading to bloating and delayed gastric emptying 77. Dysmotility of the small intestines results in a 
delayed transit of food and liquids through the small intestine, causing bacterial overgrowth and 
malabsorption, weight loss and diarrhoea 71. In the colon the dysmotility may cause constipation 
78. In some patients the dysmotility may be so severe that it produces pseudo-obstruction. This 
is a clinical syndrome caused by ineffective intestinal propulsion causing symptoms similar to 
mechanical bowel obstruction without lesions occluding the intestinal lumen 79. Furthermore, 
both the internal and external anorectal sphincters may become hypotonic, giving rise to faecal 
incontinence 71. The vascular changes in the gastrointestinal tract consist of teleangiectasias, 
which can be present in all parts of the gastrointestinal tract, and may cause intractable chronic 
blood loss. The watermelon stomach, characterised by broad, flat or slightly raised red stripes of 
subepithelial vascular ectasia and ectatic vessels in the submucosa can cause gastric hemorrhage, 
or chronic blood loss and iron deficiency 80. 
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Involvement of muscles and joints
Musculoskeletal pain is very common in SSc. Local skin thickening and involvement of tendons 
may cause loss of joint mobility, local pain and impaired function. However, proliferative 
synovitis has been described in SSc 81. The most frequent muscle involvement associated with 
SSc is inflammatory myopathy, although overlap with polymyositis, piecemeal infarction from 
scleroderma vasculopathy, fibrous myopathy and myopathy of uncertain pathogenic relationships 
are also well described 82;83. 
Psychological factors
Psychological factors and health-related quality of life have acquired more attention in the care 
for patients with scleroderma. The primary endpoint in clinical research is often survival or 
organ function, and the quality of life is often a secondary endpoint. SSc is highly distressing to 
the patient as it has an impact on many dimensions of his or her life including level of physical 
functioning, sexuality, employment opportunities, and life expectancy 22;84-89. The fibrotic process 
often affects the patients’ hands and face, a person’s most visible and socially relevant body 
parts, causing appearance to become one of their great concerns with a vast majority of patients 
expressing concern about disfigurement 90. Disfigurements and alterations in body appearance 
may affect a person’s self-esteem, i.e. the overall feeling of self-worth someone develops in various 
social situations. Self-esteem pertaining to appearance, denoted as appearance self-esteem (ASE), 
thus reflects the subjective evaluation of one’s appearance and is often decreased in people 
with actual deformities like burn injuries. Women with SSc have been known to report an even 
lower ASE than burn patients and low ASE in SSc has been related to impaired psychological 
functioning as expressed in depressive symptoms and psychological distress 86;91. Furthermore, 
health-related quality of life as perceived by patients with SSc is significantly impaired when 
compared with healthy controls 92. Half of the patients show mild to severe depression and the 
urgency of treating the symptoms of depression in SSc is increasingly recognised 93. 
Treatment
General
Therapeutic intervention in SSc has several aspects. First, in patients without major organ 
complications, the aim of treatment is to prevent these complications. Second, in patients with 
major organ complications the aim is to prevent further deterioration and stabilisation of organ 
function, besides symptomatic treatment. In treatment of SSc significant advances have been made, 
although these are mainly with respect to specific organ involvement. As Th A Medsger jr stated in 
1985 for drug therapy in SSc: “ No drug or combination of drugs has been proved to be of value 
in adequately controlled prospective trials or is generally accepted as being useful” 94. However, 
some advances have been reported in treatment options for SSc in the past years. 
20
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Two double blind placebo controlled studies in dcSSc with a disease duration < 3 years have 
shown a tendency in favour of treatment with Methotrexate on skin fibrosis and general well being 
95;96. A point still to address is whether the dosage in those trials was adequate to show a significant 
improvement in early dcSSc. In the Scleroderma Lung Study, a randomised controlled trial of oral 
Cyclophosphamide compared to placebo, patients were included when the forced vital capacity 
(FVC) was between 45 and 85% of predicted and the HRCT-scan showed signs of GGO or the 
BAL fluid showed evidence of active alveolitis. The active treatment arm showed a significant, 
although clinically modest, improvement of pulmonary function, thickening of the skin and 
quality of life in patients treated with oral Cyclophosphamide compared to placebo 29. The UK 
study of corticosteroids and intravenous Cyclophosphamide followed by oral Azathioprine for 
treatment of pulmonary fibrosis showed a trend towards improvement of pulmonary function tests 
in the patients with active treatment compared to placebo 97. Furthermore, the phase I-II studies 
of autologous stem cell transplantation (ASCT) in early dc SSc have shown an improved survival, 
skin thickening and general well being combined with stabilisation of pulmonary, cardiac and 
renal function 98;99. Because of the treatment related mortality of at least 5%, reported in the 
early trial, this treatment should be reserved for carefully selected patients at risk of organ failure 
or death due to SSc 98-100. However, due to better selection of eligible patients this treatment 
related mortality has decreased and appears now to be approximately 6%, which makes this a 
feasible treatment option. The results of the Autologous Stemcell Transplantation International 
Scleroderma (ASTIS) trial and the Scleroderma Cyclophosphamide or Transplantation (SCOT) 
trial in which 12 monthly Cyclophosphamide pulses are compared to ASCT shall define the 
safety and efficacy of stem cell transplantation.
Information from the phase I-II trials with stem cell transplantation in SSc and the 
Cyclophosphamide lung studies have suggested that early treatment can prevent major organ 
involvement in SSc. Treatment early in the course of the disease with immune suppressive 
therapies such as Methotrexate, Cyclophosphamide and stem cell transplantation seems to be 
important to prevent progression of organ involvement and thus improve survival.
In both clinical trials and daily clinical practice of patients with SSc the lack of widely accepted 
disease activity criteria is a shortcoming. The only validated disease activity criteria are the 1995 
EScSG disease activity criteria 32. Since those disease activity criteria are seldom used in clinical 
trials, most recent trials use as primary or secondary outcome parameters such as the modified 
Rodnan skin score 35 the scleroderma Health Assessment Questionnaire 101, HRCT-scanning of 
the chest, pulmonary function testing, blood pressure, renal function, CPK, 6-minute walking 
distance (6-MWT) and echocardiography. 
Recently, the EULAR has formulated recommendations on the treatment of SSc (EUSTAR business 
meeting, Barcelona, June 2007). These are based on evaluation and critical discussion of the 
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relevant literature combined with expert opinion. The first recommendation is the following: 
“The very low number of randomised controlled trials evaluating different treatments in SSc and 
the clinical heterogeneity of the disease makes the clinical experience pivotal for the choice of 
the most appropriate therapy of SSc patients. Therefore, it is strongly suggested that SSc patients 
should be sent to a referral centre to obtain proper management.” As for general treatment of 
SSc, as a result of the two earlier mentioned trials with Methotrexate, a recommendation is that 
this may be considered for treatment of skin manifestations of early diffuse SSc. Furthermore, the 
recommendation for pulmonary fibrosis is as follows: “In view of the results from two high quality 
RCTs and despite its known toxicity, Cyclophosphamide should be considered for treatment of 
SSc-related interstitial lung disease” 29;97.
Proposed treatment regimes in SSc
Treatment regimes in SSc are mainly based on experience in clinical practice, due to the low 
numbers of randomised controlled trials. The main reason to initiate treatment is progression of 
disease, that is progression of skin involvement and/or progression of organ complications. 
In patients with early disease, both in lcSSc and dcSSc, without organ involvement, Methotrexate 
is the treatment of choice, starting with 15 mg once a week and increasing to 25 mg once a week 
if well tolerated. Patients with early progressive dcSSc, that is patients with rapidly progressive 
skin involvement, tendon friction rubs and signs of major organ involvement are treated in our 
centre by either Cyclophosphamide pulses (750 mg/m2 , 6-12 monthly intravenous pulses) or 
ASCT, preferably in a randomized controlled trial, in eligible patients.
Treatment of pulmonary interstitial disease
Patients with pulmonary involvement and active inflammation are treated with monthly 
Cyclophosphamide pulses. Active inflammation is present when the HRCT-scan of the chest 
reveals GGO, when the BAL fluid shows an increased number of neutrophilia of ≥ 3% and/or 
eosinophilia of ≥ 2% 29, or when the video assisted pulmonary biopsy shows inflammation. When 
those signs of “active disease” are not present, we use a trial of the combination of Prednisolone 
(starting dose 40 mg for 1 month, followed by 30 mg for 1 month, then tapered in 6 months to 0), 
Azathioprine (2,5 mg/kg bodyweight) and high dose Acetylcysteine (thrice daily 600 mg), as has 
been described in idiopathic pulmonary fibrosis 45. Also, in very advanced pulmonary fibrosis, 
eligible patients are treated with lung transplantation. 
Treatment of pulmonary arterial hypertension associated to SSc
All patients suspected of PAH should have a complete work-up in order to determine the WHO 
class and the NYHA functional class of the patient 102. Specific treatment of PH in the Netherlands 
is only reimbursed if a patient is either WHO class 1 or 4, and NYHA functional class 3 or 4. 
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Specific treatment of patients with PAH is targeted to produce vasodilatation and vascular growth 
inhibition, and since acute vasoreactivity is absent in scleroderma patients, remodelling of the 
pulmonary vasculature is regarded as the mechanism of action in these patients. The treatment 
arsenal for PAH consists of the endothelin receptor antagonists, the prostacyclin analogues and 
phosphodiesterase-5 inhibition. Current treatment algorithms for PAH include treatment with 
oral medication such as the endothelin receptor antagonists Bosentan 103 and Sitaxentan 104, 
and the phosphodiesterase-5 inhibitor Sildenafil 105, and parenteral treatment with treprostinil 
106 and epoprostanol 107, both prostacyclin analogues. Although those treatments have shown to 
successfully delay the progression of idiopathic PAH 104;106;108-110, their efficacy in SSc-associated 
PAH still needs to be defined.
Proposed treatment regimen in PAH associated to SSc
The treatment regimen of PAH associated to SSc in our centre is based on the international 
guidelines and preferences of the patients. The outlines are shown in figure 4. 
We do not perform vasoreactivity testing for patients with PAH associated to SSc. After testing in 
80 patients we never found a vasoreactive patient, and other experts also share this experience 
(Prof L. Rubin, personal communication). The first line treatment for patients in NYHA class 3 is 
either an endothelin receptor antagonist or PDE5 inhibitor. Treatments goals are improvement 
of exercise capacity as determined by the 6 minute walking distance, reduction of symptoms 
and improvement of the functional class 111. Evaluations are at least three-monthly and consist 
of a detailed history, physical examinations, 6 minute walking distance, six-monthly pulmonary 
function testing and echocardiography. This enables us both to evaluate the treatment effect and 
to establish progression of pulmonary fibrosis or decreased cardiac function in an early stage. If 
the treatment goals, according to the PH experts, are not met, we add either a PDE5 inhibitor or 
an ERA, depending on the first line treatment. The next step is adding a prostanoid analogue. This 
is the first line treatment for patients in NYHA functional class 4. If patients deteriorate despite 
maximal treatment, atrioseptostomy or lung transplantation is a treatment option.
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Figure 4  Treatment scheme for patients with PAH associated to systemic sclerosis at the Radboud University Nijmegen 
Medical Centre. 
Abbreviations: ERA: endothelin receptor antagonist; PDE5 inhibitor: phosphodiesterase-V inhibitors. 
Outline of the thesis
The objectives of this thesis are to determine the state-of-the-art assessment and treatment of 
patients with systemic sclerosis.
In Chapter 2 the epidemiology of systemic sclerosis and its pulmonary complications in the 
Netherlands is presented.
Chapter 3 offers an overview of pulmonary hypertension in connective tissue disease.
Clinimetrics in systemic sclerosis and the present shortcomings are reviewed in Chapter 4.
The significance of the HRCT-scan in the detection of oesophageal involvement as a manifestation 
of SSc is described in Chapter 5.
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Chapter 6 comprises the appearance self-esteem in patients with systemic sclerosis.
In Chapter 7 the right ventricle Tei-index is proposed as a tool to increase the accuracy of the 
non-invasive detection of pulmonary arterial hypertension in connective tissue diseases.
The value of the 6 minute walking distance in systemic sclerosis as measurement of exercise 
capacity is described in Chapter 8.
Chapter 9 offers the long-term follow-up results after autologous haematopoietic stem cell 
transplantation for severe systemic sclerosis. 
Finally, Chapter 10 comprises a summary of the results and the conclusions of this thesis.
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Abstract
The prevalence and incidence of systemic sclerosis (SSc) in the Netherlands is unknown. The 
same holds true for its leading causes of death: pulmonary fibrosis and pulmonary arterial 
hypertension (PAH), for which effective treatment options have become available recently.
Objective: to establish the prevalence and incidence of SSc and its pulmonary complications.
Methods: detailed information of patients in the POEMAS registry, “Pulmonary Hypertension 
Screening, a Multidisciplinary Approach in Scleroderma”, consisting of 819 patients, was 
combined with a nationwide questionnaire. 
Results: By combining the two sources we found the prevalence of SSc to be 8.9 per 105 adults. 
The incidence was 0.77 patients per 105 per year. PAH was diagnosed in 9.9% of the SSc 
patients. The prevalence of interstitial lung disease in SSc varied from 19 to 47% depending on 
the definition used. 
Conclusion: This study clarifies the epidemiology of SSc in the Netherlands and confirms the 
frequent occurrence of pulmonary complications, based on 654 cases. This can and will be 
further studied in the ongoing POEMAS study.
Introduction
Systemic sclerosis (SSc, scleroderma) is an autoimmune connective tissue disease characterized 
by vascular lesions, induration and thickening of the skin, and fibrotic changes in other organs, 
predominantly in the lungs, heart, intestinal tract, kidneys, muscles and joints 1;2. The leading 
cause of death in SSc is pulmonary involvement consisting of pulmonary fibrosis with or without 
pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH) 3-5. Published estimates 
of the prevalence of SSc vary widely, depending on the observation period, methods used 
and geographical area, and it is reported from 0.4 to 469 per 105 people 2;6-13. Furthermore, 
the prevalence of PAH in SSc is unclear, but estimated to be 8% to 12% in studies based on 
right heart catheterization, the gold standard for diagnosing PAH 3;14. Recently several treatments 
that successfully delay the process of PAH such as epoprostenol 15, trepostinil 16, bosentan 17;18, 
sitaxentan 19 and sildenafil 20 have become available. In addition two studies have shown that 
cyclophosphamide has a significant though clinically minor effect on pulmonary fibrosis in SSc 
patients 5;21. In light of these treatment possibilities and given the late occurrence of symptoms of 
eventually life-threatening pulmonary involvement in SSc, screening for both pulmonary (arterial) 
hypertension and pulmonary fibrosis has become a major goal in scleroderma referral centers. 
To date, the optimal screening method for PAH has not been determined. A combination of 
decreased carbon monoxide diffusion capacity (DLCO) and elevated systolic pulmonary arterial 
pressure estimated (PAP) by echocardiography is the method used in most clinics 3;22;23. However, 
a decreased DLCO is also present in other diseases limiting oxygen uptake, and echocardiography 
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is flawed by both false positive and false negative results. Right heart catheterization is the gold 
standard for establishing the diagnosis PAH 24;25. In order to prospectively investigate the optimal 
screening method for PAH in SSc the POEMAS study was started in 2005. POEMAS, an investigators’ 
initiated study, is a Dutch acronym for “Pulmonale hypertensie Opsporing Een Multidisciplinaire 
Aanpak bij Sclerodermie” translated as “Pulmonary Hypertension Screening, a Multidisciplinary 
Approach in Scleroderma”, and intends to establish the optimal screening method for PAH in 
SSc. For this purpose, patients with SSc, without PAH or interstitial lung disease at inclusion, will 
prospectively be studied for five years. In order to find eligible patients for the POEMAS study, all 
patients with SSc treated in the participating hospitals were screened and documented according 
to our protocol. Their data were entered into the POEMAS registry.
The objectives of this study are to determine the point prevalence and incidence of systemic 
sclerosis in the Netherlands, and to establish the prevalence of PAH and interstitial lung disease 
in the same population. 
Patients and Methods
Prevalence of patients with SSc in the Netherlands
In the Netherlands, patients with systemic sclerosis are referred by the family practitioner to either 
rheumatologists or internists, mostly clinical immunologists. All rheumatologists and internists 
use a computerized diagnosis system for all patients which is designed to calculate costs for 
the health insurance. Occasionally, referral is to dermatologists, who in their turn refer patients 
with systemic sclerosis to the rheumatologists. To determine the prevalence and incidence of 
SSc and the associated PAH and interstitial lung disease in the Netherlands, cases were found 
using two sources: first, the POEMAS registry and second, a nationwide questionnaire among 
rheumatologists and clinical immunologists in the Netherlands. As denominator the total 
population in the Netherlands ≥ 18 years of age on January 1 2007 was used as provided by the 
Statistics Netherlands registry (www.cbs.nl). 
Currently, 15 hospitals participate in the POEMAS study, including both academic (n=5) and non-
academic hospitals (n=10). All patients ≥ 18 years referred to these hospitals and diagnosed with 
SSc according to the preliminary classification criteria of the American College of Rheumatology 
26 and the LeRoy criteria for early SSc 1 in the period of January 1 2005 till August 1 2007 were 
included in the registry. Demographical and clinical characteristics of all patients were obtained 
from their clinical records.
To obtain information on the number of patients treated in other hospitals in the Netherlands, a 
questionnaire was sent to all registered rheumatologists and clinical immunologists, excluding 
the hospitals participating in the POEMAS study. If the questionnaire was not returned, a 
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second was sent and the physicians were personally requested in a telephone conversation to 
return the survey. In the questionnaire they were asked to provide the number of all alive SSc 
patients ≥ 18 years of age and the number of SSc patients with PAH, as diagnosed with a right-
heart catheterization, currently treated in their practice. The source of the information for the 
questionnaire was the computerized diagnosis lists available in all Dutch hospitals.
POEMAS study population
Demographical and clinical information of the patients are shown in table 1. Interstitial lung 
disease was determined by pulmonary function tests and high-resolution computer tomography 
scan (HRCT-scan). For the assessment of signs of interstitial lung disease on the HRCT-scan 
the same method was used as in a recent, large idiopathic pulmonary fibrosis trial 2. In short, 
this scoring method consists of the evaluation of the HRCT-scan at three levels: the midarch 
of the aorta, the main carina and 1 cm above the diaphragm. Both fibrosis and ground glass 
opacity (GGO) were graded from 0 to > 75% of the pulmonary surface, providing a score 
between 0 and 5. Left and right lung scores were averaged, resulting in a total GGO score and 
a fibrosis score, both between 0 and 15 27;28. The patients were divided into two groups: one 
with HRCT-scan scores ≤ 3 for GGO and fibrosis, representing minimal or absent interstitial 
pulmonary involvement, and another with more extensive interstitial involvement. Furthermore, 
all patients were classified as having a total lung capacity (TLC) ≥ 70% or < 70% of predicted 
22;29. Systolic PAP was calculated by applying the simplified Bernoulli-equation on maximum 
tricuspid regurgitation velocity and adding estimated right atrial pressure. Right atrial pressure 
was estimated using inferior caval vein diameter and the effects of respiratory variation 30.  PAH 
was suspected when on echocardiography the estimated systolic PAP was ≥ 35 mmHg at rest 
in patients without a history of pulmonary embolism or other possible causes of PH and with 
a normal TLC. In all cases with an elevated systolic PAP on echocardiography a right-heart 
catheterization was performed, and when the mean PAP > 25 mmHg at rest with a normal 
wedge pressure, a diagnosis of PAH was established 22;25;31. 
Some patients were registered twice in the database due to referral to an academic centre or 
moving house. Those patients were recognized using date of birth and postal code and the 
duplicates were removed.
Statistical analysis
All statistical analyses were performed using Statistical Package for Social Sciences (SPSS) version 
14.0. To calculate the prevalence of SSc, the number of patients from the POEMAS registry 
was combined with the results from the survey. The response to the survey was 70%; hence 
for calculations the number of patients not included in the POEMAS registry was estimated to 
be 100/70 times the result of the questionnaires. Adding the POEMAS registry number to the 
estimated number in the other hospitals provided the total number of patients in the Netherlands. 
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To provide an estimate of the prevalence, this number was divided by the number of inhabitants 
≥ 18 years of age in the Netherlands. The percentage of patients in the Netherlands with SSc 
included in the POEMAS registry was calculated. To establish the incidence, the number of 
new cases in 2005 and 2006 in the POEMAS database was determined, generalized to the total 
population, using the calculated percentage of patients registered in the POEMAS database, and 
then divided by the total Dutch population. For determination of the prevalence of PAH both 
the POEMAS registry and the questionnaires were used. For the presence of interstitial lung 
disease, information from the POEMAS registry was the sole source. The prevalence of the latter 
complication was calculated by generalizing the POEMAS registry to the total population in 
the Netherlands. Quantitative variables were summarized as median and full range, and were 
compared using the t-test. Groups were compared using the Mann-Witney U test. All statistical 
analyses were two-tailed and P values < 0.05 were considered statistically significant.
Results
In the POEMAS registry 654 SSc patients have been included up to August 1 2007. Eighty two and 
18% of the patients were included in the academic and non-academic hospitals, respectively. 
The study population consisted of 493 (75.4%) females and 161 (24.6%) males. The median 
(range) age of the patients with SSc was 59.1 years (19-90) . The median age (range) at diagnosis 
of SSc was 50.0 years (3-86). ANA antibodies were detected in 91.7% of the SSc patients, and 
the frequency of other disease specific autoantibodies as well as the demographical description 
of the patients is displayed in table 1.
Table 1  Demographic and autoantibody status of patients evaluated in the POEMAS study
Systemic sclerosis (N=654)
1.1.1  Female sex: male sex 493 : 161
Age (median, range) 59 (19-90)
Age at diagnosis (median, range) 50 (3-86)
ANA positive (%) 588 (92%)
ACA positive (%) 191 (30%)
Anti-TOPO positive (%) 139 (22%)
Anti- RNP positive (%) 37 (6%)
TLC ≥ 70% of predicted 312/338
HRCT-scan minimal or no interstitial lung disease 103/262
ANA: antinuclear antibody; ACA anticentromere antibody; Anti-TOPO: antitopoisomerase antibody; anti-RNP: anti ribonuclear protein 
antibodies; TLC: total lung capacity; HRCT-scan: high resolution computer tomography scan.
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Prevalence of SSc
The response to the questionnaire was 70%. The response rates of physicians working in 
academic and non-academic hospitals were similar. Therefore the questionnaire was considered 
to be representative. Through the questionnaire, another 346 SSc cases were recognized. When 
combining the results of the survey and the POEMAS study, the estimated number of SSc patients 
in the Netherlands in 2005 and 2006 is 1148. The total Dutch population ≥ 18 years of age 
on the first of January 2007 was 12 793 440. Using this as the denominator population, the 
estimated prevalence of SSc is 8.9 per 105per 105 inhabitants. (Table 2)
Table 2  Prevalence and incidence of systemic sclerosis in the Netherlands, and prevalence of pulmonary hypertension with 
systemic sclerosis in the Netherlands
Systemic sclerosis
Survey (N) POEMAS (N) The Netherlands * (N)
Prevalence of SSc 346 654 1148 8.9 per 100000 persons
Portion of total N of patients 30.0% 57.0% 100%
Incidence of SSc NA 56 98 0.77 per 100000 persons
Prevalence of PH 40 56 113 9.9% of patients
* The number of patients in the Netherlands was calculated by addition of the number of patients in the survey (N), generalised to the whole 
country (N(survey)/7*10) and the POEMAS cases. 
POEMAS: searching for pulmonary hypertension, a multidisciplinary approach in scleroderma; SSc: systemic sclerosis.
Incidence of SSc 
In the hospitals participating in the POEMAS study 58 new SSc patients were diagnosed in 
2005 and 53 in 2006. Since 57.0% of the SSc patients in the Netherlands was calculated to 
be registered in the POEMAS study (654 / (100/70 * 346 + 654) * 100), the estimated annual 
number of new scleroderma patients is 103 in 2005 and 94 in 2006. Generalizing this number 
to the denominator population, the estimated incidence of SSc in the Netherlands is 0.77 per 105 
inhabitants ≥18 years of age per year. (Table 2).
Pulmonary hypertension
The presence of PH, either PAH or PH associated with pulmonary fibrosis was reported in 11.6% of 
the SSc patients in the survey. In the POEMAS registry PH was prevalent in 56 (8.6%) SSc patients. 
Combining these results the estimated prevalence of PH in SSc in the Netherlands is 9.9% (Table 
2). SSc patients with PH had a significantly lower TLC compared to patients without PH, namely 
70.5 (35-132) % of predicted and 91.0 (32-137) % of predicted respectively (p<0.01). Also, the 
median (range) age of patients with SSc and PH was significantly higher than the patients without 
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PH: 67.2 (31.6-84.7) years versus 58.5 (19.6-90.0) years. No differences regarding PH were found 
in gender or autoantibodies. When using a TLC < 70% of predicted as diagnosis of interstitial lung 
disease, this cohort consisted of 35 (61.4%) PAH and 22 (38.6%) PH patients. 
Interstitial pulmonary disease
Pulmonary function tests were performed in 480 (74.9%) SSc patients in the last six months prior 
to registration in the POEMAS database. The median (range) TLC in SSc was 90.0 (32-152) % of 
predicted. Figure 1 shows the TLC values as percentage of predicted in SSc patients. The TLC as 
percentage of predicted was ≥ 70% in 81.0% of the patients. To date, HRCT-scanning has been 
performed and scored according to the described protocol in 292 SSc patients. A score ≤3 for 
GGO and fibrosis, representing minimal or absent interstitial pulmonary involvement, was found 
in 53.0% of the HRCT-scans of the SSc patients. In SSc patients without pulmonary involvement 
according to the HRCT-scan, anticentromere antibodies were present more frequently than in 
the patients with a GGO or fibrosis score > 3 (p<0.01). No differences were found between the 
patients in the normal and abnormal HRCT-scan groups regarding age, disease duration, other 
autoantibodies or sex. The median (range) TLC in patients with an HRCT-scan score ≤ 3 was 
97.0 (46-137) % of predicted, which differed significantly from patients with higher HRCT-scan 
scores, namely 71.5 (35-134) % of predicted (p=0.01). When a HRCT-scan score > 3 is used 
to define pulmonary interstitial disease, this complication is present in 47.0% (139/296) of the 
patients . If an TLC< 70% of predicted is used to define interstitial lung disease, this complication 
is present in 18.8% (91/485) of the patients. The HRCT scores correlated significantly with the 
TLC as percentage of predicted, r=0.527 (p<0.01).
Figure 1  Total lung capacity as percentage of predicted in systemic 
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Discussion
This study of prevalence and incidence of SSc is based on the largest European population of 
SSc patients described to date. We found an estimated prevalence of SSc in the Netherlands of 
8.9 per 105 adult persons, based on 1000 cases. This finding is comparable with recent findings 
in the UK, where an estimated prevalence of 8.2 per 105 has been published 7. The prevalence 
in France and Greece is reported to be 15.8 and 15.4 per 105 persons, respectively 6;10, whereas 
the prevalence in the USA and Australia is reported to be higher, 24.2 and 23 per 105 persons 
respectively 12;32. The differences in prevalence in different countries can be explained by several 
factors, such as the criteria used to diagnose patients, the preliminary classification criteria of 
the American College of Rheumatology 26 or the LeRoy criteria for early SSc 33, or the group size 
11;12. Furthermore, differences in ethnic background may lead to a higher prevalence of SSc in the 
USA and Australia 8;12;32. For identification of SSc patients in the POEMAS registry we used both 
classification criteria 26;33, which allowed us to include patients with early disease and limited 
cutaneus involvement without interstitial lung disease.
The POEMAS study is performed by physicians with special interest in SSc and pulmonary 
hypertension. To avoid an over estimation of the prevalence of SSc, we included a questionnaire 
to all other rheumatologists and clinical immunologists in the Netherlands. The responses are 
considered to be a reflection of the total population of the Netherlands. A portion of patients with 
systemic sclerosis is not yet referred to the rheumatologist but treated only in primary care or by 
other specialists such as dermatologists or vascular surgeons, but in our opinion this is a small 
minority of the total amount of patients. By combining the results of the questionnaire and the 
POEMAS registry we were able to identify 87% of the SSc patients, and therefore the estimated 
prevalence presented in this study is robust.
The incidence of SSc was calculated using only the POEMAS study population, of which the 
date of diagnosis is known in every case. The calculated incidence of 0.77 per 105 is between 
the reported incidence in the USA (1.9 per 105), Greece (1.1 per 105) and the UK (0.4 per 105) 
6;12;34. Since our estimated incidence is based on a study period of only two years and the number 
of incident cases is somewhat smaller than the USA and Greek cohorts, this figure should be 
interpreted with care and should be confirmed in the second part of our POEMAS study, with an 
observational period of five years.
The prevalence of pulmonary hypertension in this study is a combined prevalence of PAH and 
PH associated with pulmonary fibrosis. As PH associated with fibrosis is a hypoxia driven disease 
rarely occurring in SSc, probably all patients with pulmonary hypertension in this study can be 
categorized as PAH. We found a prevalence of PH in SSc of 9.9%, which is lower than expected 
35-37. This could be caused by the possibility that patients with PH associated to SSc are treated 
by pulmonologist or cardiologists, sometimes without recognising the systemic disease, as can 
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be the case in every country. Another reason could be the fact that screening for PH by annual 
echocardiography has not yet been incorporated into the standard care in all hospitals. In the 
POEMAS study this will be performed twice yearly, providing us with the opportunity to further 
study the prevalence and incidence of PH in the scleroderma spectrum of diseases. 
The POEMAS registry provides detailed information about 654 SSc patients. The percentage of 
patients with a TLC ≥ 70% in SSc was 81.2%. The expected percentage of interstitial lung disease 
in this connective tissue diseases is much higher, but may differ depending on the definition 
and methods used. Earlier studies reported pulmonary fibrosis in 35-53% of the SSc patients 
38. Apparently, a TLC ≥ 70% does not exclude interstitial lung disease. However, combining 
TLC with HRCT-scan findings is expected to be a more sensitive method for this purpose, the 
POEMAS study will provide further information.
In summary, we have described the epidemiology of SSc in the Netherlands. Our findings reveal 
that the prevalence and incidence of SSc in the Netherlands is similar to the data from the UK. 
However, the prevalence of pulmonary hypertension and interstitial pulmonary disease is lower 
than expected. With the POEMAS study in progress, additional information about epidemiology, 
PAH and interstitial lung disease is pending.
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Abstract
Pulmonary hypertension is a devastating complication of various, but rare diseases and can also 
occur isolated. It causes morbidity and mortality in all patients. Ongoing research has provided 
some insight in pathophysiology and clinical manifestations, and new therapeutic options have 
recently become available for some types of pulmonary hypertension. In order to provide optimal 
care for an individual patient it is mandatory to establish the type and severity of the pulmonary 
hypertension in each patient. The diagnostic protocol used in our hospital is presented along 
with the description of two case histories. An algorithm of the different therapeutic strategies now 
available is given as well as recommendations for follow-up. 
Introduction
Pulmonary hypertension is a life-threatening condition which can occur either isolated or as 
a complication of various diseases. If left untreated it causes increasing breathlessness and 
eventually death in all cases. Pulmonary hypertension is defined as a mean pulmonary artery 
pressure of > 25 mmHg at rest or > 30 mmHg during exercise, measured during right heart 
catheterisation 1. The most common symptoms of pulmonary hypertension are breathlessness, 
fatigue and (near-) syncope 2. Since these symptoms are non-specific, pulmonary hypertension is 
often overlooked or diagnosed only in advanced stages.
Pulmonary hypertension is a well-known complication of connective tissue diseases such as 
systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and mixed connective tissue disease 
(MCTD). Because of the physical limitations arising from these underlying diseases, patients with 
pulmonary hypertension as a complication of these diseases complain of shortness of breath at 
a later stage than the normal population. Deaths that have previously been assigned to heart 
attacks may in fact have been caused by pulmonary hypertension.
Pulmonary hypertension usually occurs late in the course of collagen vascular diseases. Since 
the greater part of these patients are seen at regular intervals by rheumatologists or internists, 
this presents us with an opportunity to screen for pulmonary hypertension at an earlier stage, 
thus enabling to start a therapy that may prevent progression of pulmonary hypertension and 
premature death. Although pulmonary function testing and echocardiography are widely used 
as screening tests and can identify patients with advanced pulmonary hypertension, these tests 
cannot be considered to be adequate for the exclusion of pulmonary hypertension in breathless 
patients. Therefore, a clinical history of longstanding dyspnoea should potentially be regarded as 
a sign of pulmonary hypertension, irrespective of the findings of pulmonary function testing and 
echocardiography 3, and should prompt a right heart catheterisation, the gold standard for the 
assessment of pulmonary hypertension. 
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In 2003, the World Health Organization (WHO) proposed a new classification for pulmonary 
hypertension. The basis of this new classification (table 1) is the notion of common 
pathophysiological processes involving the pulmonary blood vessels in all forms of the disorder 
4. These pathophysiological processes include (a) endothelial dysfunction which results in 
exaggerated vasoconstriction and impaired vasodilatation, promoting vascular remodelling of 
all layers of the vessel wall 5; (b) proliferation of the adventitia limiting vascular elasticity; (c) 
hypertrophy of the medial smooth muscle promoting vasoconstriction and (d) occlusion of the 
vascular lumen due to intima proliferation and in situ thrombosis 6. 
Table 1  Revised WHO Clinical Classification of Pulmonary Hypertension. (Venice 2003) 1
1.  Pulmonary arterial hypertension 
Idiopathic 
Familial 
Associated with: 
– Collagen vascular disease 
– Congenital systemic to pulmonary shunts 
– Portal hypertension 
– HIV infection 
– Drugs/toxins 
– Other 
Associated with significant venous or capillary  
involvement 
– Pulmonary veno-occlusive disease 
– Pulmonary capillary haemangiomatosis 
Persistent pulmonary hypertension of the newborn 
 
2.  Pulmonary hypertension with left heart disease 
Left sided atrial or ventricular heart disease 
Left sided valvular heart disease
3.  Pulmonary hypertension associated with lung  
diseases and/or hypoxemia 
Chronic obstructive lung disease 
Interstitial lung disease 
Sleep disorder breathing 
Alveolar hypoventilation disorders 
Chronic exposure to high altitude 
Developmental abnormalities 
 
4.  Pulmonary hypertension due to chronic thrombotic  
and/or embolic disease 
Thromboembolic obstruction of proximal pulmonary arteries 
Thromboembolic obstruction of distal pulmonary arteries 
Non-thrombotic pulmonary embolism (tumour, parasites, 
foreign material) 
 
5.  Miscellaneous 
Sarcoidosis, histiocytosis X, lymphangiomatosis, compression 
of pulmonary vessels (adenopathy, tumor, fibrosing 
mediastinitis)
The availability of new therapies that have been shown to slow down or prevent progression of 
pulmonary hypertension has caused a growing interest among physicians to diagnose pulmonary 
hypertension at an early stage. Since various specialties can be confronted with patients with 
pulmonary hypertension, we started a multidisciplinary pulmonary hypertension outpatient 
clinic (MPHO clinic), existing of a rheumatologist/internist, pulmonologist, cardiologist and 
specialized nurse, in order to facilitate early and fast diagnosis according to a protocol, and to 
institute the best therapies currently available. 
In this paper we describe two patients who presented themselves at this MPHO clinic, to illustrate 
the different diagnostic procedures of our protocol and the instituted therapies.
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Case 1
A 22-year-old Asian female was referred to our outpatient clinic. She had been diagnosed with 
SLE 7 years before with symptoms of fever, Raynaud’s phenomenon, pericarditis, pleuritis, ANA 
and anti-dsDNA positivity and at a later stage also with arthritis of the knees. From the onset of 
her disease she had been treated with low dose prednisone and azathioprine until three years 
ago when her SLE was considered to be in remission.
At presentation she reported a two-year history of shortness of breath at exertion with an inability to 
exercise. Symptoms of right sided heart failure were not present. At physical examination she was 
dyspnoeic while undressing, with an unremarkable internal and rheumatological examination.
The electrocardiogram (ECG) revealed right ventricular hypertrophy. The results of the laboratory 
investigations were unremarkable except for ANA positivity with anti-SM autoantibodies and 
anti-dsDNA antibodies 10 IU/ml present. Pulmonary function testing showed no evidence of 
restrictive or obstructive lung disease, but a marked decrease of diffusion capacity was present: 
TLCO 60% of predicted. The echocardiogram showed pulmonary hypertension with normal left 
ventricular function.
A right heart catheterisation revealed a pulmonary artery pressure of 79/37 mmHg with a mean 
of 54 mmHg. Right atrial pressure was 12 mmHg(normal), and the cardiac index was 2.9 L/min/
m2. The pulmonary vascular resistance was increased to 781 dynes.sec.cm-5. Since pulmonary 
hypertension was established, a vasodilator test was performed. First the patient was breathing 
100% oxygen, and the measurement of the pulmonary artery pressure was repeated and was found 
unchanged. Next prostacyclin up to 12 nanogram/kg/min was used to dertermine vasoreactivity 
of the pulmonary arteries, that is a significant decrease in pulmonary artery pressure, which in 
this case was not present.
A ventilation/perfusion scan was negative for pulmonary embolism, as was the ultrasound of 
the abdomen for portal hypertension. A 6-minute walk test (6-MWT) was performed. This is 
the distance a patient can walk in 6 minutes with encouraging, in a standardized setting 7. A 
healthy person has a 6-MWT of 650 to 750 meters. This patient had a 6-MWT of 505 m. She was 
diagnosed with pulmonary arterial hypertension, WHO group I, related to autoimmune disorder 
(table I), NYHA functional class III. 
Treatment was started with bosentan, an orally dual endothelin receptor antagonist, 62.5 mg 
twice daily during the first 4 weeks, and 125 mg BID thereafter. Bosentan was well tolerated and 
after three months of treatment her NYHA functional class had improved from III to II and her 6-
MWT was 537 m. The treatment was considered successful and continued. Until now, 1.5 years 
later, our patient is doing well and still using the same medication. 
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Case 2
A 57-year-old Caucasian woman was referred for a second opinion. Her medical history was 
unremarkable until 8 years ago, when a gradual progression of shortness of breath occurred. 
Because the echocardiogram was suggestive of pulmonary hypertension the patient was referred 
to the MPHO clinic for further evaluation. 
At physical examination she was dyspnoeic while undressing. Internal and rheumatological 
examinations were unremarkable, particularly there were no signs of right sided heart failure 
present. Laboratory evaluation was normal. Pulmonary function testing revealed only a slight 
reduction of the diffusion capacity (TLCO was 79% of predicted), without signs of restrictive or 
obstructive lung disease. Blood gas analysis showed hypoxaemia, with PaO2 5.9 kPa at room 
air. 
The echocardiogram at our hospital was also suggestive of pulmonary hypertension, which was 
confirmed with right heart catheterisation. Her pulmonary artery pressure was 104/55 mmHg, 
with a mean of 69 mmHg. The pulmonary vascular resistance and the cardiac index were 787 
dynes.sec.cm-5 and 1.87 L/min/m2 respectively. Vasoreactivity testing was negative. A ventilation/
perfusion scan was negative for pulmonary embolism, as was the ultrasound of the abdomen for 
portal hypertension. The CT-angiography of the lungs revealed dilated central pulmonary arteries 
and was otherwise unremarkable (figure 1) Her 6-MWT was 397 m. She was diagnosed as 
idiopathic pulmonary arterial hypertension, NYHA functional class III and treatment was started 
with bosentan. After three months she improved to NYHA class II and her 6-MWT improved to 
462 m. 
Figure 1  CT-angiography of case 2, showing dilated central pulmonary arteries
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Diagnosis of pulmonary hypertension: a diagnostic protocol
Pulmonary hypertension should be suspected in any patient with unexplained shortness of 
breath. Next, two non-invasive tests can be performed to obtain further indications of pulmonary 
hypertension: pulmonary function testing and echocardiography. A decreased diffusion capacity 
with signs of mild restrictive lung disease is suggestive for pulmonary hypertension 8. With 
transthoracic echocardiography an estimation of the systolic pulmonary artery pressure from the 
tricuspid regurgitation jet velocity and the jugular venous pressure can be made 9.
The diagnosis of pulmonary hypertension should be confirmed by right heart catheterisation, 
widely considered the gold standard for the diagnosis of pulmonary hypertension. During right 
heart catheterisation direct measurements of pulmonary artery pressure, right heart pressures, 
mixed venous oxygen saturation, cardiac output, pulmonary vascular resistance, and response 
to vasodilator drugs can be made. Also, right heart catheterisation is mandatory to measure 
the pulmonary wedge pressure to exclude left sided heart disease as a cause of pulmonary 
hypertension.
Once diagnosed, pulmonary hypertension should be classified according to the WHO-
classification and to the degree of functional disability, based on exercise performance, 
according to the New York Heart Association (NYHA) criteria (table 2), in order to establish the 
best treatment options 1.
Table 2  Modified New York Heart Association functional classification 8
1 Class I 
Patients with pulmonary hypertension in whom there is no limitation of usual physical activity. Ordinary physical activity does 
not cause increased dyspnoea, fatigue, chest pain, or near syncope.
2 Class II 
Patients with pulmonary hypertension who have mild limitation of physical activity. They are comfortable at rest. There is no 
discomfort at rest, but normal physical activity causes increased dyspnoea, fatigue, chest pain, or near syncope.
3 Class III 
Patients with pulmonary hypertension who have a marked limitation of physical activity. There is no discomfort at rest, but 
less than ordinary physical activity causes increased dyspnoea, fatigue, chest pain, or near syncope.
4 Class IV 
Patients with pulmonary hypertension who are unable to perform any physical activity without symptoms and who may have 
signs of right ventricular failure. Dyspnoea and/or fatigue may be present at rest and symptoms are increased by almost any 
physical activity.
The differential diagnosis of pulmonary hypertension can be extracted from the WHO 
classification. For the analysis of patients with pulmonary hypertension we designed a protocol 
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that is performed in each patient with suspected pulmonary hypertension. These patients are seen 
at a special outpatient clinic, the MPHO-clinic, where they are examined by a multidisciplinary 
team consisting of a rheumatologist/internist, a pulmonologist, a cardiologist and a specialized 
nurse. Prior to the diagnostic work-up, a careful history of each patient is taken, with special 
attention for the complaints of dyspnoea, symptoms related to autoimmune disorders, prior drug 
and toxin use. A routine internal and rheumatological examination is performed, focussed on signs 
and symptoms of pulmonary hypertension and diseases known to be complicated by pulmonary 
hypertension. Furthermore, pulmonary function testing, including exercise tests, namely a 6-
MWT and if possible a symptom limited exercise test on a cycle ergometer, chest X-ray, ECG, 
echocardiography and blood analysis are performed directly following the consultation. When 
the results of history and examinations are further indicative of pulmonary hypertension, right 
heart catheterisation is performed, and if pulmonary hypertension is confirmed vasoreactivity 
tests are executed. The protocol used by our multidisciplinary team is schematically shown in 
figure 2. 
Figure 2  Scheme for analysis of pulmonary hypertension
This approach consists of both essential tests, which are performed on each patient, and 
complimentary tests. After the results of the tests have become available the patients are 
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discussed in the multidisciplinary team and the appropriate treatment is chosen and proposed 
to the patient during a follow-up visit. Patients with pulmonary hypertension are included in a 
prospective follow-up study. 
Treatment strategies
The general therapeutic options for pulmonary hypertension include oxygen therapy in patients 
with hypoxaemia, anticoagulant drugs if there are no contraindications and digoxin and diuretics 
in cases of right sided heart failure. If the pulmonary vasoreactive tests are positive, the treatment 
of choice is high dose calcium-channel blockers. Vasoreactivity is defined to be present when 
the mean pulmonary artery pressure has decreased at least 10 mmHg to 40 mmHg or below with 
normal or high cardiac output after intervention with pulmonary vasodilators, such as 100% 
oxygen, nitric oxide inhalation or intravenous prostacyclin 1. Only 10 - 15% of the idiopathic 
pulmonary arterial hypertension patients meet these criteria 10. The percentage of vasoreactive 
patients in the group of pulmonary arterial hypertension associated with autoimmune disorders 
is unknown, but believed to be even lower. 
Favorable clinical and prognostic effects of high dose calcium-channel blockers in vasoreactive 
patients have been shown in non-randomized, non-controlled studies 11;12. The occurrence of 
side effects like oedema, headache, tachycardia and hypotension, limits the use of high dose 
calcium channel blockers. If there is no vasoreactivity present or high dose calcium-channel 
blockers have to be discontinued because of side effects, the next treatment steps are based upon 
the WHO classification and functional NYHA classification. 
Specific treatment is available for some of the causes of pulmonary hypertension for example 
pulmonary arterial hypertension, WHO group I. Bosentan, an oral endothelin antagonist, has 
been approved for pulmonary arterial hypertension, NYHA class III. The efficacy of bosentan 
has been established in two randomized placebo-controlled trials in which a significant 
improvement of the 6-MWT occurred after 12 weeks of treatment 13;14. Epoprostenol has been 
approved for the treatment of patients of the same WHO group I, in NYHA class III but also 
NYHA class IV. In several randomized controlled trials in idiopathic pulmonary hypertension 
15-17 the beneficial effects of epoprostenol was proven on survival, exercise tolerance, functional 
class and pulmonary vascular haemodynamics. In pulmonary arterial hypertension occurring 
in association with autoimmune disorders, a randomized controlled study showed a significant 
improvement of exercise capacity and haemodynamics in the treatment group 18. Recently, 
sildenafil, an oral phosphodiesterase inhibitor, has been shown to be effective in pulmonary 
arterial hypertension patients, both in patients with idiopathic PAH and in patients with PAH 
associated to autoimmune disorders, with improvement of symptoms and exercise capacity 19-21 
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and a large placebo controlled phase III trial is pending. Other new drugs, such as treprostinil, a 
subcutaneously administrated prostaglandin, and sitaxsentan, a selective endothelin-A receptor 
antagonist, have given promising results in randomised clinical trials 22.
When pulmonary arterial hypertension is diagnosed but patients are in NYHA class I or II, they 
are evaluated again after 6 months or sooner if there are signs of clinical deterioration. If a 
patient is in NYHA class III, the treatment of choice is bosentan. At the start of this therapy the 
patient is also informed about treatment possibilities when bosentan failes, including (heart-)lung 
transplantation. The efficacy of bosentan is evaluated after 3 months and every three months 
thereafter. The treatment is considered effective if the 6-MWT is at least stable. 
If the treatment with bosentan fails, the next treatment option is continuously intravenously 
administered epoprostenol. This is also the treatment of choice for patients in NYHA class IV. 
Other therapeutic options include combination therapies with epoprostenol and bosentan 23 
and/or sildenafil 24. Atrial septostomy, a surgical procedure to create a right-to-left shunt that 
increases the cardiac output in cases of right sided ventricular failure can also be considered 
25-27. Current indications for this procedure are limited and considered a bridging therapy to 
transplantation. Treatment for the other causes of pulmonary hypertension, namely the WHO 
group II to V, is mainly supportive, and is focussed on the underlying disease. Physicians should 
have special attention for pulmonary hypertension WHOgroup IV, chronic thrombotic and/
or embolic diseases, because bilateral pulmonary thromboendarterectomy can be a curative 
treatment for these patients 28.
Conclusion
Patients with pulmonary hypertension have a life-threatening disease. In order to provide 
adequate care for these patients it is necessary to perform a complete analysis to rule out the 
other differential diagnostic possibilities and to establish the type of pulmonary hypertension. 
We have described the protocol for pulmonary hypertension in our hospital, including treatment 
and follow-up strategies. Collaboration of a multidisciplinary team of rheumatologists/internists, 
pulmonologists, cardiologists and specialized nurses accounts for the most optimal diagnostic 
and therapeutic procedures.
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What does the clinician need to improve patient care in systemic sclerosis?
Introduction
Systemic sclerosis (SSc) is a multisystemic disorder of unknown cause characterised by fibrotic 
and degenerative changes of skin, blood vessels and internal organs 1. The clinical spectrum 
of SSc, and hence its prognosis, is quite variable 2. At present validated subset classification, 
activity and severity criteria are available 2-7. Despite their usefulness these criteria have several 
limitations. Furthermore, diagnostic criteria of SSc are lacking. To improve patient care in 
scleroderma, the clinician needs to initiate optimal, early treatment. Diagnostic criteria aiding 
in early diagnosis as well as classification, severity criteria aiding in the estimation of prognosis, 
and disease activity criteria indicating active disease could help the clinician in daily practice. 
Present international collaborations such as the EULAR Scleroderma Trial and Research Group 
(EUSTAR) and the North American Scleroderma Clinical Trials Consortium (SCTC) are thriving, 
providing the ideal circumstances for clinimetric studies in SSc. 
This editorial discusses the state-of-the-art of clinimetrics in SSc and possible ways to overcome 
the present limitations.
Diagnostic criteria
Diagnostic criteria, especially for the early phase, are indispensable for estimation of prognosis 
and for timely initiation of treatment. Frequently the ACR Preliminary Criteria for the Classification 
of Systemic Sclerosis (Scleroderma), developed in 1980, are used to diagnose SSc patients 3. The 
objective of these classification criteria, was to establish a standard for definite or certain disease 
in order to permit comparison of groups of patients from different centres and to assist in the 
proper evaluation of the results of clinical and therapeutic trials and not to aid in the diagnosis 
of early systemic sclerosis in the individual patient 3. These preliminary criteria were established 
in a prospective multicentre study in which adult scleroderma patients were included who were 
diagnosed within two years prior to study entry. Patients were sub grouped in three categories: 
definite, probable or early stage, and overlap syndrome. In total 264 patients with a definite 
SSc were included and their characteristics were compared to 413 patients with systemic lupus 
erythematosus, polymyositis/dermatomyositis and Raynaud’s phenomenon not associated with 
the previously mentioned disorders.
 
The preliminary ACR classification criteria are not suitable for the early and proper diagnosis of 
SSc for several reasons. First of all, the absence in the control group of scleroderma-like diseases 
usually seen by dermatologists, caused patients with eosinophilic fasciitis, diffuse morphoea or 
other related conditions to also fulfil the preliminary ACR criteria. Secondly, the patients with 
SSc who were selected for the study were probably “classical” cases, while less differentiated, 
early disease patients were less likely to be included. Indeed a significant percentage of patients 
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with limited cutaneous disease do not fulfil the preliminary ACR criteria 2;8. Furthermore, disease 
specific autoantibodies such as antitopoisomerase 1 and anticentromere that are highly specific 
for SSc, may be of importance in the diagnosis of SSc and were not taken into account. The 
same holds true for application of wide field nail fold capillaroscopy 9. Finally, following the 
suggestions of LeRoy and Medsger, data have been provided supporting the diagnosis of SSc in 
an early “prescleroderma” stage in patients, who do not present with any skin thickening and are 
referred to as “limited” SSc 10. Uniformly applicable diagnostic criteria of SSc require that these 
are developed in patients with the early SSc, and not in patients with established disease.
Subset classification criteria 
Subset classification criteria are intended to identify and separate disease subsets in which the 
natural history and prognoses may vary. The variability in the clinical and prognostic features of 
the disease has long prompted investigators to subdivide SSc into distinct, mutually exclusive 
subsets. At present, the most widely used subsetting scheme differentiates two clinical subsets, 
namely limited and diffuse cutaneous forms, which can be distinguished by the extent of skin 
involvement, their autoantibody profile and the pattern of organ involvement. In limited cutaneous 
SSc skin involvement is present distal from the elbows and knees, usually with involvement of 
the face, whereas in diffuse cutaneous SSc skin involvement is also present more proximally 2. 
The major disadvantage of this subset classification model is that patients with early disease, 
without or with minimal skin changes and no internal organ involvement, do not fit. The amended 
2001 criteria of Le Roy and Medsger include the presence of Raynaud’s phenomenon, nail fold 
capillarroscopic changes and disease specific autoantibodies, resulting in a “prescleroderma” 
or limited SSc subset, allowing patients with early disease to be classified 10. However, this 
model has not been validated to date. Another scheme differentiates 3 subsets, namely limited, 
intermediate and diffuse cutaneous disease. Herein are represented the limited cutaneous subset 
patients with skin involvement confined to digits with or without involvement of the face; the 
intermediate cutaneous subset with skin involvement of the limbs; and the diffuse cutaneous 
subset with skin involvement of the trunk 11;12. It has been shown that this model has a greater 
discriminant power concerning survival than the 2 subset one 9;11. Since pathological alterations 
and clinical manifestations of SSc are a continuum, any subsetting model involving only the 
extent of skin changes seems arbitrary and restrictive 12. Therefore, subsetting classification 
criteria including the disease specific autoantibodies and additional imaging such as nail fold 
capillaroscopy, validated in a cohort of scleroderma patients, also with early disease, could aid 
in the development of an optimal classification model.
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Activity criteria
A measure of activity reflects the ongoing disease process and ideally could forecasts damage 
(and thus indicates when intervention is needed), whereas a measure of damage reflects the extent 
of organ dysfunction 13. The OMERACT collaboration provides validated outcome measurements 
that are available for assessment of activity and damage 14.
In 1995 the European Scleroderma Study Group (EScSG) initiated a multicentre prospective study 
to define disease activity criteria in SSc. Prospectively collected data of consecutive patients, 
fulfilling the preliminary ACR criteria, from centres in Europe 3;5 were examined. In total 290 
patients were enrolled. Detailed information was provided at inclusion, and after 6 and 12 
months 15. By applying expert opinion the authors developed criteria for disease activity in SSc 6. 
Unfortunately the results of this study were flawed by a high number of missing values, especially 
in the investigations concerning disease activity in internal organs, which were consequently 
ruled out. Further, there were three “change” items in the final scale. These “change” items 
consisted of an evaluation by the patients of complaints caused by organ dysfunction compared 
to the previous month. However, the disease could have been active in the previous month 
and those change items are therefore not necessarily a reflection of actual disease activity. The 
“change” items are actually response measurements and therefore should not be included in an 
activity score. Also, the scleroderma patients included in the study had a wide range of disease 
duration and their complaints could have been caused by damage. To avoid confounding between 
damage and disease activity, the activity criteria must preferably be assessed in scleroderma 
patients with early disease. The study of construct validity of this score was successful, but 
showed that even among experts there is a low level of agreement in the assessment of disease 
activity 16. The criteria were externally validated and, in a consensus conference of the EScSG in 
2002, the components of the criteria were chosen as the variables for the assessment of disease 
activity in SSc 7. At the same conference a core set of variables was proposed reflecting disease 
activity that have to be assessed to define each organ system involvement as shown in table 1 17. 
Validated and widely accepted disease activity criteria, which are easy to apply, could assist both 
the clinician and the clinical investigator in everyday practice.
Damage/ severity scale
A disease severity scale is useful in assessing disease status, both at a given point in time and 
evolution over time, and could aid in the evaluation of treatment effects and the establishment of 
the prognosis in the individual patient. From 1976 onwards different investigators developed a 
disease severity scale for SSc but those scales were not validated. In 1999 Medsger et al proposed 
and validated severity criteria for SSc 4. Experts from different centres identified nine organ systems 
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and chose variables to assess these organ functions depending on the overall availability and the 
importance in the physician’s judgment. The involvement of each organ system was graded from 
0 (no documented involvement) to 4 (end stage disease). The proposed scale was prospectively 
tested in 78 newly referred patients and the variables were adapted according to the results 
of this study and subsequently external validated. Finally the severity criteria were discussed 
among the experts to ensure face and content validity as well as consensus 4. Drawbacks of the 
severity scale, as pointed out by the authors themselves, include the lack of a weighting system 
discriminating more severely ill patients from the patients with a more extensive but indolent 
disease. The severity scale was modified, resulting in the revised preliminary SSc severity scale 
in 2002 5. The sensitivity to change and prognostic value of this scale however, has not been 
tested yet. 
Table 1  Core set variables to be assessed to define each organ system involvement 17
Skin Modified Rodnan skin score
Vessels Raynaud 
Digital ulcers (active/healed)
Joints FTP (finger tip distance) measurement 
DAS 28 when synovitis occurs
Tendons Number of tendon friction rubs at hands, wrists, elbows, knees, ankles
Muscles Proximal weakness 
Serum CPK
GI tract Dysphagia, heartburn, early satiety, bloating, vomiting, diarrhoea, constipation, malabsorption, intestinal 
distention, barium oesophageal and intestinal X-ray
Lung Dyspnoea, lung fibrosis (chest X-ray) 
Restrictive defect (by FVC, DLCO) 
Pulmonary hypertension (by echo colour Doppler, DLCO)
Heart Dyspnoea, palpitations, chest pain 
Dizziness/presyncope/syncope 
Heart rate, conduction defects, arrhythmias 
Oedema/venous congestion 
Pericardial effusion 
Ejection fraction; E/A ratio
Kidney Arterial pressure, serum creatinine, urinalysis
DLCO: carbon dioxide diffusion lung capacity; FTP: finger tip distance; FVC: forced vital capacity; GI: gastrointestinal
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Future research in clinimetrics
Systemic sclerosis still lacks validated clinimetric criteria that are clinically useful in the very early 
phase of the disease process. To improve patient care validated criteria for diagnosis, prognosis, 
disease activity, and severity are essential. Most important, these criteria and instruments should 
be developed and validated in the population of interest: patients with systemic sclerosis at a 
very early phase of the disease process.
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Abstract
Background: Systemic sclerosis (SSc) is a generalised autoimmune disease, which causes 
morbidity and reduced life expectancy. Recently evidence has been accumulating that 
immunosuppressive treatment in an early stage of the disease could improve survival, enhancing 
the need for early diagnosis and regular evaluation of organ involvement. Among others, a High 
Resolution Computer Tomography scan (HRCT-scan) of the chest is performed for the assessment 
of pulmonary involvement in SSc. The objective of this study is to evaluate the predictive value 
of oesophageal dilatation on the HRCT-scan for the diagnosis of SSc. 
Methods: In total 105 consecutive scleroderma patients and 107 consecutive controls were 
included in this study. The first available scan for each patient and control was evaluated in 
random order and blinded for the diagnosis, by two independent radiologists, for oesophageal 
dilatation and interstitial lung disease. 
Results: The positive predictive value of oesophageal dilatation for the diagnosis of SSc was 83%. 
No significant correlation of oesophageal dilatation and interstitial lungdisease was found in the 
scleroderma patients or controls. 
Conclusion: Oesophageal dilatation as visible on an HRCT-scan of the chest may alert physicians 
to look for other signs or symptoms of SSc in these patients, enabling early diagnosis and specific 
treatment.
Introduction
Systemic sclerosis (SSc) is a systemic autoimmune disease characterised by vascular lesions and 
variable degrees of extra cellular matrix accumulation causing fibrotic degenerative changes 
in skin, muscles, joints and viscera 1;2. The diagnosis of SSc is a clinical diagnosis, in which 
the presence of skin fibrosis and digital ulcers or pitting scars is combined with complaints of 
Raynauds phenomenon and the detection of specific auto antibodies, resulting in fulfillment 
of the ACR classification criteria for SSc or the criteria for early diagnosis of SSc as suggested 
by Leroy and Medsger 3;4. The prognosis of SSc is determined by pulmonary, cardiac and renal 
involvement causing a 5-year mortality rate of at least 30% 5;6. To date, evidence has been 
accumulating that treatment with immunosuppressive drugs in an early stage of the disease 
could improve survival, emphasizing the importance of early diagnosis 7. Although the most 
common causes of death in SSc are related to lung involvement 6;8;9, the most frequently affected 
organ is the oesophagus. Oesophageal involvement can be detected in 75-90% of the patients 10. 
The oesophageal abnormalities are characterised by decreased or absent peristalsis in the distal 
two thirds of the oesophagus and reduced lower oesophageal sphincter pressure 11, and may lead 
to reflux oesophagitis, and even to strictures. 
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The pathophysiological changes of oesophageal dysmotility in SSc are initiated by local 
cholinergic neural dysfunction, followed by smooth muscle atrophy and fibrosis, occurring 
in the early course of SSc 11-13 and occurring independently of interstitial pulmonary disease, 
whereas in fibrotic lung diseases gastroesophageal reflux, caused by oesophageal dysmotility 
is associated with pulmonary disease 14. Symptoms of oesophageal dysmotility can consist of 
dysphagia, heartburn, dyspepsia and chest pain, or may be absent 15. Extensive investigations 
have shown that the correlation between complaints and abnormal findings at the specific 
oesophageal investigations is poor and as many as 30-40% of SSc patients with abnormalities of 
oesophageal function may be asymptomatic 16. 
Various investigations are available for the evaluation of the oesophageal function, such as 
oesophageal manometry, pH monitoring of the distal oesophagus, scintigraphy, endoscopy 
and video barium oesophagram 16. Manometry is the most sensitive investigation to establish 
oesophageal dysmotility in patients with SSc and is generally considered the gold standard 17-19. 
Oesophageal manometry, endoscopy and pH monitoring are invasive investigations and poorly 
tolerated by some patients, and can therefore not be used as a screening tool. Most often a video 
barium oesophagram is used to establish or rule out oesophageal dysfunction 16, however, the 
sensitivity and specificity for radiological dysmotility has been determined at 60% and 80% 
respectively 20. In daily practice patients with SSc and complaints of either pyrosis or dysphagia 
are treated with proton pump inhibitors and invasive investigations are performed only if the 
symptoms persist 17. 
Since 2001 we perform a standardised prospective follow-up to monitor the course of the disease 
in patients with SSc. As part of this follow-up, pulmonary involvement is assessed annually by 
pulmonary function tests and a High Resolution Computer Tomography scan (HRCT-scan) of 
the chest 21. We have often observed oesophageal dilatation on the HRCT-scans in patients with 
SSc. This raised the question whether an open oesophagus on the HRCT-scan, performed for 
whatever indication, could be used to predict early SSc. The primary objective of this study is to 
evaluate whether an “open” oesophagus on the HRCT-scan of the chest points to the presence of 
SSc, in patients evaluated because of signs of interstitial lung disease. The secondary objectives 
are to determine whether oesophageal dilatation is more common in different disease subsets 
of scleroderma patients, to examine the relationship between an “open” oesophagus and the 
extent of interstitial lung disease, to evaluate the relationship between complaints of dysphagia 
and dilatation and to evaluate the correlation between an “open” oesophagus on the HRCT-scan 
and barium oesophageal radiographic studies.
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Patients and Methods
To select the cases of this study we used records of patients with SSc from our prospective 
cohort (N= 256). This cohort consists of all patients with SSc in the care of the department of 
rheumatology. A list was obtained of all HRCT-scans performed at the department of radiology 
between January 1 st 2004 and December 31 st 2004 for the indication “interstitial lung disease”, 
ordered by internists, chest physicians and rheumatologists of the Radboud University Nijmegen 
Medical Centre. We aimed to consecutively include 100 SSc patients of the cohort as cases for 
this study. The subtype of SSc, autoantibody profile, disease duration (from onset of first non-
Raynaud symptom) and clinical manifestations were recorded. From the HRCT-scan list, we 
aimed to randomly include 100 patients as controls. Their medical records were obtained to 
provide the clinical diagnosis of the controls; none were diagnosed with SSc.
For both the cases and the controls, the first available HRCT-scan of the chest in our hospital was 
retrieved. All HRCT-scans of the chest were obtained without intravenous contrast with the patients 
in supine position in suspended deep inspiration. The standard HRCT protocol was used with 
1.0 mm slice thickness at 10-mm intervals. All cases were evaluated by using lung windows with 
window level of -450 HU and a width of 1500 HU with 1.0 mm slice thickness at 10-mm intervals, 
120 kV and 240 mAs, and high-frequency spatial reconstruction algorithm. These HRCT-scans 
were examined in random order by two radiologists independently from each other, blinded for the 
diagnosis of the patients. The images were evaluated for the presence of oesophageal dilatation and 
interstitial lung disease. The coronal oesophageal diameter was measured at 5 levels on the HRCT-
scan of the chest, namely the level of the origin of the great vessels, the midarch of the aorta, the 
main carina, the pulmonary venous confluence and 1 cm. above the right dome of the diaphragm. 
Also the widest diameter of the oesophagus was measured above and below the aortic arch. (Figure 
1). Cases in which there was disagreement, that is different measurements ≥ 4 mm. supra-aortic 
and ≥ 9 mm. infra-aortic as described before as cut-off values by Pitrez et al, were discussed 
between the radiologists in a consensus meeting and consensus was reached in every case 22.
The presence and extent of interstitial lung disease was evaluated by the method of Wells 23. In 
short, this method consists of the evaluation of the scans at five levels, the same levels used for 
evaluation of the oesophageal diameter. Abnormal appearances are categorised as follows: Grade 
0 is no ground-glass pattern (GGP) or reticular pattern (RP) present, Grade 1 is GGP more extensive 
than RP, Grade 2 is GGP and RP equally extensive, and Grade 3 is RP more extensive than GGP. The 
Wells score is a summation of the findings of all levels and ranges between 0 (no GGP or RP present) 
to 15 (in all levels RP present). The results from the radiologists’ readings were correlated with the 
clinical diagnosis and disease characteristics as mentioned above. To compare the findings on the 
HRCT-scans with barium enema studies, we retrieved all available barium oesophageal radiographic 
studies of the cases and noted whether the findings were normal or abnormal. Complaints about the 
upper gastrointestinal tract of the cases were collected from the patients’ charts. 
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Figure 1 A  An HRCT-scan of the chest of a patient with systemic  Figure 1 B  An HRCT-scan of the chest of a patient 
sclerosis on the level of the main carina. The arrow indicates  with systemic sclerosis on the level of the main 
the oesophageal dilatation, measured as the luminal coronal  carina, in this patient no oesophageal dilatation 
diameter. is present.
Statistical analysis
To evaluate inter-observer reliability between the radiologists in judging the HRCT-scan on 
whether the oesophagus was open or not, Cohen’s kappa was calculated on the results reached 
before the consensus meeting. The inter-observer reliability for the Wells score was calculated 
using an intra-class correlation coefficient. Further calculations were done using consensus results 
on judging the oesophageal diameter, and the mean of the Wells score of the two radiologists. 
Using a two by two table, the sensitivity, specificity, positive and negative predicting values of 
an “open” oesophagus, for presence of SSc were calculated. The analysis were performed using 
previous described cut-off points; oesophageal dilatation was diagnosed if the luminal coronal 
diameter of the oesophagus exceeded 10 mm, whatever the content (air, liquid or solid) 22.
The Pearson correlation of the Wells score and an “open” oesophagus was calculated in both the 
cases and the controls. A comparison of barium oesophageal radiographic studies, complaints 
of the upper gastrointestinal tract and HRCT findings was performed using two by two tables 
allowing to evaluate the sensitivity, specificity, positive and negative predicting values. P-values 
< 0.05 were considered statistically significant.
Results
Cases and controls
The cases consisted of 105 patients, all fulfilling the ACR preliminary classification criteria for 
SSc or Leroy criteria for early diagnosis of SSc 3,4, 71 (68%) had the limited cutaneous form and 
34 (32%) the diffuse cutaneous form. Sixty-eight (65%) were female. The mean age at the date 
A B
→
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of the HRCT-scan of the cases was 57 (range 21-80) years and the median disease duration 
was 5.1 (range 0.1- 41.6) years from onset of the first non-Raynaud symptom (Table 1). One 
hundred-and-one patients (96%) were positive for antinuclear antibodies (ANA), 22 (21%) for 
anticentromere antibodies (ACA) and 36 (34%) were antitopoisomerase-I antibody positive. The 
mean modified Rodnan skin score (mRss) was 10.6 (range 0-44). The clinical manifestations of 
SSc were upper digestive tract complaints (N=58), digital ulcers (N=42), pulmonary hypertension 
defined as mean PAP >25 mmHg at right heart catheterisation (N=21), restrictive lung disease 
defined as a vital capacity (VC) < 70% of predicted (N=21), myositis defined as creatine kinase 
levels twice the upper limit of normal (N=7), history of renal crisis (N=5) and heart disease 
defined as diastolic dysfunction > grade 2 and/or pericardial effusion (N=3). The median age of 
the controls at the date of the HRCT-scan was 53.1 (range 20-82) years and 50% was female. The 
diagnosis of the control group consisted of leukaemia (N=48), chronic obstructive pulmonary 
disease (COPD) (N=17), sarcoidosis (N=8), multiple myeloma (N=5), pulmonary fibrosis (non 
specific interstitial pneumonia (N=4) and usual interstitial pneumonia (N=3)). In 23 cases an 
HRCT-scan was ordered to evaluate opportunistic infections in immune compromised patients, 
or side effects of chemotherapy in malignant diseases, and suspicion of vasculitis.
Table 1  Characteristics of the patients with systemic sclerosis.
Limited cutaneous SSc 
(N=71)
Diffuse cutaneous SSc 
(N=34)
Total  
(N=105)
Disease duration in years (median, range) 6.6 (0.1-41.6) 2.3 (0.4-14.2) 5.1 (0.1-41.0)
Subtype N (%) 71 (68%) 34 (32%) 105
Autoantibodies N (%) 
ANA 
ACA 
Atopo1
 
68 (96%) 
21 (30%) 
21 (30%)
 
33 (97%) 
 1  (1%) 
11 (32%)
 
101 (96%) 
 22 (21%) 
32 (30%)
mRSS mean (range) 7.1 (0-24) 18.3 (0-44) 10.6 (0-44)
Abbreviations: ANA: antinuclear antibodies, ACA: anticentromere antibodies, Atopo1: antitopoisomerase 1 antibodies, mRSS: modified Rodnan Skin Score
Reliability of the radiological assessments
The measure of agreement of the radiologists for the oesophageal dilatation measured as Cohen’s 
kappa was 0.78; the percentage of agreement was 89%. The radiologists were asked to re-
evaluate the scans in which they disagreed and to come to a consensus. The mean (SD) Wells 
scores for the radiologists were 4.3 (5.1) and 4.1 (4.3) respectively. The correlation between the 
Wells scores of the radiologists was 0.77, and the intra-class correlation coefficient was 0.76. 
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Does oesophageal dilatation point to SSc?
Infra-aortic oesophageal dilatation was present in 65 of the 105 SSc patients, resulting in a 
prevalence of 62%. In the control patients the prevalence was 12% (N=13/107). The sensitivity 
and specificity of presence of oesophagus dilatation for the diagnosis of SSc or not was 63% and 
88% respectively (Table 2). The positive predictive value of an “open” infra-aortic oesophagus 
for the diagnosis of SSc was 83%; the negative predictive value was 69%. The dilatation of the 
infra-aortic oesophagus appeared to be higher at all levels in SSc patients compared to non-SSc 
patients, but these differences were generally not statistically significant. 
Table 2  Evaluation of the HRCT-scans of the chest of patients with systemic sclerosis and control patients for the presence of 
infra-aortic oesophageal dilatation, for the combined findings of both radiologists.
Both radiologists Diagnosis SSc Diagnosis non-SSc Total
Sensitivity 63%
Oesophagus open 65 13 78 Specificity 88%
Oesophagus closed 39 88 127 PPV 83%
Total 104 101 205 NPV 69%
Abbreviations: SSc: systemic sclerosis, PPV: positive predictive value, NPV: negative predictive value
Clinical variables and oesophageal dilatation
In SSc patients with a disease duration < 2 year the prevalence of infra-aortic oesophagus 
dilatation was 47% (14/30 patients), and in SSc patients with a disease duration ≥ 2 year it was 
68% (51/75 patients), which was not significantly different. Also no significant differences were 
noted in the prevalence of an “open” oesophagus in different subsets of the patients, such as 
limited cutaneous versus diffuse cutaneous, specific antibodies positive versus negative and male 
versus female. No significant correlation was found between the presence of muscle disease, 
digital ulcers, heart disease or VC < 70% of predicted and infra-aortic oesophagus dilatation. 
Wells score and oesophageal dilatation
A Wells score of 3 in at least one section of the HRCT-scan presenting a reticular pattern i.e. 
fibrosis, was present in 52 scans, 25 cases and 27 controls. No association was present between 
these Wells scores and oesophageal dilatation, neither in the cases (p=0.52) nor in the controls 
(p=0.83).
Agreement of HRCT-scan and barium oesophageal radiography
In 61 of the 105 cases barium oesophageal radiography was performed within 4 weeks of the 
HRCT scans. 38 of those barium radiographic studies showed abnormal oesophageal motility. 
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Comparing this result with the HRCT-scan findings provided a sensitivity, specificity, positive 
predictive value and negative predictive value of 71%, 61%, 75% and 56% respectively for an 
“open” oesophagus on an HRCT-scan, assuming that abnormal oesophageal motility at barium 
oesophageal radiography reflects true dysmotility. The measure of agreement of the HRCT-scan 
for the oesophageal dilatation and the barium oesophageal radiography measured as Cohen’s 
kappa was 0.34; the percentage of agreement was 71%.
Oesophageal dilatation and complaints
Of all SSc patients, treated with or without proton pump inhibitors, 58 had complaints of 
dysphagia (55%). When combining the complaints and oesophageal dilatation, the positive 
predictive value of complaints for an open oesophagus in patients with SSc was 63%. 23% of 
the SSc patients had an oesophageal dilatation but no dysphagia. 
Discussion
In this study we tested whether oesophageal dilatation as observed on an HRCT-scan of the lungs 
could be helpful in discriminating between the diagnosis SSc and other diagnoses in HRCT-scans 
ordered for the evaluation of interstitial lung disease, and whether the results of these HRCT-
scans agree with the results of barium oesophageal radiography. An HRCT-scan is part of our 
annual screening program for pulmonary involvement in patients with SSc. If the HRCT-scan 
were to provide us with information about oesophageal dilatation, a manometric study, the gold 
standard for oesophageal dysfunction, which is poorly tolerated by the majority of the patients, 
could be avoided 24. 
The oesophageal changes in SSc patients occur in the infra-aortic region by fibrosis of the smooth 
muscle cells. The differential diagnosis of dilatation in this region is primary achalasia or secondary 
achalasia, the latter caused among others by gastric carcinoma infiltrating the oesophagus, 
lymphoma and irradiation. Pitrez and others found an optimal cut-of value of a luminal diameter 
of 10 mm in the infra-aortic oesophagus 22. The occurrence of infra-aortic oesophageal dilatation 
as measured by an HRCT-scan in our sample was 62%, which is in accordance with other 
studies using other diagnostic techniques 11;16;18;25. No difference was found in the prevalence of 
an “open” oesophagus in patients with early disease and a longer disease duration. Bhalla et al 
found an 80% prevalence of asymptomatic oesophageal dilatation in patients with scleroderma 
lung disease in a retrospective study of 25 HRCT-scans and suggested that HRCT-scans could 
potentially be useful in detecting asymptomatic oesophageal dilatation in these patients 26. 
Our study includes patients with and without interstitial lung disease and we found a lower 
prevalence. In contrast to the expected, we found no relationship between oesophageal dilatation 
and pulmonary fibrosis in both cases and controls. Oesophageal dilatation was uncommon 
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(12%) in the control sample that did not have SSc but were suspected of interstitial lung disease. 
In our study we found a positive predictive value of an “open” oesophagus for the diagnosis of 
SSc of 83%. Therefore, the presence of an oesophageal dilatation on an HRCT-scan does not 
completely predict the presence of SSc, and its absence does not rule out SSc. However, it could 
be worthwhile if a radiologist, when noticing an oesophageal dilatation on an HRCT-scan of the 
chest, reports this finding, maybe even suggests the possibility of the diagnosis of SSc, enabling 
the referring specialist to start further diagnostic workup for SSc.
The gold standard for the evaluation of the oesophageal function is manometery which is an 
invasive procedure and often uncomfortable for the patients 16;27. In clinical practice barium 
oesophageal radiography is often performed although the correlation of barium oesophageal 
radiography with manometry is unknown in SSc patients. The results of the assessment of 
oesophageal dilatation on an HRCT-scan of the lungs agreed fairly with the results of barium 
oesophageal radiography. As shown by our study and by others, complaints of dysphagia do 
not accurately predict the presence or absence of oesophageal dilatation, therefore technical 
assessment still is necessary 11;16;27.
The reliability of scoring oesophageal dilatation on the HRCT-scans of the lungs was good 
according to the percentage of agreement and Cohen’s kappa between the two radiologists. The 
two radiologists also reached considerable agreement in the Wells score. Therefore, it seems 
reasonable that in clinical practice one radiologist may determine whether an oesophageal 
dilatation is present or not. 
In conclusion we found that the positive predictive value of oesophageal dilatation, as defined 
as an infra-aortic luminal diameter ≥ 10 mm. on an HRCT-scan of the chest ordered for the 
indication “interstitial lung disease” for the diagnosis SSc was 83% and the negative predictive 
value was 69%. Thus oesophageal dilatation as visible on an HRCT may alert physicians to look 
for other signs or symptoms of SSc in these patients.
Acknowledgements
We thank A.I. Smetsers, M.A. for her technical support.
75
Oesophageal dilatation on HRCT-scan of the lungs as a sign of scleroderma
Reference List
1 Furst DE, Clements PJ. Hypothesis for the pathogenesis of systemic sclerosis. Journal of Rheumatology 
1997; 24:53-7.
2 Medsger TA, Masi AT. Epidemiology of Systemic Sclerosis (Scleroderma). Arthritis and Rheumatism 
1971; 14(1):174.
3 Leroy EC, Medsger TA. Criteria for the classification of early Systemic Sclerosis. Journal of Rheumatology 
2001; 28(7):1573-6.
4 Subcommittee for Scleroderma Criteria of the American Rheumatism Association diagnostic and 
therapeutic committee. Preliminary Criteria for the Classification of Systemic-Sclerosis (Scleroderma). 
Arthritis and Rheumatism 1980; 23(5):581-90.
5 Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with 
scleroderma - Development of a simple model using three disease factors at first visit. Arthritis and 
Rheumatism 1999; 42(12):2660-5.
6 Ioannidis JPA, Vlachoyiannopoulos PG, Haidich AB, Medsger TA, Lucas M, Michet CJ et al. Mortality 
in systemic sclerosis: an international meta-analysis of individual patient data. American Journal of 
Medicine 2005; 118(1):2-10.
7 Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al. Cyclophosphamide versus 
placebo in scleroderma lung disease New England Journal of Medicine 2006; 354(25):2655-66.
8 Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic 
sclerosis patients. Annals of the Rheumatic Diseases 1998; 57(11):682-6.
9 Simeon CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M et al. Mortality and prognostic factors 
in Spanish patients with systemic sclerosis. Rheumatology 2003; 42(1):71-5.
10 Sjogren RW. Gastrointestinal Motility Disorders in Scleroderma. Arthritis and Rheumatism 1994; 
37(9):1265-82.
11 AbuShakra M, Guillemin F, Lee P. Gastrointestinal Manifestations of Systemic-Sclerosis. Seminars in 
Arthritis and Rheumatism 1994; 24(1):29-39.
12 Cohen S, SCHUMACH.R, Turner R, Lipshutz W, Myers A, Fisher R. Pathogenesis of Esophageal 
Dysfunction in Scleroderma and Raynauds Disease Journal of Clinical Investigation 1972; 51(10):2663-
&.
13 Treacy WL, Code CF, Slocumb CH, Baggenstoss AH. Scleroderma of Esophagus - A Correlation of 
Histologic and Physiologic Findings Annals of Internal Medicine 1963; 59(3):351-&.
14 Tobin RW, Pope CE, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of 
gastroesophageal reflux in patients with idiopathic pulmonary fibrosis American Journal of Respiratory 
and Critical Care Medicine 1998; 158(6):1804-8.
15 Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterology 
Clinics of North America 1998; 27(3):563-94.
16 Clements PJ, Becvar R, Drosos AA, Ghattas L, Gabrielli A. Assessment of gastrointestinal involvement. 
Clinical and Experimental Rheumatology 2003; 21(3):S15-S18.
17 DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of Gastroesophageal 
reflux disease American Journal of Gastroenterology 2005; 100(1):190-200.
18 Lock G, Zeuner M, Straub RH, Hein R, Lang B, Scholmerich J. Esophageal manometry in systemic 
sclerosis: screening procedure or confined to symptomatic patients? Rheumatology International 1997; 
17(2):61-6.
19 Fitzgerald RC, Triadafilopoulos G. Esophageal manifestations of rheumatic disorders Seminars in 
Arthritis and Rheumatism 1997; 26(4):641-66.
20 Sellar RJ, Decaestecker JS, Heading RC. Barium Radiology - A Sensitive Test for Gastroesophageal 
Reflux. Clinical Radiology 1987; 38(3):303-7.
76
Chapter 5 
21 Vonk MC, van Dijk APJ, Heijdra YF, van der Heijden HFM, Bredie SJH, van den Hoogen FHJ. Pulmonary 
hypertension: its diagnosis and management, a multidisciplinary approach. Netherlands Journal of 
Medicine 2005; 63(6):193-8.
22 Pitrez EH, Bredemeier M, Xavier RM, Capoblanco KG, Restelli VG, Vieira MV et al. Oesophageal 
dysmotility in systemic sclerosis: comparison of HRCT and scintigraphy British Journal of Radiology 
2006; 79(945):719-24.
23 Wells AU, Hansell DM, Rubens MB, Cullinan P, Black CM, Dubois RM. The Predictive Value of 
Appearances on Thin-Section Computed-Tomography in Fibrosing Alveolitis. American Review of 
Respiratory Disease 1993; 148(4):1076-82.
24 Mariani G, Boni G, Barreca M, Bellini M, Fattori B, AlSharif A et al. Radionuclide gastroesophageal 
motor studies Journal of Nuclear Medicine 2004; 45(6):1004-28.
25 Marie I, Levesque H, Ducrotte P, Denis P, Hellot MF, Benichou J et al. Gastric involvement in systemic 
sclerosis: A prospective study. American Journal of Gastroenterology 2001; 96(1):77-83.
26 Bhalla M, Silver RM, Shepard JAO, Mcloud TC. Chest Ct in Patients with Scleroderma - Prevalence 
of Asymptomatic Esophageal Dilatation and Mediastinal Lymphadenopathy American Journal of 
Roentgenology 1993; 161(2):269-72.
27 Ling TC, Johnston BT. Esophageal investigations in connective tissue disease - Which tests are most 
appropriate? Journal of Clinical Gastroenterology 2001; 32(1):33-6.
VI
Appearance self-esteem in 
systemic sclerosis: subjective 
experience of skin deformity 
and its relationship with 
physician-assessed skin 
involvement, disease status 
and psychological variables 
78
Chapter 6 
W.G.J.M van Lankveld1 
M.C. Vonk2 
H. Teunissen1 
F.H.J. van den Hoogen1,2.
Department of Rheumatology 1 St Maartenskliniek Nijmegen and 
2 Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. 
Rheumatology 2007;5;872-6
79
Appearance self-esteem in systemic sclerosis
Abstract
Objectives. To determine the importance of skin deformity in systemic sclerosis (SSc) relative to 
other disease stressors and to find psychological correlates of Appearance Self-Esteem (ASE) after 
controlling for disease status.
Methods. Disease-related stressors, symptoms, physical and psychological functioning, 
social support, coping styles, cognitions and ASE were assessed in 123 patients with SSc. A 
rheumatologist determined disease duration, SSc subtype, presence of organ involvement and 
skin-thickness scores. Stepwise hierarchical regression analysis of disease-related cognitions on 
ASE was performed after controlling for selected variables.
Results. Skin deformities proved a core stressor of the disease, only preceded by fatigue. 
Physician-assessed disease status, including modified Rodnan skin score, was unrelated to ASE. 
Sex, self-reported functioning and symptoms were related to ASE and used as control variables. 
Both acceptance and anxiety correlated strongly with ASE. The stepwise regression procedure 
only identified the disease-related cognition acceptance. 
Conclusions. In systemic sclerosis ASE proved unrelated to the extent of skin thickness. 
Psychological interventions aimed at boosting ASE should primarily target the psychological 
factors acceptance and anxiety. 
Introduction
Scleroderma or systemic sclerosis (SSc) is an autoimmune disease characterised by excessive 
accumulation of connective tissue in skin, muscles, joints and internal organs, most notably 
lungs, heart, kidneys and gut. The extent and course of the disease are widely variable. A 
distinction is made between limited cutaneous and diffuse cutaneous SSc, with diffuse SSc being 
the more severe subtype, distinguished by early, extensive skin thickening and internal organ 
involvement 1. The syndrome is highly distressing to the patient 2,3,4 as it has an impact on many 
dimensions of his or her life 5,6 including level of physical functioning 7,8 sexuality 9, employment 
opportunities 10, and life expectancy 11. 
The fibrotic process often affects the patients’ hands and face, a person’s most visible and socially 
relevant body parts, causing appearance to become one of their great concerns 5,12,13, with a vast 
majority of patients expressing concern about disfigurement 14. Disfigurements and alterations 
in body appearance may affect a person’s self-esteem, i.e. the overall feeling of self-worth 
someone develops in various social situations 15. Self-esteem pertaining to appearance, denoted 
as appearance self-esteem (ASE), thus reflects the subjective evaluation of one’s appearance 16 
and is often decreased in people with actual deformities like burn injuries 17. Women with SSc 
have been known to report an even lower ASE than burn patients 6 and low ASE in SSC has 
been related to impaired psychological functioning as expressed in depressive symptoms and 
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psychological distress 6,12,18. These serious consequences warrant an accurate identification of 
those factors that contribute to or underlie ASE.
Although mean ASE is decreased in SSc relative to that of healthy individuals, within SSc samples 
the extent of objective disfigurements or skin involvement proved largely unrelated to ASE 6,12. 
Studies in other conditions have shown that social support and coping styles correlate with 
ASE 17,19,20. As yet, no studies have been conducted to determine the relationship between these 
latter aspects and ASE in SSc. Furthermore, disease related cognitions attached to the condition 
should be considered as well. A condition like SSc and its accompanying skin deformities has 
a strong inherent negative or aversive connotation. Yet, patients can attach negative, neutral, 
or even positive cognitive connotations to the inherently negative condition 21. Such re-
evaluations, i.e. the use of disease-related cognitions, proved highly correlated to differences 
in psychological distress in SSc. The negative connotation of helplessness, for instance, was 
related to higher levels of depression 22, whereas attaching the neutral appraisal of control to the 
condition was associated with lower levels of depression 23. These findings suggest that attaching 
different cognitive connotations to the condition may also be crucial in explaining ASE variance 
between SSc patients with similar disfigurements. The one study that specifically looked into 
the relationship between cognitions and ASE found acceptance to be related to higher ASE 24. It 
needs to be noted that the study involved healthy students only and the findings have to date not 
been replicated in SSc, nor has the factor been studied relative to observed skin deformity, social 
support and coping styles.
To foster interventions aimed at improving ASE in patients with systemic sclerosis, we first need 
to identify the variables that underlie or contribute to the development of their perceptions and 
cognitions. With the current study we wished to determine the importance of the stressor skin 
deformity relative to other SSc-related stressors. We subsequently analysed the psychological 
correlates with the patients’ ASE after controlling for relevant demographic and disease-related 
variables. Based on the earlier finding in healthy subjects, we expected the disease-related 
cognition acceptance to also be associated with higher ASE in our patient population. 
Materials and methods
Sample
Participants were 138 patients with systemic sclerosis as diagnosed in accordance with the 
1980 preliminary classification criteria of the American College of Rheumatology 25 who were 
enrolled in a prospective follow-up study conducted by the Departments of Rheumatology of 
the Sint Maartenskliniek and the Radboud University Nijmegen Medical Centre in Nijmegen, 
The Netherlands. The study was approved by the local medical ethics committee and written, 
informed consent was obtained of all patients prior to their participation. 
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Procedure and measures
Demographic variables and disease status
All patients received a questionnaire by post with the request to complete the list and return it to 
the hospital. In an accompanying letter the purpose of the study was explained. They were also 
asked to indicate their sex, age, years of education, marital and work status. A rheumatologist 
(the 2nd author) had earlier assessed the patients within the context of our prospective follow-up 
with reference to the following variables: disease duration from the first sign of skin thickening, 
subtype of SSc (limited cutaneous versus diffuse cutaneous), degree of skin involvement, and 
involvement of internal organs. Degree of skin involvement was assessed using the modified 
Rodnan Skin Score (mRSS): in 17 places of the body the skin is taken between thumb and 
index finger and the folding of the skin is rated from 0 (no tethering) to 3 (serious tethering; 
26). Involvement of internal organs and muscles was assessed based on clearly defined criteria 
27-33, which are summarized in Table 1. Dichotomous yes/no scores were used to indicate the 
involvement of the various organs. 
Table 1  Definition of organ and muscle involvement
Organ system Involvement, if any, of
Heart Diagnosted by echocardiography: 
Diastolic dysfunction 
Ejection fraction < 50% 
Pericardial effusion  
Mean PAP > 25 mmHg
Lungs Fibrosis on chest X-ray  
Reticular pattern on HRTC-scan 
Ground glass appearance on HRCT-scan 
Pleural effusion 
TLC < 70% of predicted 
FEV1 < 70% of predicted  
DLCO < 70% of predicted
Gastrointestinal system Weight loss > 10% in the last 6 month 
Hypoalbuminaemia (< 30 g/l) 
Malabsorption (increased fecal fat, impaired xylose absorption and/or decreased serum iron 
and/or vitamine B12) 
Diarrhoea > 3 times a day
Kidneys Estimated Cockroft < 80 ml/min 
Proteinuria 
Urine analysis positive for blood 
Hypertension > 140/90
Muscles CK > 2 times upper limit of normal  
Proximal muscle weakness on physical examination
PAP: pulmonary arterial pressure, HRCT-scan: high resolution computer tomography scan, TLC: total lung capacity, FEV1: forced expiratory 
volume in first second, DLCO: total lung diffusion capacity, CK: creatine kinase
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Disease-related stressors
Patients completed a questionnaire comprising 18 items referring to 18 disease-related stressors 
that was an adaptation of an inventory of disease stressors used in previous research in patients 
with rheumatoid arthritis (RA) 34. To adapt it for SSc, the original 13 items were reviewed by two SSc 
patients, two rheumatologists and two psychologists. The following 5 items were added: shortness 
of breath, skin deformities, gastrointestinal problems, kidney complaints and incontinence. Patients 
rated each stressor on a 4-point scale from 1 ‘not annoying at all’ to 4 ‘very annoying’. 
Appearance self-esteem (ASE)
The patients rated their ASE on the 6-item Appearance subscale of the State Self-Esteem Scale 15 
based on a 5-point Likert scale ranging from ‘not at all’ 1 to ‘extremely’ 5. The range of total possible 
scores ranges from 6 to 30, with higher scores depicting higher levels of ASE. The subscale had 
been used in an SSc sample before and appeared to be a reliable and valid instrument for the 
SSc population 18. 
Physical Functioning and Symptoms
The Scleroderma Health Assessment Questionnaire (SHAQ) was used to measure the patients’ 
physical functioning and symptoms 35. The first part of the SHAQ consists of the original Health 
Assessment Questionnaire Disability Index (HAQ-DI) as developed by Fries in 1982 for use in 
patients with RA 36. The HAQ-DI has good reliability and validity in patients with SSc 35,37,38. It 
comprises 20 items measuring the following eight functions: dressing and grooming, arising, 
eating, walking, personal hygiene, reach, grip strength, and activities. The scores range from 
0 (best function) to 3 (worst function). A patient’s mean score for the eight HAQ-DI functions 
was used to indicate overall physical functioning. Symptoms of SSc were assessed using six 
Visual Analogue Scales (VAS) gauging pain, gastrointestinal tract involvement, lung involvement, 
Raynaud’s phenomenon, digital ulcers, and patients’ perceived overall disease severity. For the 
present study we added a VAS to assess fatigue. 
Psychological distress
The ‘Depressive Mood’ and ‘Anxiety’ scales of the Dutch Impact of Rheumatic Diseases 
on General Health and Lifestyle (IRGL) were used to assess psychological distress 39. In the 
Netherlands, the IRGL is a well-accepted instrument to assess physical, psychological and 
social functioning in patients with rheumatologic conditions. The 6-item Depressive Mood scale 
measures the patient’s mood in the previous week using a 5-point Likert scale ranging from ‘not 
at all’ to ‘a lot’. The 10-item Anxiety scale measures anxiety in the previous month on a 4-point 
Likert scale ranging from ‘almost never’ to ‘almost always’.  
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Social support
Two other IRGL scales assessed Potential Support (5 items) and Actual Support (3 items) both 
rated on a 4-point Likert scale. An example of an item of the former scale reads “When I am 
in pain, there is someone to support me” and an example of the latter “I discus problems with 
others”.
Coping
Patients completed the Utrecht Coping Scale (UCL) 40 to assess the following six coping styles: 
Active coping, Comforting cognitions, Seeking social support, Avoidance, Expression of emotions 
and Palliative reaction. We left out one subscale of the UCL because of its conceptual overlap 
with depression and depressive mood.
Cognitive evaluations (Cognitions)
The 18-item Illness Cognitions Questionnaire (ICQ) 21 measures three generic illness cognitions, 
i.e. cognitive connotations attached to the condition: Helplessness, Acceptance, and Disease 
Benefits. The three constructs reflect the values associated with the cognitive evaluation. 
Helplessness emphasizes the negative values of the stressor, acceptance diminishes the adverse 
meaning and disease benefits confers a positive meaning to the stressor. Examples of the latter 
are positive personality changes, changes in life priorities and stronger personal relationships. 
The items are rated on a 4-point Likert scale and the ICQ has excellent construct and internal 
validity 21.
Statistical Analysis
The sample’s ASE-score dispersion was tested with the Kolmogorov-Smirnov test for normality. 
Between-group differences were tested by means of T-tests for independent samples, or an 
ANOVA. Associations between numerical variables are expressed in Pearson correlations. 
For groups of variables, multiple correlations (R2s) with ASE were computed to determine the 
degrees of variance explained. Because we used pairwise exclusion of missing values in our 
calculations, the degrees of freedom could vary slightly. Demographics, disease status, physical 
function and symptom variables with significant Pearson correlations with ASE were selected for 
further analysis. These variables were used first as controls in a stepwise regression analysis with 
ASE as the dependent variable. Psychological variables with significant Pearson correlations with 
ASE were entered next, again following a stepwise procedure. For each R2 the F-change statistics 
and its degrees of freedom are given. For the variables entered into step 2 of the regression 
analysis standardized Beta coefficients were computed to provide an indication of the relative 
importance of the variables in this second step. For all statistical analyses the Statistical Package 
Social Sciences, version 9.1 was applied and significance levels were set at p < .05. 
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Results
Of the 138 patients that were approached, 123 patients returned a completed questionnaire 
(89%). Table 2 lists the patients’ demographics and disease characteristics.
Table 2  Patient characteristics (n=123).
Mean age in years 54.3  (SD =12.9; range = 20-77)
Number of Women 84  (68.0%)
Education 
 < 9 years 
 9-14 years 
 15-17 
 > 18
 
11  (9.0%) 
87  (71.0%) 
18  (14.5%) 
6  (4.9%)
Work status 
 Employed or housekeeping 
 Social benefit 
 Retired
 
64  (51.0%) 
34  (27.2%) 
24  (18.4%)
Marital status  
 Single 
 Married/Cohabiting 
 Widowed
 
20  (16.0%) 
93  (76.0%) 
10  (8.0%)
Mean duration of the disease in years 10.6  (SD=9.7; range = 1-58)
Disease status 
 Patients with limited SSc 
 Mean mRSS 
 Number of organs involved
 
87  (71%) 
9.9  (SD=7.6; range 0-44) 
1.5  (SD=0.7; range = 1-5)
The majority of patients were married, middle-aged women and half of the patients (51%) was 
employed, studying or active in the home. The majority of patients (71%) had limited cutaneous 
SSc. Oesophageal involvement was observed in 90% of the patients and lungs were affected 
in 41% of the patients. Other organ involvement was far less common (heart 9%, kidneys 5%, 
intestines 4%, muscles 4%). No organ involvement was reported for 5 patients (4.2%) only.
Distribution on the ASE was normal, with a mean score of 19.1 (SD = 3.9), which was similar to 
the mean score reported for another SSc sample 18. Internal consistency of the scale in this sample 
was good (Cronbach’s alpha = .71). Next, the relationship between demographics and disease 
status on the one hand and ASE on the other was analysed. Gender was the only demographic 
variable that proved related to ASE. The male patients reported higher levels of ASE than the 
female patients (mean scores 20.3 and 18.5, respectively; T (119) = 2.35, p < .05). The physician-
assessed disease-status variables were all unrelated with ASE. Comparing mean scores on ASE for 
both SSc subtypes did not show significant differences (average scores for limited and diffuse SSc 
respectively 19.1 and 19.0), while mRss and number of organs involved did not show significant 
correlations with ASE.
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The means and standard deviations (SD) for the self-reported disease status measures are depicted 
in Table 3. Univariate pearson correlations were computed between physical functioning and 
disease-symptom variables on the one hand and ASE. 
Table 3  Sample descriptives of physical functioning and disease symptoms and their univariate association with ASE
Mean (SD) r
Physical functioning (HAQ-DI)  
 Dressing and grooming 
 Getting up 
 Eating 
 Walking 
 Hygiene 
 Reach 
 Grip strength 
 Activities
 
1.0  (0.9) 
0.6  (0.7) 
1.1  (0.9) 
0.8  (0.9) 
1.1  (1.0) 
1.0  (0.9) 
0.9  (0.8) 
1.4  (1.0)
- 
0.36** 
-0.32** 
-0.43** 
-0.27** 
-0.20* 
-0.48** 
-0.40** 
-0.29**
Disease symptoms (VAS) 
 Pain 
 Intestines 
 Breath 
 Raynaud’s phenomenon 
 Digital ulcers 
 Disease severity 
 Fatigue
 
3.4  (2.7) 
1.8  (2.2) 
3.3  (3.1) 
4.3  (3.1) 
3.0  (3.4) 
4.0 (2.6) 
4.5  (2.7)
 
-0.20* 
-0.14 
-0.17 
-0.22* 
-0.16 
-0.37** 
-0.40**
r = Pearson correlation; *p < .05, ** p < .01 
Mean HAQ-DI for all 8 scales was 0.98 (SD = 0.70). All 8 HAQ-DI scales showed significant 
negative correlations with ASE, demonstrating that higher levels of limitations were related to 
lower levels of ASE. The correlation between mean HAQ-DI and ASE was –0.44 (P < .01). A 
multivariate regression analysis showed that the eight HAQ-DI scales together explained 28% of 
the variance in ASE ( R2=.28; F = 5.28; df = 8,109; p < .001).
As regards disease symptoms, fatigue was the symptom with the highest mean VAS scores. 
Individual symptom VAS scores for pain, Raynaud’s phenomenon and fatigue all had significant 
negative correlations with ASE. The VAS for disease severity showed similar negative correlations 
with more and severer symptoms and perceived disease severity being related to lower ASE. 
Together, the seven symptom scales explained 18% of the variance in ASE (R2=.18; F = 3.37; df 
= 7,110; p < .01).
To determine the relative weight of skin deformities in comparison with other disease-related 
stressors, we obtained a rank ordering for the main stressors of SSc in our sample. Table 4 shows 
the distribution of the scores on the stressors with a mean score equal to or exceeding 2 (i.e. a 
mean rating of at least ‘a little annoying’). Items are ranked based on their mean score from most 
annoying to least annoying. Frequencies and percentages for each of the four categories for each 
item are given. 
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Table 4  Distribution of scores on the disease-related stressors (n=123)
Mean1 N(%)
1# 2 3 4
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10.
Fatigue 
Limitations 
Skin deformities 
Pain 
Disfigurement 
Dependency on others 
Shortness of breath 
Being misunderstood by others 
Fear for the future 
Changes in the work situation
3.07 
2.89 
2.89 
2.55 
2.49 
2.49 
2.32 
2.22 
2.06 
2.02
10  (8) 
8 (7) 
12 (10) 
21 (17) 
29 (24) 
31 (25) 
37 (30) 
27 (22) 
37 (30) 
55 (45)
24 (20) 
38 (31) 
34 (28) 
40 (33) 
34 (28) 
30 (23) 
35 (29) 
49 (40) 
43 (35) 
21 (17)
36 (29) 
37 (30) 
33 (27) 
35 (29) 
30 (24) 
33 (26) 
26 (21) 
36 (29) 
23 (18) 
14 (11)
53 (43) 
40 (33) 
44 (36) 
27 (22) 
30 (24) 
29 (24) 
25 (20) 
11 (9) 
20 (16) 
24 (20)
# 1 = not annoying at all; 2 = a little annoying; 3 = rather annoying; 4 = very annoying.
Fatigue proved the most annoying SSc stressor, closely followed by limitations and skin 
deformities. Patients thus rated skin deformities as more annoying than pain. Only 12 of the 
123 patients reported to find skin deformity not in the least annoying. The patients with different 
scores on the single item assessing annoyance with skin deformity differed in mean ASE scores. 
The mean scores for the group of patients rating skin deformity as not annoying at all = 22.2; 
a little annoying = 19.9; rather annoying = 19.2; very annoying = 17.5 (ANOVA for difference 
between groups F = 5.8; df = 3, p < .001). As might be expected, higher levels of annoyance 
with skin deformity assessed using 1 item is strongly related with lower ASE assessed using the 
six item scale. 
The stressors depressed mood, feeling judged by others, problems with bowels, side effects of the 
medication, social isolation, changes in financial situation, incontinence, and kidney problems 
all had mean scores below 2 (i.e. rated as ‘not annoying’). 
As to the relationship between psychological variables and ASE, again, pearson correlations were 
computed between individual indices of psychological functioning, social support, cognitions, 
and coping on the one hand and ASE on the other. Table 5 shows the mean scores for each 
individual variable and pearson correlations with ASE, as well as multiple correlations for groups 
of variables with ASE. 
Psychological functioning and cognitions showed strong multivariate associations with ASE, 
explaining 19% and 20% of ASE the variance, respectively. Social support and coping explained 
8% and 13% of the variance, respectively. Together, the psychological variables explained 
31% of ASE variance (R2 change = .31, F change = 3.2, df = 14,101 , p < .01). The univariate 
indicators of psychological functioning have significant inverse correlations with ASE. Although 
depression and anxiety were highly intercorrelated (r = .76), anxiety proved more strongly 
correlated with ASE than depressed mood. Two of the three disease cognitions had significant 
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univariate associations with ASE, with higher helplessness scores being related to lower ASE 
and higher levels of acceptance with higher levels of ASE. Disease benefits were unrelated to 
ASE. The correlations for individual social support and coping indices were weaker. Only higher 
levels of potential support and an active coping style were significantly associated with higher 
levels of ASE. 
Table 5  Univariate correlations of psychological variables with ASE, and multivariate relations between psychological 
functioning, social support, cognitions and coping styles and ASE
Mean (SD) r R2
Psychological functioning 
 Depressed mood 
 Anxiety
 
4.6  (4.5) 
20.15  (6.2)
 
-0.30** 
-0.44**
0.19**
Social support 
 Potential support 
 Actual support
 
15.3 (4.1) 
6.7  (1.8)
 
0.28** 
0.17
0.08**
Cognitions 
 Helplessness 
 Acceptance 
 Disease benefits
 
13.4  (4.6) 
15.3  (4.3) 
14.5  (4.0)
 
-0.39** 
0.44** 
0.15
0.20**
Coping styles 
 Active coping 
 Comforting cognitions 
 Seeking social support 
 Avoiding 
 Expression of emotion 
 Palliative reaction
 
17.6  (3.6) 
13.5  (2.6) 
12.8  (3.3) 
16.3 (3.1) 
6.0  (1.8) 
17.6  (3.6)
 
0.23* 
-0.07 
0.16 
-0.17 
0.16 
-0.07
0.13**
R2 = Multiple correlation; r = Pearson correlation; *p < .05, ** p < .01 
A multiple regression analysis entering those psychological variables showing significant Pearson 
correlations with ASE revealed that, together, the six variables explained 28% of the variance in 
ASE (F-change = 7.03, df 6,110, p < .001). In a stepwise procedure acceptance was selected first 
and anxiety second. Together, the two variables explained 23% of the variance with almost equal 
but reversed Standardized Coefficients Beta (.27 and -.25, respectively). The same procedure was 
repeated while controlling for sex, HAQ-DI and the VAS scores for pain, Raynaud’s phenomenon, 
disease severity and fatigue. When these variables were forced into the equation at step 1 of the 
regression analysis they explained 28% of the ASE variance (F-change = 6.87, df 6,106, p < 
.001). Acceptance and anxiety were entered in a stepwise procedure at step 2. Only acceptance 
explained an additional 7% of the variance in ASE (F-change = 12.06, df = 1,105, p < .001).
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Discussion
Most of our patients with systemic sclerosis (SSc) perceived skin deformity as annoying, making 
skin deformity the second main stressor of the disease, only preceded by fatigue. The patients’ 
appearance self-esteem (ASE) was decreased to the same level as reported in another SSc study 
18. Also consistent with previous research, our female patients reported significantly lower levels 
of ASE than their male counterparts 12,18. In our sample ASE proved unrelated to disease-status 
variables, including the extent of skin involvement as assessed by the rheumatologist. Although 
previous studies had reported weak associations between self-assessed skin thickening and ASE 
6,12, in both studies ASE was largely unrelated to objectively-assessed skin thickening.
Self-reported functioning was related to ASE, confirming previous findings 12. Possibly, an impaired 
physical functioning in terms of difficulties in performing daily activities, for instance, may intensify 
the patient’s focus on the disease and its negative consequences, in particular appearance. The 
same might be true for the observed correlations between ASE and the self-assessed symptoms 
of pain, Raynaud’s phenomenon, perceived disease severity and fatigue. As fatigue was judged 
the most annoying symptom showing the strongest correlation with ASE, a separate VAS scale 
measuring this symptom proved an important addition to the other six SHAQ scales.
Individual social support and coping indices showed weak but significant correlations with 
ASE. Comparable to previous research in burn patients 19, social support was marginally related 
to higher levels of reported ASE explaining approximately 8% of the variance. When other 
psychological variables were considered simultaneously social support no longer remained 
associated with ASE. The relationship between active coping and ASE was even weaker and 
most coping styles being unrelated to ASE. Our findings thus seem to support the notion that, as 
patients cannot control skin involvement by their coping behaviour, ASE is more dependent on 
their ability to cognitively re-evaluate their situation.
Both the disease-related cognitions helplessness and acceptance showed strong correlations with 
ASE. In the final analysis acceptance was the psychological variable most strongly associated 
with ASE, showing a higher Beta coefficient than any other of the psychological variables. Earlier 
studies among students had already demonstrated the importance of acceptance in ASE 24. In 
SSc, a patient’s ASE is thus primarily related to his or her ability to attach connotations to a 
stressful event that diminish its aversive meaning 21. Although highly correlated with ASE, after 
controlling for acceptance anxiety did not add to the proportion of explained variance in ASE. 
In our sample the ASE associations of anxiety and acceptance were similarly strong and highly 
intercorrelated (r = -.69), suggesting that patients reporting high levels of anxiety are unlikely to 
attach positive connotations to their disease. Interventions aimed at improving ASE in SSc should 
hence focus on the patients’ acceptance as well as their anxiety. 
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Of course, the ASE scale we used in this study has not been widely applied to assess ASE in 
SSc or in other chronic diseases. Although it did show good internal consistency in our sample, 
equalling that reported by Malcarne et al. 18, additional studies are needed to confirm the 
scale’s validity and reliability in chronic diseases. Another limitations of this study is that no 
data are available on the 15 subjects that were approached for the study but failed to return the 
questionnaire. Therefore, a non-response effect in this sample can not be ruled out.
Moreover, the correlational nature of our study prevents causal conclusions. It cannot be ruled out 
that the causal roles of social support and coping styles in the process of the patients’ cognitive 
evaluations of their situation and in shaping ASE are more pronounced than has become apparent 
from our approach. Longitudinal studies should determine whether patients who do not feel 
supported by their social network or whose coping efforts are ineffective are more anxious and 
experience more difficulties in coming to terms with their skin deformities.
Despite the study’s limitations, our findings have several implications for the evaluation and 
treatment of SSc. Firstly, objectively-assessed skin involvement can not be seen as an indication of 
decreased ASE. Rather, ASE should be assessed in each SSc patient independently and only those 
patients whose ASE is substantially diminished should be eligible for treatment aimed at raising 
ASE. Secondly, as strong correlates of ASE, anxiety and acceptance are likely psychological focal 
points in treatment. Cognitive-behavioural techniques should be considered that train patients 
to replace the negative connotations of their condition with more neutralizing connotations to 
help them reduce their anxiety and boost their ASE. Again, it will require longitudinal research 
and randomly controlled trials to determine whether changing disease-related cognitions like 
acceptance will have a causal effect on ASE in this population.
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Abstract
Objective: To assess the accuracy of echocardiography for predicting pulmonary arterial 
hypertension (PAH) in a cohort of patients with systemic sclerosis and other connective tissue 
diseases, and to evaluate whether addition of the right ventricular (RV) Tei-index contributes to 
the non-invasive diagnosis of PAH in this patient group.
Patients and methods: Ninety-eight patients with systemic sclerosis and other connective tissue 
diseases in whom an echocardiography was performed in the period from January 1st 2004 to 
July 1st 2005 were included. Echocardiographic systolic pulmonary arterial pressure (PAP), end-
diastolic PAP and RV Tei-index were calculated. In cases with a high suspicion of PAH right heart 
catheterization was performed and systolic, diastolic and mean PAP as well as pulmonary wedge 
pressure, cardiac output and pulmonary vascular resistance were obtained. These results were 
compared to the echocardiographic measurements.
Results: The average RV Tei-index of our patients was substantially above normal values. In 
35 (36%) patients a right heart catheterization was performed and PAH was confirmed in 28 
patients. In 6 of 7 patients without PAH, the RV Tei-index was below the upper limit of normal. 
A significant correlation was found between the RV Tei-index and the catheterization parameters 
such as systolic PAP, diastolic PAP and mean PAP.
Introduction
Pulmonary arterial hypertension (PAH) is a life-threatening complication of autoimmune 
disorders, especially systemic sclerosis (SSc) 1. PAH is defined as a mean pulmonary artery 
pressure (PAP) of > 25 mmHg at rest or > 30 mmHg during exercise, measured during right 
heart catheterization (RHC) 2. The symptoms of PAH are non-specific, and are therefore often 
overlooked. This is especially true in patients with SSc, who are already limited in their activities 
by fatigue and other complications of their condition 3. The prevalence of PAH in SSc patients is 
estimated between 12% and 29% in catheterization-based studies 4;5. Since effective treatments 
have become available, screening for PAH in patients with SSc on a yearly basis is recommended 
1. PAH is suspected when a patient reports dyspnea at exertion, when pulmonary function testing 
reveals an isolated decrease in diffusion capacity of the lungs, and/or the echocardiographic 
criteria for PAH are met 3. These criteria consist of an estimated PAP ≥ 35 mmHg and/or an 
estimated mean PAP ≥ 25 mmHg 2. Because echocardiographic results are flawed by both false 
positive and false negative results RHC is necessary to confirm the diagnosis of PAH and to 
exclude other forms of pulmonary hypertension 6. To avoid unnecessary RHCs, the diagnostic 
potentials of echocardiography must be fully utilized. 
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As shown in Figure 1, the myocardial performance index, also known as Tei-index, is defined as 
the sum of the isovolumic contraction and isovolumic relaxation time divided by ejection time, 
and thus incorporates elements of both systolic and diastolic phases in the assessment of global 
ventricular function 7;8. 
Figure 1  Scheme for meassurement of the RV Tei-index. The index is defined as the isovolumetic contraction time (ICT) and 
isovolumetic relaxation time (IRT) divided by the ejection time (ET). 
Addapted with permission of C Tei et al, JACC 1996;28:658-664
The Tei-index can be estimated for both the left ventricle (LV) and the right ventricle (RV). An 
increased Tei-index results from ventricular dysfunction, provides prognostic information for a 
variety of myocardial conditions. The RV Tei-index is a candidate to increase the non-invasive 
diagnosis of PAH because it reflects the RV function, is easy to assess, and can be estimated in the 
same session as the echocardiographic PAP. The normal value of the RV Tei-index is 0.28 ± 0.04 
7. An increased RV Tei-index is associated with either LV diastolic abnormalities or pulmonary 
hypertension 9;10. In this study we assessed the accuracy of echocardiography for predicting PAH 
in a cohort of patients with SSc and other connective tissue diseases (CTD) and determined 
whether the RV Tei-index can be used as a tool to increase the accuracy of echocardiographic 
measurements for the detection of PAH in these patients.
Patients and Methods
Ninety-eight patients with CTDs, in whom echocardiography was performed from January 1st 2004 
to July 1st 2005, were included in this study. The majority of the patients had SSc (n=91, 93%), the 
other diagnoses were mixed connective tissue disease (n= 3, 3%), systemic lupus erythematosus 
( n=2, 2%), and undifferentiated connective tissue disease (n=2, 2%). Echocardiography is part 
of the yearly screening protocol for PAH in our cohort of patients with SSc 11. The characteristics 
of the patients are shown in table 1. 
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Table 1  Patient characteristics of study population (n=98)
Mean age (±SD) years 58  (± 13)
Male : Female 31 : 67
Mean duration (±SD) of CTD (years) 8.5  (± 7.1)
% SSc: other CTD 93 : 7 
% dcSSc: lcSSc 21 : 79 
Mean echo systolic PAP (± SD) (min-max) 55.7 mmHg  (± 20.9) (21-106)
Mean echo diastolic PAP (± SD) (min-max) 17.7 mmHg  (± 9.0) (2-39)
Mean echo mean PAP (± SD) (min-max) 30.7 mmHg  (± 11.0) (10-53)
Mean % predicted vital capacity (± SD) (min-max) 87.5 (± 24.8) (31-137)
Mean % predicted CO diffusion capacity (± SD) (min-max) 51.6  (± 19.4) (17-116)
% NYHA class 1-2 : 3-4 67 : 33
CTD: connective tissue disease; dcSSc: diffuse cutaneous systemic sclerosis; lcSSc: limited cutaneous systemic sclerosis; NYHA class: the 
degree of functional disability, based on exercise performance, according to the New York Heart Association (NYHA) criteria; PAP: pulmonary 
artery pressure.
Echocardiography
All echocardiographics were performed by the same cardiologist who was only aware of 
the diagnosis CTD, but not of other clinical aspects of the patients. Using the GE Vivid 7.0 
(second harmonic imaging; 1,7/3,4 MHz), the RV Tei-index was calculated with Doppler-
echocardiography in all patients as previously described 7. Echocardiographic systolic PAP was 
calculated from the tricuspid regurgitation-velocity and right atrium pressure estimation 12. End-
diastolic PAP was estimated by using end-diastolic pulmonalis regurgitation-velocity and right 
atrium estimation. By applying a regression equation the mean PAP was calculated from the RV 
acceleration time and ejection time ratio. 
Right heart catheterization
In 35 cases, all with an echocardiographic systolic PAP ≥ 35 mmHg, an RHC was performed. 
During RHC systolic, diastolic and mean PAP and pulmonary wedge pressure were measured. 
Thermo dilution cardiac output was established, and pulmonary vascular resistance was 
calculated. The latest echocardiography available prior to the RHC was used for comparison of 
the PAP values. 
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Statistical analysis
For descriptive statistics the mean ± SD was calculated. Prevalence for the echocardiographic 
diagnosis of PAH based on the systolic threshold, elevated RV Tei-index, and a combination 
of those two were calculated. We compared continuous variables using Student’s t test. The 
correlation between hemodynamic variables, echocardiographic estimates of hemodynamics 
and the RV Tei-index was calculated using Spearman’s rho. P-values < 0.05 were considered 
statistically significant.
Results
Echocardiography versus right heart catheterization
Thirty-five of the 98 patients (36%) met the echocardiographic threshold of systolic PAP ≥ 35 
mmHg; in these patients an RHC was performed. The echocardiographically calculated systolic 
PAP values appeared to be significantly higher than the values measured during RHC (60.7 
mmHg ± 18.2 mmHg vs. 55.1 mmHg ± 21.3 mmHg (mean ± SD; p <0.001)). However, the 
diastolic PAP values of RHC were significantly higher than the values of echocardiography (19.9 
mmHg ± 8.2 mmHg vs. 23.5 mmHg ± 9.2 mmHg; p = 0.04).
Tei-index 
In 2 out of 98 patients the RV Tei-index could not be determined for technical reasons. The RV 
Tei-index in our patient population was 0.33 ± 0.20 (mean ± SD), which differs substantially 
from the normal value: 0.28 ± 0.04 7.The RV Tei-index was above the upper limit of normal (95% 
CI of normal value 0.20-0.36) in 41 of 96 (43%) of our patients.
Tei-index and echocardiographic systolic PAP
RHC confirmed the echocardiographic suspected PAH in 28 of the 35 (80%) examined patients. 
of the RV Tei-index was evaluated in these patients. Using the systolic threshold of ≥ 35 mmHg 
the correlation of the systolic PAP with the RV Tei-index was significant (r=0.46; p=0.01). When 
raising the systolic threshold, this did not change.
Tei-index and catheterization variables
The mean RV Tei-index of the catheterized patients was 0.41 (± 0.21). In an attempt to improve 
the accuracy of the echocardiography for PAH in patients with SSc an RV Tei-index > 0.36 was 
combined with the systolic threshold. Table 2 shows that by doing so the prevalence of PAH 
as confirmed by RHC was raised to 95% (19/20 patients). However, in 9 patients with PAH at 
RHC, the RV Tei-index was ≤0.36. In 6 out of 7 patients with a negative RHC, the RV Tei-index 
was ≤ 0.36. Therefore, a combination of RV Tei-index and echocardiographically systolic PAP 
has a higher predictive value for diagnosing PAH at RHC than the systolic threshold alone. 
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When comparing the RV Tei-index with other parameters such as the systolic, diastolic, and 
mean PAP measured during catheterization, the correlation is constantly significant. However, 
no correlation was found with pulmonary vascular resistance measured during catheterization 
(r=0.33, p=0.08). In the 35 patients with RHC, the correlation of the mean PAP measured during 
RHC and RV Tei-index was the strongest (r=0.46, p=0.01) (Figure 2).
Table 2  Combination of echocardiografic estimated systolic PAP ≥ 35 mmHg and RV Tei-index with PAH diagnosis at RHC
PAH confirmed PAH not confirmed Total (N)
Tei > 0.36 (N) 19 1 20
Tei ≤ 0.36 (N) 9 6 15
Total (N) 28 7 35
Figure 2  Correlation of mean PAP measured during right heart catheterization and RV Tei-index
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Discussion
This study shows that the mean RV Tei-index in a cohort with CTD differs substantially from the 
normal value in literature. The RV Tei-index was elevated in 43% of the patients, suggesting RV 
dysfunction. This finding confirms earlier findings of asymptomatic diastolic RV dysfunction in 
40% of patients with SSc 9. The RV Tei-index is elevated due to an increased pulmonary vascular 
resistance, and a decreased myocardial contraction 13. Thus, in patients with PAH the RV Tei-
index is expected to be above the normal range. In our patients with a RV Tei-index > 0.36 PAH 
was confirmed by RHC in all but one case. This case provided a diagnostic dilemma, an RHC, 
also during exercise, was negative twice in a 6 months period. 
When combining the systolic threshold with the RV Tei-index > 0.36, the predictive value of 
echocardiography for PAH increases. Using the echocardiographic systolic PAP ≥ 35 mmHg 
we found a prevalence of PAH of 80% . This result confirms earlier findings 1. In daily clinical 
practice an echocardiografic systolic PAP ≥ 35 mmHg is used as a preliminary diagnosis of PAH. 
As has been shown before, we found that the echocardiographically systolic PAP is significantly 
higher than the values found by RHC 1. For the diastolic PAP we found the opposite. So, 
echocardiography overestimates the systolic PAP and underestimates the diastolic PAP, which 
results in an overestimation of the mean PAP. This leads to unnecessary RHCs. As accuracy 
of echocardiography alone is not optimal, the combination of clinical evaluation, calculated 
systolic and mean PAP should determine whether or not an RHC has to be performed. Also in our 
study negative catheterizations occurred in 7 out of 35 patients (20%), underlining the necessity 
of increasing the diagnostic potential of echocardiography to select patients at risk without 
increasing the number of undiagnosed patients. The RV Tei-index is easy to assess and has a low 
inter- and intraobserver variability. It could therefore be used as an additional screening tool 
for PAH. Other promising echocardiographical techniques, such as tissue Doppler and contrast 
echocardiography can perhaps contribute to the accuracy of echocardiography, but their values 
have yet to be established. The RV Tei-index correlated significantly with hemodynamics, but no 
significant correlation was found with the pulmonary vascular resistance. In theory, an elevated 
RV Tei-index should be the result of either diastolic dysfunction of the LV, of RV dysfunction, 
or of elevated pulmonary vascular resistance. The fact that the correlation was not significant 
might be caused by the small number of patients with an RHC. We did not analyze the influence 
of medication but in previous studies we found no impact of calcium channel blockers or 
immunosuppressive agents for the occurrence of PAH 14;15
 In total 9 patients had an RV Tei-index ≤ 0.36 but a positive echocardiogram and catheterization 
for pulmonary hypertension. The patients’ characteristics of this group were not different from 
the patients with a positive echocardiogram, catheterization and RV Tei-index > 0,36. The 
results of this study might be biased by the fact that we only performed RHC in cases when the 
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echocardiographic criteria for pulmonary hypertension were met. This resulted in small numbers. 
Furthermore, the echocardiography and RHC were not performed simultaneously. As the natural 
variability of PAP and pulmonary vascular resistance can be as high as 13% 16 some blurring of 
the findings could be the result. 
Conclusion
Echocardiography is a useful screening tool for PAH. The accuracy of echocardiography for 
predicting PAH might increases when the systolic PAP threshold of ≥ 35 mmHg is combined 
with an RV Tei-index > 0.36. Thus, in patients with SSc the combination of an increased systolic 
PAP and an increased RV Tei-index should prompt RHC. Further development of a combination 
of reliable, non-invasive tests to improve the pretest probability of PAH should be investigated in 
order to reduce the number of negative RHCs without missing cases of PAH.
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Abstract
Introduction: The six minute walk test (6MWT) is a reproducible sub maximal exercise test that 
has been found to be an independent predictor of mortality in pulmonary arterial hypertension 
(PAH). To date, the 6MWT has not been validated in systemic sclerosis (SSc). The objective of 
our study was to determine the 6MWT distance in SSc patients compared to expected values 
in healthy subjects and to determine differences in groups of SSc patients with and without 
pulmonary complications.
Methods: In 184 prospectively followed SSc patients a 6MWT, pulmonary function tests and 
echocardiography were performed.
Results: The median 6MWT distance was 429 m, which was significantly lower than the 
expected value of 557 m. After dividing the patients into 4 diagnosis groups, namely no 
pulmonary involvement, pulmonary fibrosis without pulmonary hypertension (PH), fibrosis and 
PH, and PAH, we found a decreased 6MWT distance in all groups. The lowest value of the 
6MWT was present in patients with fibrosis and PH, followed by patients with PAH. Significant 
correlations of the 6MWT were found with various pulmonary function test results, but not with 
auto antibodies, disease duration or anaemia.
Conclusion: The 6MWT results are significantly lower in patients with SSc compared to healthy 
subjects. The impairment of the exercise capacity as measured by the 6MWT is most apparent in 
SSc-patients with pulmonary fibrosis and PH, but also present in scleroderma patients without 
pulmonary involvement.
Introduction
Systemic sclerosis (SSc, scleroderma) is an autoimmune connective tissue disease characterised 
by vascular lesions, induration and thickening of the skin, and fibrotic changes in internal 
organs 1;2. The mortality of SSc is high with a 5-year mortality rate of at least 30% 3. The leading 
cause of disease-related mortality is pulmonary involvement consisting of pulmonary fibrosis 
with or without pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH) 4;5. 
Depending on the method of identification, pulmonary fibrosis is prevalent in up to 40% of 
the patients, whereas the prevalence of PAH is 12% 4;6. Recently, two studies have shown that 
cyclophosphamide has a significant though clinically modest effect on pulmonary fibrosis in SSc 
patients 5;7. Furthermore, several treatments that successfully delay the progression of idiopathic 
PAH such as epoprostanol, treprostinil, bosentan, sitaxentan, and sildenafil have become 
available 8-12, although their efficacy in SSc-associated PAH still needs to be defined. Evaluation 
of the different treatment options usually consists, among others, of “time to clinical worsening” 
and six minute walk test (6MWT) distance. The 6MWT is a reproducible, safe and simple sub 
maximal exercise test that can be used to evaluate exercise limitation in patients with cardiac 
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and pulmonary diseases 13. In patients with PAH, the 6MWT distance has been recognised as 
a strong and independent predictor of mortality 14. To date, however, the 6MWT has not been 
validated in SSc. Normal values derived from healthy American volunteers between 40 and 80 
years of age, based on height, weight, age and gender, are used as gold standard to compare 
the measured values in patients 15. Recently, Buch and co-workers found that the 6MWT is 
reproducible in patients with scleroderma related pulmonary fibrosis, but no information is 
available on scleroderma patients without pulmonary complications or patients with PAH 16. 
Besides pulmonary complications, limitation of exercise capacity in SSc patients can be caused 
by cardiac involvement, deconditioning, fatigue and anaemia 17;18. Although these aspects have 
not been studied intensively in SSc, it is likely that they also cause lower 6MWT results compared 
to normal subjects. 
The main objective of our study was to determine the 6MWT distance in SSc patients compared to 
expected values from the healthy population and to determine differences in the 6MWT distance 
in groups of SSc patients with and without pulmonary complications. Also, we evaluated whether 
the 6MWT distance correlated with pulmonary function test results, SSc specific variables, age 
and organ complication associated parameters.
Patients and Methods
All adult patients with SSc, fulfilling either the preliminary American College of Rheumatology 
classification criteria 19 or the LeRoy criteria for early SSc 20 prospectively followed at the 
Radboud University Nijmegen Medical Centre and St Maartenskliniek Nijmegen were asked 
to perform a 6MWT in the period between January 1st 2006 and January 1st 2007. Patients with 
diffuse cutaneous SSc (DcSSc) and limited cutaneous SSc (LcSSc) were included. The 6MWT was 
performed according to the guidelines of the American Thoracic Society 13. Pulmonary function 
tests were performed on the same day. The echocardiography with estimation of the systolic 
pulmonary arterial pressure (sPAP) and high-resolution computed tomography (HRCT-scan), 
to evaluate the presence of interstitial pulmonary involvement, were all performed within 2 
months of the 6MWT. In those cases where the echocardiography revealed an estimated systolic 
pulmonary arterial pressure (PAP) ≥ 35 mmHg, or when other signs of pulmonary hypertension 
were found, a right heart catheterisation, the gold standard to diagnose PAH, was performed 21. 
A diagnosis of PAH was established when at right heart catheterisation the mean PAP was > 25 
mmHg at rest with a normal wedge pressure, ruling out left sided heart disease 22. To investigate 
the origin of PH, a complete evaluation for those patients was performed, as described before 
23.
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For the assessment of pulmonary interstitial disease, the HRCT-scan was scored at three levels: 
namely the midarch of the aorta, the main carina and 1 cm above the diaphragm. Both fibrosis 
and ground glass opacity (GGO) were graded between 0% to > 75% of the pulmonary surface, 
providing a score between 0 and 5, left and right lung scores were averaged, resulting in a total 
GGO and fibrosis score, both between 0 and 15 24;25.
Statistical analysis
For the calculation of the predicted 6MWT distance, the equation of Enright et al 15 was used. All 
statistical analyses were performed using Statistical Package for Social Sciences (SPSS) version 
14.0. Quantitative variables were summarised as median and full range. Groups were compared 
using the Mann-Witney U test or the Kruskal-Wallis test. Spearman’s correlation coefficient was 
applied to determine the correlation between 6MWT and pulmonary function test results. All 
statistical analyses were two-tailed and P values < 0.05 were considered to be significant.
Results
Disease characteristics
In this study 184 patients were included, 61 men and 123 women. Twenty-eight patients were 
not included, due to mistakes in appointments (n=14), refusal (n=6), myositis (n=3) and life-
threatening disease (n=5). In all, 47 (25.5%) were classified as having diffuse cutaneous SSc 
(DcSSc) and 137 (74.5%) as limited cutaneous SSc (LcSSc). Median (range) age was 56.5 (20-
83) years, with a median (range) disease duration of 6.1 (0.0-42.4) years. Antinuclear antibody 
was tested positive in 181 (98%), anticentromere antibody, antitopoisomerase antibody, and 
antiribonuclear protein antibodies in 41 (22%), 55 (30%) and 18 patients (10%) respectively. The 
median (range) modified Rodnan skin score was 7.0 (0-44) (Table 1).
Table 1  Patient characteristics
All (N=184) DcSSc N=47 LcSSc N=137
Diffuse:limited SSc ratio 2.9 : 1
Male:female ratio 2.0 : 1 1.1 : 1 3.5 : 1
Age (median, range) 56.5  (20-83) 52.0  (21-79) 58.0  (20-83)
Disease duration yr (median, range) 6.1  (0.0-42.4) 4.3  (0-22.5) 7.4  (0-43.4)
MRSS (median, range) 7.0  (0-44) 16.0  (0-44) 6.0  (0-19)
ANA positive (%) 181  (98%) 47  (100%) 134  (98%)
ACA positive (%) 41  (22%) 1  (2%) 40  (29%)
Anti-TOPO positive (%) 55  (30%) 19  (40%) 36  (26%)
Anti-RNP positive (%) 18  (10%) 2  (4%) 16  (12%)
DcSSc: diffuse cutaneous SSc; LcSSc: limited cutaneous SSc; mRss: modified Rodnan skin score; ANA: antinuclear antibody; ACA 
anticentromere antibody; Anti-TOPO: antitopoisomerase antibody; anti-RNP: anti ribonuclear protein antibodies.
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Six minute walk test
The median (range) 6MWT was 429 (57-756) m, which was significantly lower than the expected 
value of 557 (357-874) m (p<0.001). The 6MWT results did not differ between patients with 
DcSSc and LcSSc (p=0.40) (table 2). Also, no difference was found in patients with long-standing 
disease, that is > 5 years, and early disease and the presence of the various auto-antibodies.
Pulmonary function testing
The median (range) total lung capacity (TLC) in all patients was 85.0 (26-135)% of predicted, 
and did not differ between patients with LcSSc and DcSSc. The median (range) predicted vital 
capacity (VC) of all patients was 95.5 (25-143)%. In patients with DcSSc this was 87.0 (25-128)% 
which was significantly lower than the value measured in patients with LcSSc: 98.0 (27-143)% 
(p=0.023). The median (range) of predicted FEV1 in all patients was 86.0 (30-142)%, which was 
equal in both disease subtypes. A relatively high Tiffenau index (FEV1 / VC) was found, which 
did not differ between DcSSc and LcSSc, the median value in all patients was 94.0 (44-192)%. 
Measurement of single-breath carbon dioxide diffusion lung capacity (DLCO) was available in 
172 patients. In 12 patients the forced expiratory volume in one second (FEV1) was < 1.0 l, 
making DLCO measurement impossible. No difference was found in DLCO values in the two 
disease subtypes. In all patients the median predicted DLCO was 59.0 (13-119)% (table 2).
Table 2  six minute walking distance, pulmonary function and right heart catheterisation results
All patients DcSSc LcSSc
Distance m (median, range) 429  (57-756) 414  (91-608) 435  (57-756)
Distance predicted (median, range) 556.5  (357-874) 594  (378-874) 539  (357-845)
Percentage distance pred. (median, range) 77  (11-114) 70  (19-114) 79  (11-110)
TLC (% of predicted)(median, range) 85.0  (26-135) 86.0  (26-135) 80.0  (32-125)
VC (% of predicted)(median, range) 95.5  (25-143) 87.0  (25-128) 98  (27-143)
FEV1 (% of predicted)(median, range) 86.0  (30-142) 90.0  (30-142) 83.5  (30-125)
FEV1/VC (median, range) 94.0  (44-192) 92.0  (44-165) 83.5  (30-125)
DLCO (% of predicted) (median, range) 59.0  (13-119) 57.5  (13-93) 60.5  (18-119)
Pulmonary hypertension present (%) 31  (17%) 2  (4%) 29  (21%)
GGO score (median, range) 0  (0-13) 0  (0-7) 0  (0-13)
Fibrosis score (median, range) 2.0  (0-15) 2.5  (0-12) 1.5  (0-15)
Total score (median, range) 2.75  (0-17) 3.0  (0-12) 2.0  (0-17)
DcSSc: diffuse cutaneous systemic sclerosis; LcSSc: limited cutaneous systemic sclerosis; TLC: total lung capacity; VC: vital capacity; FEV1: 
forced expiratory volume in 1 second; FEV1/VC: tiffenau index; DLCO: carbon dioxide diffusion lung capacity; GGO: ground glass opacity; Total 
score: ground glass opacity and fibrosis score combined.
Right heart catheterisation
Pulmonary hypertension as diagnosed with right heart catheterisation was present in 31 (17%) of 
the patients; 2 (4%) with DcSSc and 29 (21%) with LcSSc. 
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HRCT-scan
A GGO or fibrosis score ≤ 3, representing minimal or absent interstitial pulmonary involvement, 
was present in 99 (53.8%) of all SSc patients. Median (range) GGO score was 0.0 (0-13) and 
fibrosis score was 2.0 (0-15); the scores were not different in DcSSc compared to LcSSc patients 
(p=0.09 for GGO and p=0.40 for fibrosis). 
Patient groups
Patients were divided into 4 groups according to their pulmonary involvement. The first group 
(N=89) represented patients without PH and with a GGO and fibrosis score ≤ 3 on HRCT-scan 
score, i.e. no lung complications. In the second group (N=53), patients had a GGO or fibrosis 
score >3, but no PH, i.e. pulmonary fibrosis. The third group (N=28) consisted of patients with 
PH and GGO and/or fibrosis scores >3 (fibrosis and PH), and the last group (N=10) represented 
patients with PH but a GGO and fibrosis score ≤ 3, PAH. The highest median (range) 6MWT 
was 450 (91-756) m in the patients without lung complications, followed by 429 (57-594) m in 
patients with fibrosis, then 355.5 (148-537) m in PAH patients and the lowest value, 351 (120-
609) m was found in patients with fibrosis with PH (figure 1). The differences between the groups 
were significant (p<0.001). The median (range) differences between predicted and measured 
6MWT distance were around 120 metres (20% of predicted) for SSc patients without PH (group 
1 and 2) and 160 metres (32% of predicted) for patients with PH. The same pattern of impairment 
as found with the 6MWT was found in the predicted DLCO, which was 71.5%, 55.0%, 46.5% 
and 34.0% respectively (p<0.001), as well as in the predicted VC (p<0.001), as shown in table 
3 and figure 1.
Table 3  six minute walking distance, pulmonary function and right heart catheterisation results for each patient group
No lung complications 
N=89
Fibrosis, no PH 
N=53
Fibrosis with PH 
N=28
PAH 
N=10
Distance m (median, range) 450  (91-756) 429  (57-594) 351  (120-609) 355  (148-537)
Distance pred. (median, range) 567  (364-874) 539  (378-790) 517  (403-741) 515  (357-737)
Percentage distance pred. (med, range) 80.0  (19-108) 77.0  (11-114) 69.5  (25-98) 71.0  (27-97)
GGO score (median, range) 0  (0-3) 0  (0-13) 0  (0-13) 0  (0-2)
Fibrosis score (median, range) 0  (0-3) 7.0  (4-15) 7.5  (0-15) 0  (0-3)
TLC (% of pred.)(med, range) 95.5  (54-128) 78.0  (26-134) 66.5  (42-135) 88.0  (56-100)
VC (% of pred.)(med, range) 106  (56-143) 87.0  (25-123) 71.5  (44-114) 99.0  (56-114)
FEV1 (% of pred.)(med, range) 95.0  (54-142) 82.5  (30-127) 71.0  (37-116) 82.5  (61-102)
FEV1/VC % 93.0  (44-148) 97.0  (49-192) 96.5  (54-132) 88.5  (60-106)
DLCO (% of pred.) (med, range) 71  (27-119) 55.5  (19-85) 34.0  (13-74) 46.5  (25-64)
PH: pulmonary hypertension; PAH: pulmonary arterial hypertension; GGO: ground glass opacity; TLC: total lung capacity; VC: vital capacity; FEV1: 
forced expiratory volume in 1 second; FEV1/VC: tiffenau index; DLCO: carbon dioxide diffusion lung capacity.
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Diagnosis 1: No lung involvement; Diagnosis 2: Fibrosis; Diagnosis 3: Pulmonary hypertension and fibrosis; Diagnosis 4: Pulmonary arterial 
hypertension; DLCO: carbon dioxide diffusion lung capacity; TLC: total lung capacity; VC: vital capacity.
Figure 1  Median (95% confidence interval) of (a) six-minute-walking distance results, (b) diffusion capacity as percentage of 
predicted, (c) total lung capacity as percentage of predicted, and (d) vital capacity as percentage of predicted in each diagnosis 
group. 
Correlation of 6MWT with pulmonary function indices
The measured 6MWT distance correlated with the TLC (r=0.26, p=0.015), VC (r=0.24; p=0.01) 
and DLCO (r=0.43; p<0.001). After dividing the patients into the 4 previously mentioned diagnosis 
groups, a correlation was found between the 6MWT distance and TLC in the patients without 
pulmonary involvement (r=0.26; p=0.015), and in the pulmonary fibrosis patients (r=0.29; 
p=0.038). In both patients without pulmonary involvement and in the patients with pulmonary 
fibrosis and PH a correlation was found between DLCO and 6 MWT distance (r=0.45, p<0.001 
and r=0.52, p=0.008 respectively). No significant correlations were present in the other 2 groups. 
Obstructive lung disease, defined as FEV1/VC ≤ 0.70 26, was present in 10 patients (6%). The 6MWT 
distance in these patients did not differ from the patients without obstructive lung disease.
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Relationship with anaemia
In 17 patients (9.2%) anaemia, i.e. a blood haemoglobin < 6.7 mMol/l, was present. No 
significant differences in 6 MWT distance, VC and DLCO were found between anaemic patients 
and non-anaemic patients (data not shown). 
Relationship with age
The median (range) age of our patient cohort was 56.5 (20-83) years, with only 20 patients (10.9 
%) < 40 years. The median (range) 6MWT in patients < 40 years was significantly higher compared 
to the patients > 40 years, 532.5 (240-686) and 417.5 (57-756) respectively (p<0.001).
Discussion
In this study we found that the 6MWT results of SSc patients were significantly lower than the 
expected values based on healthy controls. Sub maximal exercise testing, such as the 6MWT, 
plays an important role in evaluating different treatments in scleroderma patients, particularly 
in studies of PAH associated with SSc. We evaluated whether the 6 MWT distance in a large 
cohort of patients with SSc was comparable to expected values derived from the healthy 
population 15. Since pulmonary involvement, consisting of pulmonary fibrosis with or without 
pulmonary hypertension and PAH reduce the 6MWT distance, we categorised the patients in 
four different groups according to their pulmonary involvement 16;27. However, also in patients 
without pulmonary fibrosis and without PH or PAH, the median 6MWT was only 80% of 
predicted. Impairment of the exercise capacity, as measured by the 6MWT, was most explicitly 
present in patients with both pulmonary fibrosis and PH, with a median 6MWT of 69.5% of 
predicted. These results suggest that the reduction of the 6MWT distance in patients with SSc is 
only partially caused by pulmonary involvement. Co-morbidities such as myositis, arthritis, skin 
fibrosis and digital ulcers localised at the toes, could also cause a decrease in exercise capacity. 
Furthermore, the systemic disease and inactivity may lead to deconditioning and subsequently to 
reduced exercise capacity 28. Also, the frequently present, but at rest often not clinically apparent 
ventricular systolic or diastolic dysfunction, may contribute to the decrease in 6MWT results 14. 
Furthermore, anaemia due to the disease process itself and/or chronic blood loss in the digestive 
tract may result in diminished 6MWT results. The latter was present in 9.2% of the patients in our 
study, but was not associated with a further decline in 6MWT results. 
In a descriptive study of 6MWT and oxygen saturation in a cohort of selected SSc patients 
Villalba and co-workers found an association between 6MWT <400 m and age > 36 years, a 
higher dyspnea index, fibrosis on chest radiography and sPAP by echocardiography ≥ 30 mm 
Hg 29. Since the normal values for the 6MWT are derived from a healthy American population 
between 40 and 80 years of age, we compared patients < 40 years to patients ≥ 40 years in our 
112
Chapter 8 
study. In accordance to the results of Villalba, we also found that younger patients, i.e. < 40 years 
of age had significantly higher 6MWT results than older patients, which was expected 29. Younger 
patients are in general in better physical condition than older patients, and tend to have shorter 
disease duration.
A moderate correlation between 6MWT and DLCO was found in our study in the total cohort, in 
the patient group without pulmonary involvement, and in the patients with pulmonary interstitial 
disease. Moderate correlations, however, can be expected here. We found a decreased DLCO in 
all 4 diagnosis groups. Since a decreased diffusion capacity causes a limiting of oxygen uptake, 
the correlation between 6MWT and DLCO was expected. Also, we found a correlation between 
6MWT and TLC and VC in the total cohort, although this correlation was not strong either. The 
impact of this finding is yet undetermined, since the prognostic value of VC measurement in 
SSc patient has recently been debated in light of the results of two cyclophosphamide studies. 
Those studies showed an improvement in quality of life measures but little change in forced vital 
capacity 5;7. Results of other studies differ. In the study of interstitial lung disease associated to SSc, 
Buch and co-workers found a weak correlation between 6MWT and forced vital capacity, and 
no correlation with DLCO 16. Also in the previously mentioned study by Villalba, no significant 
association was found between 6MWT distance and pulmonary function test results, but patients 
with severe organ involvement were excluded in this study 29. In keeping with our findings, 
Eaton et al found a significant correlation of both VC and DLCO with the 6MWT in patients with 
idiopathic interstitial pneumonia 30. 
Our study population consisted of mostly Caucasian Dutch patients aged between 20-83 years. 
The reference values are derived from healthy Americans between 40 and 80 years of age. To 
date, it is unknown whether these values can be applied to Dutch patients. However, since 
a correction for age, gender, length and weight is employed, and only 10.9% (N=20) of our 
patients were < 40 years and 1.1% (N=2) were > 80 years of age we feel confident to use them 
at this moment. 
The HRCT-scan scoring method described here is used extensively in idiopathic pulmonary 
fibrosis (IPF) patients, but has not been validated in interstitial lung disease associated with SSc 
to date 24;25. We have chosen this method because of the similarities of IPF and interstitial lung 
disease in SSc, and the simplicity of this method. Another point to address is that the 6MWT 
values in our study are derived from a single measurement. Since both Eaton 30 in IPF and Buch 
16 in SSc associated interstitial lung disease have shown a high reproducibility of the 6MWT, we 
chose to use one value only. 
In summary, we have shown that the 6MWT results are significantly lower in patients with 
SSc compared to healthy subjects. The impairment of the exercise capacity as measured by the 
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6MWT is most apparent in scleroderma patients with pulmonary fibrosis and PH. However, 
also in SSc patients without pulmonary involvement, the median 6MWT is only 80% of the 
predicted value. Although significant correlations were found between 6MWT and TLC, VC and 
DLCO, further investigations of exercise capacity in patients with SSc, focussing on sub clinical 
cardiovascular and muscle impairment as well as ventilation and oxygen uptake impairment 
should be performed to identify options to improve exercise tolerance in SSc patients. 
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Abstract
Systemic sclerosis (SSc) is a generalised autoimmune disease, causing morbidity and a reduced 
life expectancy, especially in patients with rapidly progressive diffuse cutaneous SSc. Since no 
proven treatment exists, autologous haematopoietic stem cell transplantation (HSCT) is employed 
as a new therapeutic strategy in patients with a poor prognosis.
Objective: This study reports the effects on survival, skin and major organ function of HSCT in 
patients with severe diffuse cutaneous SSc. 
Patients and methods: Twenty-six patients were evaluated. Peripheral blood stem cells were 
collected using cyclophosphamide (4 g/m2) and rHu G-CSF (5 to 10 µg/kg/day) and were 
reinfused after positive CD34+ selection. For conditioning, cyclophosphamide 200 mg/kg was 
used. 
Results:  After a median follow-up of 5.3 (1-7.5) years, 81% (n=21/26) of the patients demonstrated 
a clinically beneficial response. The Kaplan-Meier estimated survival at 5 years was 96.2 % (95% 
CI 89% – 100%) and at 7 years 84.8% (95% CI, 70.2%-100%) and event-free survival, defined 
as survival without mortality, relapse or progression of SSc, resulting in major organ dysfunction 
was 64.3 % (95% CI 47.9 – 86%) at 5 years and 57.1% (95% CI, 39.3%-83%) at 7 years. 
Conclusion: This study confirms that autologous HSCT in selected patients with severe diffuse 
cutaneous SSc results in sustained improvement of skin thickening and stabilisation of organ 
function up to seven years after transplantation. 
Introduction
Systemic sclerosis (SSc) is a generalised connective tissue disorder characterised by vascular 
lesions, resulting in thickening of the skin, fibrotic degenerative changes in muscles, joints and 
viscera, mainly the intestinal tract, the heart, the lungs and the kidneys 1;2. Although its exact 
pathogenesis remains unknown, this autoimmune disease is characterised by predominant T-cell 
activation, the production of specific auto antibodies, and cytokine release 3;4. Two main clinical 
subsets, namely limited and diffuse cutaneous forms, can be distinguished by the extent of skin 
involvement, their autoantibody profile and the pattern of organ involvement. The mortality of 
SSc is high with a 5-year mortality rate of at least 30% 5;6. In rapidly progressive diffuse cutaneous 
SSc the 5-year mortality is estimated to be 40 - 50% (5-9). In these patients the cause of death 
is secondary to pulmonary, cardiac and renal involvement 5;6;10. To date, no treatment has been 
shown to prevent disease progression and reverse fibrosis, but immunosuppressive therapy, given 
at an early stage of the disease, could result in disease improvement. Reduction of the skin score 
and stabilisation or improved global response was suggested by one small placebo controlled 
study with methotrexate 11. This was later confirmed in a second, larger placebo-controlled 
randomized study 12. More recently, a large, double-blind placebo controlled trial with oral 
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cyclophosphamide in SSc patients with interstitial lung disease showed a statistically significant, 
although clinically modest effect, namely a reduction of decline of forced vital capacity (FVC) 
13. A similar study with monthly intravenous bolus of cyclophosphamide and prednisolone 20 
mg every other day for 6 months, followed by oral azathioprine (2.5 mg/kg/day) for 6 months 
showed positive effects on the FVC, but not on carbon dioxide diffusion lung capacity (DLCO) 
or abnormalities on high resolution CT-scan 14.
Since 1996 autologous peripheral blood stem cell (PBSC) transplantation has been employed 
worldwide with a low early mortality of < 5% (15-18). Based on these data, we have used 
intensive myelo- and immuno-suppression followed by autologous haematopoietic stem 
cell transplantation (HSCT) to treat severe SSc 15;17;19. Since 1996, approximately 1000 PBSC 
transplantations for autoimmune diseases have been reported 20;21 with 140 SSc patients in the 
EBMT (European Group for Blood and Marrow Transplantation) and EULAR (European League 
Against Rheumatism) database as to March 2007. The early results from the phase I/II clinical 
trials showed that HSCT is feasible in carefully selected patients with diffuse SSc 16;19;22;23. In 
2004, a follow-up report from the EBMT-EULAR database, consisting of different centres and 
treatment schemes, showed positive responses at 3 years in two thirds of 57 patients with an 
early treatment related mortality of 8.7 % 15. We describe herein the long-term follow-up results 
of all the Dutch and French patients included in two similar phase I/II trials, using uniform 
eligibility criteria and a single transplantation protocol 24. The specific aims of this study were to 
evaluate the survival and the durability of responses up to 7 years of follow-up in SSc patients 
treated by autologous HSCT.
Patients and Methods
We report results from patients with SSc, treated by HSCT at the Radboud University Nijmegen 
Medical Centre and the Leiden University Medical Centre in the Netherlands and at the Hôpital 
Saint-Louis in Paris, France, with at least 6 months follow-up after HSCT. All patients fulfilled the 
ACR preliminary criteria for SSc and had the diffuse cutaneous form 3. Patients were eligible if 
they had the following characteristics: (a) age < 66 years and (b) rapidly progressive disease ≤2 
years duration with a modified Rodnan skin score (mRSS) above 20, plus ESR > 25 mm/1st hour 
and/or Hb < 11 g/dL, not explained by other causes than active SSc or (c) a disease duration > 
2 years plus a progression of the mRSS (>20%) plus major organ involvement related to SSc as 
defined by either: i) lung involvement: with a vital capacity (VC) or DLCO below 70% predicted, 
or a mean pulmonary artery pressure (PAP) above 40 mmHg (measured by echocardiography); 
ii) digestive tract involvement: with serum albumin < 25 g/L or weight loss exceeding 10% 
body weight in the preceeding year; iii) kidney involvement: with 24-hour urinary protein 
above 0.5 g or serum creatinine above 120 µmol/L. The exclusion criteria were: uncontrolled 
arrhythmia, echocardiographic left ventricular ejection fraction (LVEF) < 50% or mean PAP > 50 
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mm Hg, DLCO < 45% of predicted, creatinine clearance < 20 ml/min, platelets < 80,000/mm3, 
hemorrhagic cystitis, HIV or HTLV1 seropositivity, malignancy, pregnancy, a cardiac or vascular 
prosthesis, and no vascular access 19. These studies were approved by the local ethics committees 
19. After obtaining written informed consent, eligible patients were included in the protocol. 
Pre-treatment evaluation
Pre-transplant evaluation included: 1) Disease characteristics such as the disease duration (in 
years from the first non-Raynaud symptom), autoantibody profile, previous disease specific 
treatment and determination of WHO performance status, grade 0-5; grade 0 being a patient 
who is fully active without restriction; grade 1 being a patient who is restricted in physically 
strenuous activity, but ambulatory and able to carry out work; grade 2 representing a patient who 
is ambulatory and capable of all self-care but unable to carry out any work, up and about > 50% 
of the waking hours; grade 3 being a patient who is capable of only limited self-care, confined to 
bed or chair > 50% of waking hours; grade 4 representing a patient who is completely disabled 
and cannot carry out any self-care, who is totally confined to bed and chair; and grade 5 a 
deceased patient 25; 2) organ involvement according to: a) the extent of skin sclerosis using the 
mRSS 10; b) chest X ray or High Resolution CT-scan, pulmonary function tests with total lung 
capacity (TLC), VC, forced expiratory volume in first second (FEV1), and DLCO, all in % of 
predicted; c) echocardiography to measure LVEF (%) and mean mPAP (mm Hg); d) estimation of 
the creatinine clearance according to the method of Cockcroft and Gault 26. 
Stem cell mobilisation, collection and selection: transplantation procedure
The transplantation procedure was performed as previously reported 19. In short, the mobilisation 
and collection of PBSC was performed with 4 g/m2 cyclophosphamide followed 4-5 days later by 
rHu G-CSF (Lenograstim, Aventis and Chugai Pharma France or Filgrastim, Amgen, Thousand 
Oaks, USA) 5 or 10 µg/kg/day until the last apheresis. Autologous PBSC were collected when 
CD34+ cells were above 20/µl in peripheral blood. At least 9.5x106 CD34+/kg had to be 
collected by successive daily apheresis to obtain 7x106 CD34+/kg for positive selection (using 
Nexel Isolex®300i Stem Cell Collection System at St Louis Hospital and Clinimacs of Miltenyi 
in Nijmegen and Leiden) and 2.5x106 CD34+/kg for haematopoietic rescue 27. The graft was 4-5 
log T-cell depleted. Conditioning was performed at least 4 weeks later using cyclophosphamide 
at 50/mg/kg/day from day –5 to day –2 prior to PBSC reinjection.
Clinical follow-up
To assess the survival and disease response to treatment, clinical evaluation was conducted 
at least every 6 months, consisting of the same investigations that were used in the pre-
transplantation evaluation. Event-free survival (EFS) was defined as survival without mortality, 
relapse or progression of SSc, resulting in heart, lung or kidney dysfunction. Organ dysfunction 
was defined as follows: heart: an echocardiographic LVEF< 40% or mean PAP > 50 mmHg; 
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pulmonary: respiratory failure with a paO2 < 8 kPa/60 mmHg; kidney failure necessitating 
dialysis. Response to therapy was assessed segregating major (MR) or partial (PR) responses, 
no response, disease progression or relapse as previously described 19. A major response was 
defined as: A) performance status at 0; plus B) decrease > 50% in the mRSS and/or an increase 
in FEV1 > 30%, plus an LVEF > 45% without any pericardial effusion and serum creatinine ≤ 
baseline values. A partial response was defined as: A) performance status ≤1; plus B) decrease 
25% - 50% in mRSS and/or an increase in FEV1 15% - 30%, plus an LVEF > 45% with no or small 
pericardial effusion plus serum creatinine at baseline values or < 180 µmol/L. No response was 
defined by stable disease compared to inclusion. Relapse was defined by the onset of progression 
after prior response. Disease progression was defined as an increase in mRSS > 25 % compared 
to the baseline values, a decrease in VC or DLCO >15% and/or major organ dysfunction as 
defined above. 
Statistical analysis
Categorical variables were summarised as counts and percentage, while numerical variables 
were summarised as median and full range. Outcomes were reported for each follow-up year. 
Groups were compared using Fisher’s exact test for the categorical variables and non-parametric 
paired Wilcoxon rank sum test for numerical variables. The significance level of p-values was 
set to 0.05. The survival curve was calculated by the Kaplan Meier method. A piecewise linear 
mixed model was used to represent the mRSS over follow-up, with the first linear part from 
inclusion to the first year of follow-up, and the second part from the first up to the seventh year 
of follow-up 28. Random subject main effect and slope were added to the model, to account for 
the correlation between measurements on the same subjects. All computation analyses were 
performed using R (cran) version 2.1 for Windows. 
Results
Patients
Twenty-six patients (19 females and 7 males), median age 42 (16-65) years, with diffuse 
cutaneous SSc were included in the study (11 from Nijmegen, 10 from Paris and 5 from Leiden) 
from March 1998 to May 2004. Table 1 shows baseline patients’ clinical characteristics. Two 
included patients were found as having one of the exclusion criteria (one with a DLCO at 21% 
and one with a LVEF of 46%), which were considered as violation of the protocol and could 
be kept in the study according to the study committee advice. Twelve patients had early diffuse 
SSc, with a median disease duration of 1.4 (0.8-2) year, and fourteen patients had progressive 
organ involvement with a median disease duration 3.7 (2.1-13) year. The median mRSS of 32 (9 
- 51) and 85% (n=22) had an mRSS ≥ 20. Pulmonary involvement was present in 65% (n = 17), 
and 19% (n = 5) had a creatinine clearance below 70 ml/min. Significant weight loss was one 
123
Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis
of the eligibility criteria in 19% of the cases (n = 5). All but three patients had been treated with 
immunosuppressive agents prior to the HSCT [methotrexate, prednisolone, cyclophosphamide 
with a maximum of 9 gram per patient, d-penicillamine, colchicine, azathioprine, sulphasalasine, 
interferon alpha, infliximab, and anti-TGF beta]. These agents were discontinued at least 1 month 
prior to PBSC mobilisation. In five patients relevant co-morbidity, such as diabetes mellitus (n = 
1), asthma (n = 2) and ischemic heart disease (n = 2) was present.
Table 1  Baseline clinical characteristics in severe SSc patients treated by autologous Hematopoietic Stem Cell Transplantation 
with at least 6 months follow-up after the procedure.
N=26
Age (years), median (range) 42  (16-65)
Sex (F/M) 19/7
Disease duration (years), median (range) 2.0  (0.8-13)
Skin involvement: 
Modified Rodnan skin score > 50% maximum 
Modified Rodnan skin score, median (range)
 
19  (73%) 
32  (9-51)
Lung involvement: 
TLC < 70% of predicted value 
VC < 70% of predicted value 
DLCO < 70% of predicted value
 
8  (31%) 
9  (35%) 
17  (65%)
Cardiovascular involvement: 
Arterial hypertension 
LVEF > 40% 
Pericardial effusion present
 
1  (4%) 
26  (100%) 
2  (8%)
Kidney involvement:  
Creatinine clearance > 100 ml/min 
Creatinine clearance >70 and < 100 ml/min 
Creatinine clearance <70 ml/min
 
12  (46%) 
11  (42%) 
3  (12%)
Digestive tract involvement: 
Weight loss > 10% in last 6 months 
Diarrhea > 4 times/day 
Parenteral nutrition
 
7  (27%) 
3  (12%) 
2  (8%)
WHO Performance status: 
Grade 0 
Grade I 
Grade II 
Grade III 
Grade IV
 
1  (4%) 
9  (35%) 
9  (35%) 
5  (12%) 
2  (8%)
Serum auto antibodies: 
ANA positive 
Anticentromere positive 
Antitopoisomerase positive
 
25  (96%) 
1  (4%) 
12  (46%)
DLCO: carbon dioxide diffusion lung capacity; TLC: total lung capacity; VC: vital capacity; LVEF: left ventricle ejection fraction; WHO World 
Health Organization.
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The treatment regimen is described in table 2. In one patient PBSC mobilisation failed, but 
enough bone marrow stem cells were harvested 4 weeks later and autologous bone marrow 
transplantation was performed with Antilymphocytes Globulins and Cyclophosphamide 15. 
Another patient received PBSC transplantation without T cell depletion due to technical problems 
at the time of the selection procedure. 
Table 2  Regimen used in severe SSc patients treated by autologous Hematopoietic Stem Cell Transplantation with at least 6 
months follow-up after the procedure
Number of patients (%)  
Total N = 26
Mobilization procedure 
CMP 2 g/m2 /d, two successive days + G-CSF 
CMP 4 g/m2/d, one day + G-CSF 
Number of apheresis/patient 
No mobilization and no selection 
No CD34+ selection 
CD34+ selection 
CD34+ . 106 /kg  
 
10  (39%) 
16  (62%) 
1.2  (0-2) 
1  (4%) 
1  (4%) 
24  (92%) 
6.7  (2.4-17.4)
Conditioning regimen 
CMP alone (200 mg/ kg x 4)  
ALG + CMP (200mg/ kg x 4)
 
25  (96%) 
1  (4%)
Autologous transplantation 
CD34+ PBSC  
Non-selected PBSC  
Bone marrow stem cells
26 
24  (92%) 
1  (4%) 
1  (4%)
CMP: cyclophosphamide; ALG: anti-lymphocyte globulins; PBSC: peripheral blood stem cell.
Survival
The early mortality, within 6 months after HSCT, was previously reported for all patients 15;19. In 
short, among 28 severe SSc patients treated by HSCT 2 died within 6 months (7.1%), leaving 26 
patients with at least 6 months of follow-up after HSCT. The causes of death of these 2 patients 
was considered as treatment related at 1 month for one patient and due to disease progression 
for another at 6 months after HSCT. As illustrated in figure 1, the probability of survival of SSc 
patients with at least 6 months follow-up after HSCT was 96.2 % (95% CI 89% – 100%) at 5 
years and 84.8% (95% CI, 70.2%-100%) at 7 years. At the time of analysis, no patients were 
lost to follow-up. After a median follow-up of 5.2 (1-7.5) years, death from disease progression 
occurred in 2 patients (8%): both from relapse at 18 months after transplantation, one after 
initial PR and the other after intial MR. A third patient, a heavy smoker, died from small cell lung 
cancer 64 months after HSCT. Among the others showed 35 % (n = 9) sustained MR, 50 % (n = 
13) sustained PR, and 3 % (n = 1) progressed after PR. All together, the event free survival (EFS) 
for the patients with at least 6 months of follow-up after autologous HSCT was 64.3 % (95% CI: 
47.9%-86.3%) at 5 years and 57.1% (95% CI: 39.3%-83.1%) at 7 years (Figure 1).
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Figure 1  Kaplan-Meier survival curve (Figure 1 A) and Event Free Survival (EFS) curve (Figure 1 B) in 26 severe SSc patients 
with at least 6 months follow-up after autologous Haematopoietic Stem Cell Transplantation and 95% confidence intervals.
Long-term morbidity
Infectious complications occurred in 19% (n= 5) of the patients, caused by herpes zoster 
reactivation (n=3) and atypical mycobacterium (n=2). One patient with persistent pancytopenia 
after HSCT received 16 units of red blood cells and recovered suboptimal blood counts after 
discontinuing simultaneous treatment with co-trimoxazole. One patient developed a basal 
carcinoma of the facial skin at 4 years after transplantation, which was surgically removed.
Clinical evolution 
The WHO performance status improved throughout the follow-up, from baseline values at 
median 2.12 (0-4, n=26) to 0.60 (0-2, n=15 p<0.05) after 5 years of follow-up (Figure 2).
A significant fall in mRSS was observed up to 7 years after HSCT with faster regression within the 
first year and sustained fall thereafter. The representation of the mRSS by a linear mixed model 
resulted in a median mRSS decrease of 11.57 units in the first year (p<0.001) and of 2.57 units 
per year after that (p<0.001) (Table 3 and Figure 3). A significant decrease (> 25%) in mRSS was 
achieved in 73% (n = 19/26) of the patients after 1 year and in 94% (15/16) after 5 years.
Repeated assessments of pulmonary function parameters were obtained in all patients every 
6 months with 15 patients completing 5 years of follow-up. The median VC (% predicted) was 
76% (37-143%) at inclusion and 73% (33-114%) after 5 years of follow-up. In comparison with 
baseline values for all patients, there was no significant change in FEV1 or DLCO during follow-
up. Cardiac and renal function remained stable during follow-up. (Table 3) 
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Figure 2  WHO performance status among the 26 severe SSc patients with at least six months follow-up after treatment by 
autologous Haematopoietic Stem Cell Transplantation.
Figure 3  Evolution of Modified Rodnan skin score during the follow-up. Dashed lines represent the evolution of skin scores 
for each patient (n =26) with at least 6 months follow-up after autologous Haematopoietic Stem Cell Transplantation. The bold 
solid line represents the average Modified Rodnan skin score as estimated by the mixed linear regression model. 
After autologous HSCT 81% (n = 21/26) of the patients with at least 6 months follow-up 
demonstrated a positive response at one year with either major ( n=5) or partial (n=16) response, 
whereas 5 patients had no response (Figure 4) 19. Longer follow-up showed that after 5 years 82% 
(n=14/17) had a response to the transplantation.
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Table 3  Clinical evolution in the 26 SSc patients treated by autologous Hematopoietic Stem Cell Transplantation with at least 
6 months follow-up after the procedure.
Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7
mRSS
Median (range) 32 (9-51) 19 (3-51) 12 (0-49) 7 (3-43) 4 (0-35) 4 (0-34) 5 (0-19 3 (2-10)
N 26 26 20 18 16 15 6 3
DLCO
Median (range) 55 (21-100) 52 (26-100) 58 (21-100) 58 (15-94)* 50 (16-85)° 52 (17-75) 62 (11-74) 75 (18-76)
N 26 25 18 19 15 11 4 3
VC
Median (range) 76 (37-143) 84 (43-138) 84 (37-133) 96 (32-128)* 74 (30-114)° 73 (33-114) 79 (34-95) 81 (32-95)
N 26 26 19 19 16 11 4 3
FEV1
Median (range) 76 (44-116) 85 (37-128) 89 (40-129) 80 (38-120) 75 (40-114) 71 (39-114) 73 (38-83) 71 (37-143)
N 26 26 19 19 16 11 4 3
LVEF
Median (range) 63 (46-84) 64 (49-75) 62 (45-71) 60 (52-70) 60 (50-71) 67 (57-74) 63 (59-67) NA
N 22 18 16 10 8 9 2 0
Creatinine clearance
Median (range) 92 (55-188) 92 (49-222) 92 (49-203) 90 (60-180) 84 (60-175) 92 (60-232) 98 (67-280) 92 (51-97)
N 26 25 21 19 17 15 6 3
* For the 19 patients evaluated at 3 years, VC was 77 (43-130) at inclusion and 96 (32-128) at 3 years, meanwhile FEV1 was 76 (48-116) at 
inclusion and and 80 (38-120) at 3 years. ° For the 16 patients analyzed at 4 years, VC was 74 (43-111) at inclusion and 73 (30-114) at 4 years, 
meanwhile FEV1 was 73 (48-112) at inclusion and and 74 (40-114) at 4 years. DLCO: carbon dioxide diffusion lung capacity; VC: vital capacity; 
FEV1: forced expiratory volume in first second; LVEF: left ventricular ejection fraction
Figure 4  Percentage of response to autologous Haematopoietic Stem Cell Transplantation (HSCT) in 26 patients with severe 
systemic sclerosis during the follow-up.
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Relapses occurred in 28% (n=6) of the initial major (n=2) or partial (n=4) responders within 
2.7 (range 2-4) years after transplantation. Treatment of the relapses consisted of either 
corticosteroids (n = 3), corticosteroids plus mycophenolate-mophetil (n=1), or corticosteroids 
plus mycophenolate-mophetil plus cyclosporine A (n = 2). After a median follow-up of 5.3 (1-
7.5) years, 88 % (n = 23/26) of the patients with at least 6 months follow-up after HSCT were 
alive: 35 % (n = 9) with MR, 50 % (n = 13) with PR, and 3 % (n = 1) with progression after PR. 
Discussion
The data presented here were obtained from the combined Dutch-French database of patients 
with SSc treated by HSCT in a phase I/II study. The primary objectives of this study were to assess 
the long-term survival. The secondary objectives were to evaluate the disease response after 
HSCT, using previously published criteria 19, to assess the evolution of the functional status, the 
skin involvement as well as organ involvement.
The cohort of patients studied represented a group with SSc and poor prognosis, as assessed 
by their initial high mRSS, the number of patients with lung disease and the presence of anti-
topoisomerase auto antibodies 6-9;29-39. The treatment regimen, as well as clinical follow-up 
after transplantation employed in the three hospitals were similar. To our knowledge, this is the 
largest cohort of severe SSc patients studied, with a median follow-up period of 5.3 years after 
autologous HSCT, providing valuable information on long-term outcome. 
This study illustrates the benefits that can be observed after HSCT in severe SSc patients. The 
adequate selection of patients with a poor prognosis, but without irreversible organ damage, 
is important to reduce the treatment risks and to improve the treatment success 22;29. After a 
median follow-up of 5.3 (1-7.5) years, death from disease progression occurred in 8% of our SSc 
patients. This rate is strikingly lower compared to the 5-year mortality rate estimated at 40% in 
such severe SSc patients, according to a recently published meta-analysis 6. The positive effect of 
HSCT on survival rate needs to be interpreted with care, due to a wide range in the duration of 
patients’ follow-up and the uncontrolled nature of this study, but the results are encouraging.
Autologous HSCT induced a rapid skin score decline. To our knowledge, no other therapeutic 
intervention in diffuse SSc has ever shown such a rapid and sustained improvement in skin 
condition. In our cohort, a significant decrease in mRSS was achieved in 73% after 1 year 
and in 94% (15/16) after 5 years. The skin thickness in patients with early SSc may improve 
spontaneously. However, the time span of such changes has always appeared much slower than 
observed within the first year after autologous HSCT 40. Further studies will help to clarify the 
pathological mechanisms associated with regression of skin sclerosis as recently shown after 
autologous HSCT in SSc 41.
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Interstitial pulmonary disease accounts for a large part of mortality in SSc patients. The effects of 
current treatment protocols of interstitial pulmonary disease in SSc is not very successful 13. In 
our study 65% of the patients with severe SSc had significant lung involvement at inclusion. All 
pulmonary function parameters remained stable after 5 and 7 years of follow-up. 
The strongest effect of treatment by HSCT was observed on functional status, as assessed by the 
WHO performance status, possibly due to improvement of the skin condition. Five years after 
transplantation, the percentage of patients with a WHO performance status of zero had increased 
to 56% compared to 4% at baseline. Therefore, HSCT treatment showed a sustained positive 
effect on the combination of functional status, skin-, lung-, heart- and kidney involvement 19. 
Our study has several limitations. First, this uncontrolled study and the promising results 
obtained in a relatively small number of patients will have to be confirmed in larger numbers 
as aimed in the two ongoing Phase III randomized trials comparing autologous HSCT to 
monthly cyclophosphamide i.v., the European ASTIS trial and the North American SCOT study. 
Nonetheless, to our knowledge this is the largest cohort of SSc patients studied after autologous 
HSCT, providing a rather good estimation of the long-term outcome and treatment effects at 5 
years. Secondly, the natural history of SSc in some patients may lead to a more indolent disease 
after a period of active disease, resulting in stabilisation of organ functions and reduction of 
the mRSS. However, no study has yet found the predictive factors to distinguish such patients. 
Furthermore, large cohorts of SSc patients prospectively studied by Steen 37 and Scuzel 42 have 
shown the very severe spontaneous evolution of SSc in some cases. 
In conclusion, for the first time this extended report shows the long-term follow-up results of 
HSCT in patients with severe SSc. It is confirmed that this treatment is feasible with acceptable 
toxicity 15, 19, 22-24. Clinical significant and sustained improvement was found on the skin condition 
and functional status with pulmonary cardiac and renal function stabilisation. Combined results 
allowed us to show that the majority of the patients experienced a sustained complete or partial 
remission of SSc. 
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Summary and conclusions
The main objective of this thesis is to determine the state-of-the-art assessment of patients with 
systemic sclerosis. Further objectives are to improve the assessment of the complications that 
occur in patients with systemic sclerosis and the treatment possibilities.
The studies described in this thesis were performed in the Nijmegen Scleroderma cohort, 
which was started in 1989, and is prospectively followed since 2001. Currently this cohort 
consists of 323 patients, treated at the Radboud University Nijmegen Medical Centre and Sint 
Maartenskliniek Nijmegen. 
Chapter 1 is a general introduction including the definition of systemic sclerosis (SSc), the 
epidemiology, clinimetrics, and organ complications of systemic sclerosis. Current treatment 
possibilities are described and a proposed treatment regimen for pulmonary arterial hypertension 
(PAH) associated to systemic sclerosis is offered.
In chapter 2 we describe the epidemiology of systemic sclerosis and its pulmonary complications in 
the Netherlands. The source of this study was a nationwide questionnaire among rheumatologists 
and clinical immunologists in the Netherlands combined with the POEMAS study. POEMAS, an 
investigators’ initiated study, is a Dutch acronym for “Pulmonale hypertensie Opsporing Een 
Multidisciplinaire Aanpak bij Sclerodermie” translated as “Pulmonary Hypertension Screening, 
a Multidisciplinary Approach in Scleroderma”, and intends to establish the optimal screening 
method for PAH in SSc. In the POEMAS study detailed information of 654 SSc patients is 
provided, including demographics, pulmonary function test results and high resolution computer 
tomography (HRCT) scans. With the nationwide questionnaire information of another 346 
patients with SSc was obtained, together with the presence of PAH diagnosed by right heart 
catheterization. The prevalence of SSc in the Netherlands was found to be 8.9 per 105 inhabitants 
> 18 years, based on 1000 cases, and the incidence was 0.77 patients per 105 per year. The 
prevalence of PAH associated to SSc was established to be 9.9%. A definition of interstitial 
lung disease in SSc is lacking. If a HRCT-scan is used to diagnose interstitial lung disease, this 
complication is present in 47% of the SSc patients, when the total lung capacity is used, this is 
19%. We conclude that the prevalence and incidence of SSc in the Netherlands is similar to the 
data from the UK, but that the prevalence of pulmonary hypertension and interstitial pulmonary 
disease is lower than expected. 
Chapter 3 offers a diagnostic protocol of pulmonary hypertension, based on current literature 
and the multidisciplinary approach in our centre. Pulmonary hypertension is a devastating 
complication of various, but rare diseases, including SSc and can also occur isolated. It 
causes morbidity and mortality in all patients. Ongoing research has provided some insight in 
pathophysiology and clinical manifestations. Furthermore, in this chapter two case reports of 
patients with pulmonary hypertension and an algorithm of the different therapeutic strategies are 
described, as well as recommendations for follow-up.
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Current flaws and possibilities in clinimetrics in SSc are described in chapter 4. To improve 
patient care in scleroderma, the clinician needs to initiate optimal, early treatment. However, 
diagnostic criteria of SSc are lacking. Frequently the ACR Preliminary Criteria for the Classification 
of Systemic Sclerosis, developed in 1980, are used to diagnose SSc patients. However, these 
classification criteria are not suitable for the early and proper diagnosis of SSc, because they were 
developed using “definite” cases, the control group consisted not of scleroderma-like diseases, 
and disease specific auto antibodies and capillaroscopic abnormalities were not included in 
the study. Subset classification criteria are intended to identify and separate disease subsets 
in which the natural history and prognoses may vary. At present, the most widely used sub 
setting scheme differentiates two clinical subsets, namely limited and diffuse cutaneous forms. 
The major disadvantage of this subset classification model is that patients with early disease, 
without or with minimal skin changes and no internal organ involvement, do not fit. In 1995 the 
European Scleroderma Study Group (EScSG) initiated a multicentre prospective study resulting 
in the preliminary disease activity criteria for SSc. Due to a high number of missing values; these 
criteria include three “change” items. The “change” items are actually response measurements 
and should therefore not be included in an activity score. Also, the patients included in the study 
had a wide range of disease duration and their complaints could have been caused by damage. 
In the 1999 severity criteria for SSc, nine organ systems were identified and the involvement of 
each organ system was graded from 0 to 4. The sensitivity to change and prognostic value of this 
scale however, has not been tested yet. Diagnostic criteria aiding in early diagnosis as well as 
classification, severity criteria aiding in the estimation of prognosis, and disease activity criteria 
indicating active disease could help the clinician in daily practice.
The predictive value of oesophageal dilatation on the HRCT-scan of the chest for the diagnosis 
of SSc is examined in chapter 5. In this study, 105 consecutive scleroderma patients from the 
Nijmegen SSc cohort and 107 consecutive controls were included. The controls were patients 
without SSc of whom a HRCT-scan of the chest was performed for evaluation of interstitial 
lung disease. The first available HRCT-scan for each patient and control was evaluated for 
oesophageal dilatation and interstitial lung disease in random order and blinded for the diagnosis 
by two independent radiologists. The positive predictive value of oesophageal dilatation for the 
diagnosis of SSc was found to be 83%. We concluded that oesophageal dilatation as visible on 
an HRCT-scan of the chest may alert physicians to look for other signs or symptoms of SSc in 
these patients, enabling early diagnosis and specific treatment.
Chapter 6 describes the importance of skin deformity in systemic sclerosis (SSc) relative to other 
disease stressors and other psychological correlates of Appearance Self-Esteem (ASE), which is 
self-esteem pertaining to appearance. In 123 patients of the Nijmegen SSc cohort disease-related 
stressors, symptoms, physical and psychological functioning, social support, coping styles, 
cognitions and ASE were assessed. Skin deformities proved a core stressor of the disease, only 
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preceded by fatigue. Physician-assessed disease status, including modified Rodnan skin score, 
was unrelated to ASE. Sex, self-reported functioning and symptoms were related to ASE and used 
as control variables. Both acceptance and anxiety correlated strongly with ASE. We concluded 
that psychological interventions aimed at boosting ASE should primarily target the psychological 
factors acceptance and anxiety in scleroderma patients.
In chapter 7 the right ventricular (RV) Tei-index as a tool to improve the non-invasive diagnosis 
of PAH in patients with SSc is presented. In 98 patients of the Nijmegen SSc cohort the 
echocardiographic systolic pulmonary arterial pressure (PAP), end-diastolic PAP and RV Tei-
index were calculated. In cases with high suspicion of PAH right heart catheterisation was 
performed, and the results were compared to the echocardiographic measurements. We found 
the average RV Tei-index to be above normal values. When combining the echocardiographic 
PAP with an elevated RV Tei-index, the predictive value of the echocardiography increases and 
the number of negative right heart catheterisation decreases.
The objective of the study described in chapter 8 was to determine the six minute walk test 
(6MWT) distance in SSc patients compared to expected values in healthy subjects and to 
determine differences in groups of SSc patients with and without pulmonary complications. One 
hundred and eighty four patients from the Nijmegen SSc cohort performed a 6MWT combined 
with pulmonary function tests and echocardiography to determine pulmonary involvement, 
namely interstitial lung disease and/or pulmonary hypertension. We found the median 6MWT 
distance in SSc patients to be significantly lower than the expected value. This distance was 
decreased in all groups of patients, with or without pulmonary involvement, but the lowest value 
was found in patients with fibrosis and pulmonary hypertension, followed by patients with PAH. 
Significant correlations of the 6MWT were found with various pulmonary function test results, 
but not with auto antibodies, disease duration or anaemia.
Chapter 9 reports the long-term follow up results of patients with severe diffuse cutaneous SSc 
treated with autologous haematopoietic stem cell transplantation (HSCT). Twenty-six patients 
were evaluated. Peripheral blood stem cells were collected using cyclophosphamide (4 g/m2) 
and rHu G-CSF (5 to 10 µg/kg/day) and were reinfused after positive CD34+ selection. For 
conditioning, cyclophosphamide 200 mg/kg was used. After a median follow-up of 5.3 years, 
81% of the patients demonstrated a clinically beneficial response. The estimated survival at 
5 years was 96.2 % and event-free survival, defined as survival without mortality, relapse or 
progression of SSc, resulting in major organ dysfunction was 64.3 %. This study confirms that 
autologous HSCT in selected patients with severe diffuse cutaneous SSc results in sustained 
improvement of skin thickening and well being, and stabilisation of pulmonary, cardiac and 
renal function up to seven years after transplantation. 
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General conclusions of the present thesis are
– The prevalence of SSc in the Netherlands is 8.9 per 105 inhabitants, but the prevalence of 
PAH and interstitial lung disease in SSc is lower than described before. 
– Diagnostic criteria, especially for early SSc, generally accepted disease activity criteria for 
SSc as well as outcome measures for evaluation of treatment and clinical trials are warranted, 
to improve daily clinical care and facilitate clinical trials in SSc.
– Oesophageal dilatation on the HRCT-scan of the chest can be a sign of SSc and should 
initiate further investigations.
– Skin deformity is a core stressor of SSc, only preceded by fatigue.
– The predictive value of the echocardiography for pulmonary hypertension in SSc increases 
when the echocardiographic pulmonary arterial pressure is combined with an elevated right 
ventricle Tei-index.
– The six minute walking distance in SSc is decreased compared to healthy subjects, also in 
patients without pulmonary complications.
– Autologous haematopoietic stem cell transplantation is a potential treatment option for 
carefully selected patients with diffuse cutaneous SSc with a sustained improvement of skin 
involvement, well being and stabilisation of major organ functions, also after 5 years of 
follow up.
Aims for future research
Future research in SSc should focus on both sides of the disease spectrum. First: early disease. The 
prognosis of SSc could improve substantially with timely treatment. To initiate timely treatment, 
we need to diagnose SSc early in the disease course. The main objective for future research should 
be to improve clinimetrics in scleroderma, providing clinicians with diagnostic criteria for early 
disease, outcome measures for evaluation of treatment and clinical trials and generally accepted 
disease activity criteria. Furthermore, clinical trials, conducted in patients with early disease and 
with different treatment possibilities are necessary to determine appropriate treatment for the 
different subsets of SSc.
Second: organ complications. Treatment of interstitial lung disease in SSc, although the subject 
of recent attention with two randomised trials, has to be the subject of future research in order to 
improve survival. The prognosis of PAH associated to SSc is still poor compared to other forms 
of PAH. The reason for this poor prognosis and treatment possibilities for these patients should 
be a focus of attention in PAH research. A possible reason for this poor prognosis are cardiac 
complications of SSc, which are still a black box. Collaborations in research with cardiologists 
could fill in the blanks and provide for better outcome in the future. 
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Samenvatting
In dit proefschrift worden de resultaten beschreven van onderzoek naar de hedentijdse evaluatie 
van de complicaties van systemische sclerose voor de patiënt. Bovendien zijn mogelijkheden ter 
verbetering van de evaluatie en behandelingsmogelijkheden beschreven.
Het Nijmegen Sclerodermie cohort
De studies die in dit proefschrift beschreven worden zijn uitgevoerd met het Nijmegen 
Sclerodermie cohort, gestart in 1989 en momenteel bestaande uit 323 patiënten, behandeld in 
het UMC St. Radboud en de Sint Maartenskliniek Nijmegen.
Systemisch sclerose
De naam sclerodermie komt van het Griekse woord skleros, wat hard betekent en derma, wat 
huid betekent, samen dus “harde huid”. Sclerodermie, of beter systemische sclerose (SSc) is een 
zeldzame ziekte, die wereldwijd voorkomt en in Nederland een op de 100.000 volwassenen 
treft. De ziekte komt 4 maal zoveel voor bij vrouwen als bij mannen en treedt het meest op tussen 
de 30-50 jarige leeftijd. SSc is een verworven bindweefsel aandoening die zich karakteriseert 
door verdikking en verlittekening van de huid, spieren, gewrichten en inwendige organen, in 
het bijzonder de slokdarm, de longen, het hart en de nieren. De oorzaak van sclerodermie 
is onbekend. Kenmerkend voor SSc zijn vaatbeschadigingen, activatie van witte bloedcellen, 
type T-lymfocyt, de productie van eiwitten gericht tegen lichaamseigen structuren, zogenaamde 
autoantistoffen, en het vrijkomen van celaantrekkende eiwitten, zogenaamde cytokines. Door 
deze combinatie van afweerverschijnselen wordt SSc beschouwd als een gegeneraliseerde auto-
immuunziekte. Autoantistoffen zijn bij 95% van de patiënten aantoonbaar. De autoantistoffen 
anti-topoisomerase I en anticentromeer antistoffen zijn specifiek voor SSc, maar ook andere 
antistoffen kunnen voorkomen, zoals anti-RNP en Jo1 antistoffen. 
Op grond van de uitgebreidheid van de huidafwijkingen wordt sclerodermie onderverdeeld in 
een diffuse huidvorm, waarbij de huidverharding zich uitstrekt tot boven de ellebogen, knieën 
en/of romp, en een gelimiteerde huidvorm, waarbij de huidveranderingen zich beperkt tot de 
onderarmen, onderbenen en het gezicht. Over het algemeen is de prognose van patiënten met 
de gelimiteerde huidvorm gunstiger dan die van patiënten met de diffuse huidvorm. Patiënten 
kunnen veel verschillende klachten en verschijnselen hebben. Ruim 90% van de patiënten heeft 
het fenomeen van Raynaud, dat is verkleuring van de huid van de vingers en/of tenen bij koude 
of emoties waarbij de huid achtereenvolgens blauw, wit en rood verkleurt. Andere verschijnselen 
hangen samen met de inwendige orgaanbetrokkenheid. 
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Orgaancomplicaties
Huidafwijkingen
Huidafwijkingen bij sclerodermie bestaan uit verdikking van de huid, kalkafzettingen en zweren 
aan de vingers, de zogenaamde digitale ulcera. Patiënten bemerken in een vroeg stadium 
van de ziekte vaak dat de vingers opgezwollen zijn, in het beloop van de ziekte kan de huid 
toenemend verstrakken en verharden, dit kan over het hele lichaam optreden of beperkt blijven 
tot de vingers en tenen. Door deze verstrakking van de huid is de bewegelijkheid van spieren en 
gewrichten beperkt. De huidaantasting kan worden gekwantificeerd door de modified Rodnan 
skin score, vastgesteld door de huidstructuur te voelen. Er treedt verandering van pigmentatie op en 
lichaamshaar en zweetkliertjes gaan verloren. Het gezicht verandert mee, de gezichtsuitdrukkingen 
gaan verloren en de mond wordt klein en rimpelig. Er kunnen uitgezette bloedvaatjes verschijnen, 
deze heten teleangiectasieën. Verder in het ziekte beloop wordt de huid weer zachter, maar wordt 
nu atrofisch en kwetsbaar, waardoor op stootplekken wondjes kunnen ontstaan die slecht genezen 
en erg pijnlijk zijn. Digitale ulcera ontstaan door een slechte doorbloeding, deze zweertjes kunnen 
geïnfecteerd raken en veroorzaken veel pijn en functieverlies. Ook kalkafzetting in of onder de 
huid kan aanleiding geven tot slecht genezende wonden. 
Longfibrose
Na de aantasting van de slokdarm is de meest voorkomende orgaanbetrokkenheid aantasting 
van de longen. De ontsteking van het longweefsel door SSc geeft verlittekening en wordt 
longfibrose genoemd. Met voorscheiding van dit proces treedt een afname van de longinhoud 
en het zuurstofopnemend vermogen op. Longfibrose komt waarschijnlijk in zo’n 80% van de 
patiënten voor. Een deel van deze patiënten krijgt er ook klachten van, te weten vermoeidheid, 
kortademigheid bij inspanning en, indien de longfibrose ernstig is, ook in rust. Een tweede 
ernstige complicatie in de longen is pulmonale hypertensie.
Pulmonale hypertensie
Pulmonale hypertensie (PH), dat is verhoogde bloeddruk in de longvaten, is een levensbedreigende 
complicatie van sclerodermie die bij 12% van de patiënten optreedt. Pulmonale hypertensie kan 
alleen worden vastgesteld met een rechter hart katheterisatie. Bij sclerodermie patiënten kunnen 
verschillende vormen van pulmonale hypertensie voorkomen. Ten eerste is er pulmonale arteriële 
hypertensie (PAH). PAH wordt waarschijnlijk door het ontstekingsproces van SSc veroorzaakt en 
kenmerkt zich door vaatafwijkingen, namelijk verdikking en vernauwingen in de slagaders die 
zuurstof arm bloed naar de longen transporteren. Door deze vernauwingen en hoge bloeddruk 
in de longen is de zuurstof opname ernstig verstoord, wat aanleiding geeft tot een zuurstof tekort, 
aanvankelijk bij inspanning, maar later ook in rust. Ook veroorzaakt dit een toename van de 
arbeid die de rechterkant van het hart moet verrichten, waardoor de rechterhartkamer verdikt 
en vergroot wordt, en zelf te weinig zuurstof krijgt, en uiteindelijk niet meer in staat is deze 
hoge druk op te bouwen en faalt. Een andere vorm is PH bij longfibrose, waarbij de druk in de 
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longvaten gewoonlijk minder hoog is en het proces minder fulminant verloopt. Ook PH door 
ziekte aan de linkerkant van het hart is mogelijk, tengevolge van hartklepafwijkingen of slecht 
functie van de linker hartkamer. Een zeldzame, maar ernstig verlopende oorzaak van PH in SSc 
is vaatafsluitingen in de kleine afvoerende bloedvaten van de longen, PVOD genaamd. Ook 
alle andere mogelijke oorzaken van PH, zoals chronische longembolieën of lever falen komen 
voor bij sclerodermie patiënten. Er dient dus altijd een compleet onderzoek te worden verricht. 
Er zijn behandelingen voor PH voorhanden, die ook bij SSc goede resultaten geven, maar de 
meerderheid van de patiënten reageert slechts tijdelijk op de behandeling. De vooruitzichten 
van PH bij sclerodermie zijn slechter dan elke andere vorm van PH.
Hartafwijkingen
Aantasting van het hart bij SSc is vaak zonder duidelijke verschijnselen. Het meest voorkomend is 
pleksgewijze fibrose in de hartspier waardoor de ontspanning in de vullingsfase van de hartcyclus 
afneemt en bij een deel van de patiënten aanleiding geeft tot een verminderde knijpkracht. Door 
deze afwijkingen, tesamen met functiestoornissen van het onwillekeurige zenuwstelsel, kunnen 
hartritme stoornissen ontstaan. Bij patiënten met een actieve ziekte kan er ook vocht in het 
hartzakje ophopen als uiting van de ontsteking.
Nierafwijkingen
De klassieke nieraantasting bij sclerodermie is de zogenaamde renale crise, waarbij er snel 
een ernstige hoge bloeddruk ontstaat gecombineerd met een nierfunctie verlies. Dit was de 
belangrijkste doodsoorzaak in SSc patiënten tot dat er, eind jaren 80, een effectieve behandeling 
werd gevonden. 
Aantasting van het maag-darm stelsel
SSc veroorzaakt in het maag-darm stelsel verlies van de normale bewegelijkheid, waardoor het 
eten minder goed door de slokdarm, maag en darmen passeert. De slokdarm passage klachten 
zijn vaak al bij patiënten met een korte ziekteduur (minder dan 1 jaar) aanwezig. Afgenomen 
bewegelijkheid in de rest van het maag-darm stelsel treedt in de regel later in het ziektebeloop 
op en kan in de dunne en dikke darm aanleiding geven tot overgroei van bacteriën. Hierdoor 
kunnen deficiënties van bepaalde vitamines ontstaan en diarree of juist obstipatie worden 
veroorzaakt. Ook chronisch bloedverlies in het maag-darm stelsel uit uitgezette bloedvaatjes, 
met als gevolge bloedarmoede, is een complicatie van SSc. 
Aantasting van spieren en gewrichten
Frequent hebben patiënten met SSc pijnklachten van het bewegingsapparaat. Bewegings-
beperkingen kunnen optreden door de verstrakking van de huid. Spierontsteking kan aanleiding 
geven tot spierkrachtverlies, ook gewrichtsontstekingen kunnen voorkomen. Een klein deel 
van de patiënten heeft een zogenaamd overlap syndroom met polymyositis, hierbij is er een 
uitgebreide ontsteking van de grote skeletspieren aanwezig.
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Prognose
Sclerodermie is een ongeneeslijke ziekte. Het natuurlijk ziektebeloop is wisselend en kan 
variëren van spontane genezing, wat zelden voorkomt, tot geleidelijke of zeer snelle toename 
van de huidafwijkingen en inwendige orgaanschade. De sterfte is aanzienlijk; in 5 jaar sterft 
tenminste 30% van de patiënten. Aantasting van de inwendige organen, de uitgebreidheid van 
de huidafwijkingen, de aanwezigheid van anti-topoisomerase I antistoffen en het mannelijk 
geslacht zijn ongunstige factoren voor de prognose.
Clinimetrie
Clinimetrie betekent “meten aan ziekte”, en kan ziekteactiviteit, classificatie en prognose 
omvatten. Ziekteactiviteits criteria weerspiegelen het ziekteproces en voorspellen idealiter 
schade, en geven dus aan wanneer ingrijpen noodzakelijk is. Een meting van beschadiging 
echter, weerspiegelt de uitgebreidheid van orgaan functie verlies. In 1995 heeft de European 
Scleroderma Study Group (EScSG) een multicenter prospectief onderzoek geïnitieerd om 
ziekteactiviteits criteria op te stellen. Deze studie heeft echter geen algemeen geaccepteerde 
criteria opgeleverd, omdat het discutabel is of de criteria activiteit of schade meten. In 1999 is de 
zogenaamde “preliminaire SSc severity scale” ontworpen om de prognose van een individuele 
sclerodermie patiënt te bepalen, maar deze schaal maakt geen onderscheid tussen een ernstig 
zieke patiënt en een patiënt met een uitgebreide, maar rustige ziekte. Een ander groot gemis in 
de zorg voor patiënten met SSc is dat er geen diagnostische criteria zijn. Als surrogaat worden 
vaak de “ACR Preliminary Criteria for the Classification of Systemic Sclerosis” gebruikt, maar 
deze volstaan niet bij patiënten met een vroege ziekte. En juist een vroege diagnose en vroege 
behandeling lijkt de prognose van patiënten met SSc te kunnen verbeteren. 
Behandeling
Voor patiënten met sclerodermie zijn er een aantal mogelijkheden voor behandeling. Bij patiënten 
zonder inwendige orgaanbeschadiging is de behandeling erop gericht die te voorkomen, bij 
patiënten met inwendige orgaanschade om erger te voorkomen. Symptomatische behandeling, 
dat is behandeling gericht op klachten vermindering is bij beide groepen patiënten mogelijk, 
bijvoorbeeld maagzuurremmers tegen het zuurbranden en medicijnen voor een betere 
doorbloeding van de vingers. Behandelingsmogelijkheden ter preventie van orgaanschade zijn 
Methotrexaat, Cyclophosphamide en bij geselecteerde patiënten met een slechte prognose ook 
stamceltransplantatie, nu nog in onderzoeksverband. In de behandeling van orgaanschade zijn er 
de afgelopen jaren twee studies verschenen met voorzichtig positieve resultaten bij de behandeling 
van longfibrose. Behandeling van pulmonale hypertensie geassocieerd aan SSc is nog steeds 
moeizaam. Patiënten reageren wel op de behandeling, maar meestal voor een beperkte duur.
In hoofdstuk 2 wordt de epidemiologie van SSc en de longcomplicaties in Nederland 
beschreven. De gegevens zijn afkomstig van een nationale enquête onder reumatologen en 
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klinisch immunologen gecombineerd met de POEMAS studie. POEMAS, een door onderzoekers 
geïnitieerde studie staat voor “Pulmonale hypertensie Opsporing Een Multidisciplinaire Aanpak 
bij Sclerodermie” en heeft als doel om de optimale screeningsmethode voor het ontstaan van 
pulmonale hypertensie in SSc patiënten vast te stellen. In de POEMAS studie is gedetailleerde 
informatie over 654 SSc patiënten, inclusief demografie, longfunctieonderzoek en hoge resolutie 
computertomografie (HRCT) scans voor handen. Met de enquête werd informatie over 346 
andere sclerodermie patiënten verkregen, inclusief de eventuele aanwezigheid van pulmonale 
hypertensie zoals vastgesteld met een rechterhart katheterisatie. De prevalentie in Nederland 
bleek 8.9 per 105 inwoners > 18 jaar te zijn, gebaseerd op 1000 patiënten, en de incidentie was 
0.77 patiënten per 105 per jaar. De prevalentie van pulmonale hypertensie geassocieerd aan SSc 
bleek 9.9%. Een definitie van longfibrose in SSc is niet voorhanden. Indien de HRCT-scan wordt 
gebruikt om deze complicatie vast te stellen, blijkt longfibrose aanwezig bij 47% van de SSc 
patiënten, en wanneer de totale long inhoud wordt gebruikt, is deze 19%. Wij concluderen dat 
de prevalentie en incidentie van SSc in Nederland vergelijkbaar is met de gegevens afkomstig 
uit Groot Brittannië, maar dat het voorkomen van pulmonale hypertensie en longfibrose is lager 
dan verwacht. 
Hoofdstuk 3 bevat een diagnostisch protocol van pulmonale hypertensie, gebaseerd op de 
bestaande literatuur en de multidisciplinaire aanpak in ons centrum. Pulmonale hypertensie is 
een verwoestende complicatie van verschillende, zeldzame ziekten, waaronder sclerodermie, 
maar kan ook geïsoleerd voorkomen. Het veroorzaakt morbiditeit en mortaliteit in alle patiënten. 
Wetenschappelijk onderzoek heeft enig inzicht verschaft in de pathofysiologie en klinische 
manifestaties. In dit hoofdstuk worden ook twee patiënten met pulmonale hypertensie en een 
behandel algoritme beschreven, evenals adviezen voor het monitoren van patiënten.
De tekortkomingen en potenties van de clinimetrie in SSc worden beschreven in hoofdstuk 
4. Om de zorg voor SSc patiënten te verbeteren, moet vroege, optimale behandeling worden 
toegepast. Echter, er zijn geen diagnostische criteria voor sclerodermie. Frequent worden de 
“ACR Preliminary Criteria for the Classification of Systemic Sclerosis”, ontwikkeld in 1980, 
gebruikt om SSc te diagnosticeren. Deze classificatie criteria zijn echter niet geschikt om een 
juiste en vroege diagnose te stellen. De redenen hiervoor zijn de volgende: de studie waarin 
de criteria ontwikkeld zijn bevatte uitsluitend “klassieke” patiënten, de controle groep bestond 
niet uit patiënten met scleroderma-achtige ziekten en ziekte specifieke autoantistoffen en 
capillairoscopische afwijkingen zijn niet in de studie meegenomen. Subset classificatie criteria 
hebben als doel om verschillende groepen patiënten te onderscheiden waarin het natuurlijk 
beloop en de prognose zou kunnen verschillen. Momenteel zijn de meest gebruikte subset 
classificatie criteria die waarbij twee klinische groepen van patiënten worden onderscheiden te 
weten de gelimiteerde huidvorm en de diffuse huid vorm. De grootste beperking van dit systeem 
is dat patiënten met vroege ziekte, zonder of met slechts geringe huidafwijkingen en zonder 
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inwendige orgaanbetrokkenheid niet geclassificeerd kunnen worden. In 1995 heeft de EScSG 
een prospectief, multicenter onderzoek gestart wat geresulteerd heeft in de voorlopige ziekte 
activiteitscriteria voor SSc. Door een groot aantal missende gegevens in “technisch onderzoek” 
bevatten deze criteria drie zogenaamde “change items”. Deze “change items” zijn maten voor 
respons, en horen niet in een ziekte activiteitsscore. Bovendien was er een zeer grote spreiding 
in ziekteduur van de geïncludeerde patiënten, zodat de klachten en symptomen ook het gevolg 
zouden kunnen zijn van schade door SSc en niet ziekteactiviteit. In de in 1999 ontwikkelde 
Severity criteria voor SSc, zijn negen orgaan systemen geïdentificeerd en de betrokkenheid 
per orgaansysteem wordt gescoord tussen 0 en 4. Tot nu toe is de prognostische waarde en 
gevoeligheid voor verandering nog niet vastgesteld. Criteria die bijdragen aan zowel een vroege 
diagnose als classificatie, criteria voor de mate van ernst en prognose, en ziekte activiteitscriteria 
die aangeven wanneer de ziekte actief is kan de clinicus helpen in de dagelijkse zorg voor 
sclerodermie patiënten. 
De voorspellende waarde van een openstaande slokdarm op de HRCT-scan van de borstkast 
voor de diagnose SSc is onderzocht in hoofdstuk 5. Deze studie bevat 105 opeenvolgende SSc 
patiënten uit het Nijmeegse sclerodermie cohort en 107 opeenvolgende controle patiënten. 
De controle patiënten waren patiënten zonder SSc waarbij de HRCT-scan werd verricht om 
ziekten van het longweefsel te evalueren. De eerst beschikbare HRCT-scan van de patiënten 
en controles werden gescoord op een openstaande slokdarm en afwijkingen in het longweefsel 
in willekeurige volgorde door twee onafhankelijk werkende radiologen die geblindeerd waren 
voor de diagnose. De positief voorspellende waarde van een openstaande slokdarm voor de 
diagnose SSc bleek 83% te zijn. Wij concludeerden dat indien er een openstaande slokdarm 
aanwezig is op de HRCT-scan de behandelaar geattendeerd zou moeten worden om te zoeken 
naar andere verschijnselen van SSc in deze patiënten, om tot een vroege diagnose te kunnen 
komen en specifieke behandeling te kunnen instellen.
Hoofdstuk 6 beschrijft het belang van huid deformiteiten in SSc gerelateerd aan andere ziekte 
stressoren en psychologische correlaties tot het gevoel van eigenwaarde door het uiterlijk. In 
123 patiënten van het Nijmeegse sclerodermie cohort werden ziekte gerelateerde stressoren, 
lichamelijk en psychologisch functioneren, sociale steun, coping stijlen en cognities vastgesteld. 
Huid deformiteiten bleken, na vermoeidheid, de belangrijkste stressor in SSc te zijn. De door de 
arts vastgesteld ziekte status inclusief de gemodificeerde Rodnan huidscore, was onafhankelijk 
van het gevoel van eigenwaarde door het uiterlijk. Sexe, zelf gerapporteerd functioneren en 
symptomen bleken gerelateerd aan het gevoel van eigenwaarde door het uiterlijk. Acceptatie en 
angst correleerden sterk met het gevoel van eigenwaarde door het uiterlijk. Wij concludeerden dat 
psychologische interventies gericht op het versterken van het gevoel van eigenwaarde door het 
uiterlijk primair gericht zouden moeten zijn op de psychologische factoren acceptatie en angst in 
sclerodermie patiënten. 
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In hoofdstuk 7 wordt de rechter hartkamer (RV) Tei-index geïntroduceerd als methode om 
de niet-invasieve diagnose van PAH in SSc patiënten te verbeteren. In 98 patiënten van het 
Nijmeegse sclerodermie cohort werden de echografische systolische longslagader druk (PAP), 
einddiastolische PAP en de RV Tei-index berekend. In patiënten met een sterke verdenking op 
PAH werd een rechter hart katheterisatie verricht, en de resultaten hiervan werden vergeleken met 
de echocardiografische metingen. Wij vonden dat de gemiddelde RV Tei-index in SSc patiënten 
boven de normaal waarde was. Wanneer de echografische systolische PAP gecombineerd werd 
met een verhoogde RV Tei-index, nam de voorspellende waarde van de echocardiografie toe en 
zou het aantal negatieve rechterhart katheterisaties afnemen. 
Het doel van de studie beschreven in hoofdstuk 8 was om de zes minuten looptest (6MWT) afstand 
in SSc patiënten te vergelijken met verwachte waarden van gezonde controles en om vast te stellen 
of er verschillen aanwezig waren tussen groepen SSc patiënten met en zonder longcomplicaties. 
Honderd vierentachtig patiënten van het Nijmeegse sclerodermie cohort verrichtten een 
6MWT samen met longfunctie onderzoek en echocardiografie om de longbetrokkenheid zoals 
longfibrose, PAH of pulmonale hypertensie ten gevolge van longfibrose vast te stellen. Wij vonden 
dat de mediane 6MWT afstand in SSc patiënten significant lager is dan verwacht. De afstand 
is verminderd in alle groepen van patiënten, met en zonder longcomplicaties, maar de laagste 
waarde werd gevonden in patiënten met longfibrose en PH, gevolgd door patiënten met PAH. Er 
werden significante correlaties gevonden met verschillende longfunctie test resultaten, maar niet 
met de aanwezigheid van autoantistoffen, ziekteduur of de aanwezigheid van bloedarmoede.
Hoofdstuk 9 rapporteert de lange termijn resultaten van patiënten met ernstige, diffuse cutane SSc 
die behandeld zijn met autologe bloedstamcel transplantatie (HSCT). Zesentwintig patiënten werden 
geëvalueerd. Perifere bloedstamcellen werden verkregen met cyclofosfamide en rHU G-CSF en 
gereinfundeerd na positieve CD34+ selectie. Voor de conditionering werd cyclofofamide gebruikt. 
Na een mediane follow-up van 5.3 jaar vertoonde 81% van de patiënten een gunstige klinische 
respons. De ingeschatte 5- jaaroverleving was 96.2% en de “gebeurtenis vrije overleving”, dat is 
overleving zonder sterfte, terugkeer van ziekteactiviteit of progressie van SSc of orgaan falen, was 
64.3%. Deze studie bevestigt dat HSCT bij geselecteerde patiënten met ernstige, diffuse cutane 
SSc resulteert in een blijvende verbetering van de huidverdikking en een stabilisatie van de long-, 
hart- en nierfunctie in ieder geval tot 7 jaar na de transplantatie. 
Algemene conclusies van dit proefschrift zijn:
– De prevalentie van SSc in Nederland is 8.9 per 105 volwassenen, echter de prevalentie van 
PAH en longfibrose in SSc is lager dan eerder beschreven.
– Diagnostische criteria, vooral voor vroege SSc, algemeen geaccepteerde ziekte activiteitscriteria 
en uitkomstmaten voor behandelingen en klinische trials zijn noodzakelijk teneinde de 
dagelijkse klinische zorg te optimaliseren en klinische trials in SSc te faciliteren.
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– Een openstaande slokdarm op de HRCT-scan van de borstkast kan een teken van SSc zijn en 
zou andere onderzoek naar deze ziekte moeten initiëren.
– Huid deformiteiten zijn, na vermoeidheid, de belangrijkste stressor in SSc
– De voorspellende waarde van echocardiografie voor pulmonale hypertensie in SSc neemt 
toe indien de echografische pulmonaal druk wordt gecombineerd met een verhoogde RV 
Tei-index.
– De zes minuten looptest afstand in SSc is afgenomen ten opzichte van gezonde controles, 
ook in patiënten zonder longcomplicaties.
– Autologe bloedstamcel transplantatie kan een succesvolle behandelmogelijkheid zijn voor 
zorgvuldig geselecteerde patiënten met diffuse cutane SSc; met een blijvende verbetering 
van de huidverdikking en algemeen welbevinden en een stabilisatie van de belangrijke 
orgaanfuncties, ook 5 jaar na de transplantatie.
Doelen voor toekomstig onderzoek
Toekomstig onderzoek in SSc moet zich focussen op de twee uiteinden van het ziekte spectrum. 
Ten eerste: vroege ziekte. De prognose van SSc zou sterk kunnen verbeteren indien er vroegtijdig 
behandeld wordt. Om deze tijdige behandeling te kunnen toepassen, moet de diagnose vroeg 
in het ziektebeloop worden gesteld. Het voornaamste doel van toekomstig onderzoek zou het 
verbeteren van de clinimetrie van SSc moeten zijn, zodat clinici beschikken over diagnostische 
criteria voor vroege ziekte, uitkomst maten en algemeen geaccepteerde ziekte activiteitscriteria. 
Bovendien zijn klinische trials met meerder behandelmogelijkheden, toegepast in patiënten met 
vroege ziekte, noodzakelijk om uiteindelijk vast te kunnen stellen welke behandel optie bij 
welke patiënt optimaal is.
Ten tweede: orgaancomplicaties. Hierbij moet men zich richten op de belangrijkste doodsoorzaak 
van SSc en dat is longfibrose en PAH. De behandeling van longfibrose heeft met de twee 
longstudies van de afgelopen jaren aandacht gekregen en er is een kleine stap vooruit gezet. 
Verder onderzoek is noodzakelijk om de overleving van patiënten met deze orgaancomplicatie te 
verbeteren. De prognose van PAH geassocieerd aan SSc is nog steeds slecht. De reden voor deze 
slechte prognose en de behandelopties zou de focus van PAH onderzoek moeten zijn. Mogelijk 
dat hart complicaties, waarover tot nu toe nog weinig bekend is, van de slechte prognose van 
PAH bij SSc een belangrijke oorzaak zijn. Samenwerking in onderzoek met cardiologen zou een 
manier zijn om de lacunes op te vullen en uiteindelijk een betere uitkomst voor onze patiënten 
te bewerkstelligen. 
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Dankwoord
Met het afronden van dit proefschrift is een mooie en bijzondere periode afgerond waarin ik met 
veel mensen prettig heb samen gewerkt en steun heb gehad van anderen. Een ieder wil ik hierbij 
hartelijk bedanken, en ik hoop ook in de toekomst een beroep op je te mogen doen.
Allereerst gaat mijn dank uit naar alle patiënten die belangeloos hebben meegewerkt aan de 
diverse onderzoeken. Daarbij ook dank voor het in mij gestelde vertrouwen. 
De initiator en inspirator van dit onderzoek was dr. F.H.J. van den Hoogen. Beste Frank, je gaf mij 
de mogelijkheid om mijn liefde voor sclerodermie met jou te delen en hebt het mogelijk gemaakt 
om dit onderzoek te starten en dit proefschrift te voltooien. In onze gezamenlijke discussies 
werden ideeën en artikelen gestroomlijnd en ontstonden nieuwe onderzoeksvragen. Voor ons 
overleg maakte je altijd tijd vrij, en na zo’n discussie en peptalk kon ik weer de hele wereld aan. 
Met jouw vertrek ben ik mijn sparringpartner kwijt, maar gelukkig ligt “de Berg” op de route naar 
huis. Ik hoop dat onze fijne samenwerking zal blijven bestaan. Dank voor alles.
Prof.dr. P.L.C.M. van Riel, beste Piet. Jij hebt mij de kans gegeven om dit project aan te gaan: 
het combineren van de zorg voor sclerodermie en PH patiënten met het schrijven van een 
proefschrift. Jouw steun en kritisch commentaar heb ik zeer gewaardeerd. Je maakte mij meer 
dan eens duidelijk dat je mijn werk een warm hart toe draagt, en er toekomst in ziet. Het 
voltooien van dit proefschrift gaat naadloos over in het uitbouwen van deze onderzoekslijn, ook 
voor deze kans dank ik je zeer.
Prof dr. P.N.R. Dekhuijzen, Prof. dr. J.W. Bijlsma en Prof. dr. J.M. van Laar, de manuscript 
commissie, wil ik hartelijk danken voor het beoordelen van dit manuscript.
Overige stafleden van de afdeling reumatische ziekten: Annelies, Hedwig, Marjonne, Pilar en 
Roland, dank voor jullie fijne samenwerking en steun.
Jaap Fransen, dank voor alle ondersteuning op methodologisch gebied en de kritische blik op de 
statistiek. Maar bovenal voor de levendige discussies over hoe het allemaal beter moet kunnen 
en wat ons daarvoor te doen staat. We gaan door!
Arie van Dijk, ik ken geen andere cardioloog die de diagnose sclerodermie accuraat kan stellen. 
Dank voor je enthousiasme en kennis in onze PH samenwerking en bij het opzetten en uitvoeren 
van de projecten op ons grensvlak.
Yvonne Heijdra, onze samenwerking op gebied van patiëntenzorg en onderzoek is een bron van 
inspiratie voor meer en beter. Dank voor jouw deskundigheid en interesse.
De overige leden van het Pulmonale Hypertensie Team Nijmegen. Beste Jolanda, Nicole en 
Saartje. Het is een groot voorrecht om te kunnen werken met mensen die zo’n stimulerend en 
hecht team vormen waarbij er elke dag weer geleerd wordt.
Tim Radstake, jij hebt je geïnteresseerd in het fundamentele onderzoek in de sclerodermie, 
waardoor een verbreding van onze onderzoekslijn is opgetreden. Dank voor de steun en 
discussies.
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Wim van Lankveld, het onderzoek op het gebied van de psychologie in de sclerodermie was een 
onontgonnen gebied, wat hopelijk ook door onze samenwerking wat ingekleurd kan worden. 
Dank hiervoor.
Mijn kamergenoten Lia en Hanneke, dank jullie wel voor de gezelligheid, steun en de goede 
sfeer. Wietske: op naar de volgende fase!
Lieke, Renske, Mieke, Tamara en Gracia, in ons hectische secretariaat, de gezelligste kamer van 
de afdeling. Ondanks de drukte hebben jullie altijd tijd voor een kletspraatje en een klusje. Dank 
voor jullie steun en enthousiasme.
Onze VRC’s: Carine, Ellis, Jacqueline en Joke, door de groeiende stroom patiënten met 
sclerodermie is ook jullie kennis en werklast gegroeid. Dank voor de fijne samenwerking die we 
nu verder zullen gaan intensiveren.
Geen manuscript gaat de deur uit zonder dat jij kritisch het Engels hebt beoordeeld! Dank voor 
je hulp Aggie.
Dank voor de stimulerende samenwerking, leden van de POEMAS werkgroep. Dit onderzoek 
zal uiteindelijk de zorg voor patiënten met sclerodermie verbeteren. 
Alle medewerkers van de kliniek, polikliniek, datacentrum en laboratorium, dank je wel voor 
jullie bijdrage.
Edwin Vonk en Heidi van Voorthuizen, ik ben er trots op dat jullie mijn paranimfen willen zijn. 
De nabije toekomst zal wat meer tijd brengen voor familie en LDD (leuke dingen doen)!
Lieve vrienden en familie, ik dank jullie voor de interesse in mijn werk. De aanmoedigingen die 
ik van jullie heb gekregen hebben mij goed gedaan. 
Lieve papa en mama, graag wil ik jullie bedanken voor jullie stimulering om dat te doen waar 
mijn hart ligt. Jullie hebben mij geleerd dat veel te bereiken is met hard werken, doorzetten en 
plezier. Een fijne, warme jeugd is de basis voor wat daarna komt! Ook nu is jullie rol in mijn 
leven nog groot, altijd zijn jullie bereid om mij te helpen en menig “opvang probleempje” wordt 
met liefde door jullie opgelost. Dank je wel!
Lieve Ad en Jannie, mijn schoonouders. De aanmoedigingen van jullie hebben geholpen om de 
moeilijke momenten te overwinnen. De liefde voor ons gezin is koesterend en het bijspringen in 
tijden van drukte onmisbaar. Dank jullie wel!
Lieve Rita, al 8 jaar de constante factor in ons huis. Jij begrijpt het “alle ballen in de lucht 
houden” van mij als geen ander. Je hebt onze kinderen mee opgevoed tot wat ze nu zijn, en ik 
zal zorgen dat ook in de toekomst de band zo hecht zal blijven. Dank voor al je hulp en liefde 
die je ons gezin toedraagt.
Met twee werkende ouders is er ook regelmatig oppas ’s avonds nodig, en ik laat de kinderen 
altijd graag aan jouw zorgen over Karlijn, en ben blij dat je voor ons regelmatig uit Amsterdam 
terug komt. 
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En ”last but not least”: Lieve Paul, jij hebt mij gesteund om deze uitdaging aan te gaan en tot een 
goed eind te brengen. Van dichtbij heb jij mijn plezier, adrenaline, maar ook bloed, zweet en 
tranen van deze promotie gezien. Jouw optimisme en kritische houding hebben mij geholpen, en 
op de juiste momenten trok je mij achter de laptop vandaan om te genieten van ons Nijmeegse 
leven. Ik dank je voor alles, maar vooral voor jouw liefde. Met jou “never a dull moment”.
Liefste Daphne, liefste Lisa en liefste Valentijn. Wat een geluk dat ik jullie in mijn leven heb. Ik 
word altijd blij van jullie, thuiskomen bij jullie is het mooiste dat er is. Bij jullie zijn is het grote 
genieten van het plezier, groeien, ontwikkelen en leren afgewisseld met de routine van alle 
dag. Het is niet altijd makkelijk voor jullie om een mama met ambitie te hebben, maar jullie 
aanpassingsvermogen is bewonderenswaardig, en ik ben er trots op dat ik jullie dit ook mee kan 
geven.
Wat mag je nooit vergeten? Mama houdt van jou.
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